Alere 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 04, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	1,145,460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		86,254,320

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net product sales	$ 470,404	$ 507,625	$ 1,446,837	$ 1,499,302
Services revenue	128,341	137,403	378,825	406,547
Net product sales and services revenue	598,745	645,028	1,825,662	1,905,849
License and royalty revenue	3,299	4,182	13,691	15,998
Net revenue	602,044	649,210	1,839,353	1,921,847
Cost of net product sales	246,055	271,250	743,177	785,918
Cost of services revenue	79,803	75,102	232,137	221,356
Cost of net product sales and services revenue	325,858	346,352	975,314	1,007,274
Cost of license and royalty revenue	1,137	1,236	4,431	3,900
Cost of net revenue	326,995	347,588	979,745	1,011,174
Gross profit	275,049	301,622	859,608	910,673
Operating expenses:
Research and development	36,011	38,726	91,225	114,855
Sales and marketing	106,493	122,760	322,756	391,605
General and administrative	101,306	104,794	254,810	338,986
Impairment and (gain) loss on dispositions, net	2,074	0	42,408	638
Operating income	29,165	35,342	148,409	64,589
Interest expense, including amortization of original issue discounts and deferred financing costs	(52,333)	(52,332)	(158,258)	(156,276)
Other income (expense), net	4,745	(8,087)	7,735	2,164
Loss from continuing operations before provision (benefit) for income taxes	(18,423)	(25,077)	(2,114)	(89,523)
Provision (benefit) for income taxes	(18,924)	65,489	(10,009)	69,273
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	501	(90,566)	7,895	(158,796)
Equity earnings of unconsolidated entities, net of tax	5,000	6,277	10,320	13,716
Income (loss) from continuing operations	5,501	(84,289)	18,215	(145,080)
Income (loss) from discontinued operations, net of tax	0	(14,401)	216,777	(4,082)
Net income (loss)	5,501	(98,690)	234,992	(149,162)
Less: Net income (loss) attributable to non-controlling interests	(61)	(306)	386	(136)
Net income (loss) attributable to Alere Inc. and Subsidiaries	5,562	(98,384)	234,606	(149,026)
Preferred stock dividends	(5,367)	(5,367)	(15,926)	(15,926)
Net income (loss) available to common stockholders	$ 195	$ (103,751)	$ 218,680	$ (164,952)
Basic net income (loss) per common share:
Income (loss) from continuing operations	$ 0	$ (1.08)	$ 0.02	$ (1.94)
Income (loss) from discontinued operations	0	(0.17)	2.55	(0.05)
Net income (loss) per common share	0	(1.25)	2.57	(1.99)
Diluted net income (loss) per common share:
Income (loss) from continuing operations	0	(1.08)	0.02	(1.94)
Income (loss) from discontinuing operations	0	(0.17)	2.51	(0.05)
Net income (loss) per common share	$ 0	$ (1.25)	$ 2.53	$ (1.99)
Weighted-average shares - basic	85,895	83,115	85,141	82,719
Weighted-average shares - diluted	87,169	83,115	86,279	82,719

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 5,501	$ (98,690)	$ 234,992	$ (149,162)
Other comprehensive loss, before tax:
Changes in cumulative translation adjustment	(88,812)	(96,425)	(122,428)	(69,950)
Unrealized losses on available for sale securities	0	0	0	(17)
Unrealized gains on hedging instruments	0	7	0	21
Minimum pension liability adjustment	419	481	(1,337)	468
Other comprehensive loss, before tax	(88,393)	(95,937)	(123,765)	(69,478)
Income tax provision (benefit) related to items of other comprehensive loss	0	0	0	0
Other comprehensive loss, net of tax	(88,393)	(95,937)	(123,765)	(69,478)
Comprehensive income (loss)	(82,892)	(194,627)	111,227	(218,640)
Less: Comprehensive income (loss) attributable to non-controlling interests	(61)	(306)	386	(136)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (82,831)	$ (194,321)	$ 110,841	$ (218,504)

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 479,381	$ 378,461
Restricted cash	430,821	37,571
Marketable securities	157	259
Accounts receivable, net of allowances of $89,915 and $76,163 at September 30, 2015 and December 31, 2014, respectively	452,366	466,106
Inventories, net	362,226	365,165
Deferred tax assets	15,424	112,573
Prepaid expenses and other current assets	121,023	132,413
Assets held for sale - current	25,312	315,515
Total current assets	1,886,710	1,808,063
Property, plant and equipment, net	445,315	453,570
Goodwill	2,842,921	2,926,666
Other intangible assets with indefinite lives	28,744	43,651
Finite-lived intangible assets, net	1,052,949	1,276,444
Restricted cash	44,148
Deferred financing costs, net and other non-current assets	63,279	67,832
Investments in unconsolidated entities	73,882	91,693
Deferred tax assets	7,632	8,569
Non-current income tax receivable	2,537	2,468
Assets held for sale - non-current	126,048	0
Total assets	6,574,165	6,678,956
Current liabilities:
Short-term debt and current portion of long-term debt	604,092	88,875
Current portion of capital lease obligations	3,505	4,241
Accounts payable	194,246	213,592
Accrued expenses and other current liabilities	315,336	375,494
Liabilities related to assets held for sale - current	8,836	78,843
Total current liabilities	1,126,015	761,045
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	2,987,658	3,621,385
Capital lease obligations, net of current portion	6,270	10,560
Deferred tax liabilities	207,451	214,639
Other long-term liabilities	135,200	161,582
Liabilities related to assets held for sale - non-current	9,603	0
Total long-term liabilities	$ 3,346,182	$ 4,008,166
Commitments and contingencies (Note 17)
STOCKHOLDERS' EQUITY:
Series B preferred stock, $0.001 par value (liquidation preference: $709,763 at September 30, 2015 and December 31, 2014); Authorized: 2,300 shares; Issued: 2,065 shares at September 30, 2015 and December 31, 2014; Outstanding: 1,774 shares at September 30, 2015 and December 31, 2014	$ 606,468	$ 606,468
Common stock, $0.01 par value; authorized: 200,000 shares; Issued: 93,868 shares at September 30, 2015 and 91,532 shares at December 31, 2014; Outstanding: 86,189 shares at September 30, 2015 and 83,853 shares at December 31, 2014	94	92
Additional paid-in capital	3,436,666	3,355,672
Accumulated deficit	(1,444,946)	(1,679,552)
Treasury stock, at cost, 7,679 shares at September 30, 2015 and December 31, 2014	(184,971)	(184,971)
Accumulated other comprehensive loss	(315,875)	(192,110)
Total stockholders' equity	2,097,436	1,905,599
Non-controlling interests	4,532	4,146
Total equity	2,101,968	1,909,745
Total liabilities and equity	$ 6,574,165	$ 6,678,956

Consolidated Balance Sheets (u5

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 89,915	$ 76,163
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,763	$ 709,763
Series B preferred stock, shares authorized	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	93,868,000	91,532,000
Common stock, shares outstanding	86,189,000	83,853,000
Treasury stock, shares	7,679,000	7,679,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows from Operating Activities:
Net income (loss)	$ 234,992	$ (149,162)
Income (loss) from discontinued operations, net of tax	216,777	(4,082)
Income (loss) from continuing operations	18,215	(145,080)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Tax benefit related to discontinued operations	0	9,594
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	10,627	11,824
Depreciation and amortization	233,511	250,763
Non-cash stock-based compensation expense	19,596	7,751
Impairment of inventory	201	1,536
Impairment of long-lived assets	378	6,866
Loss on sale of fixed assets	3,273	4,679
Equity earnings of unconsolidated entities, net of tax	(10,320)	(13,716)
Deferred income taxes	(46,740)	9,557
Loss related to impairment and net loss on dispositions	42,408	638
Loss on extinguishment of debt	3,480	0
Other non-cash items	(4,785)	3,683
Non-cash change in fair value of contingent purchase price consideration	(51,911)	17,042
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	(11,269)	12,643
Inventories, net	(58,781)	(30,446)
Prepaid expenses and other current assets	(14,953)	(8,646)
Accounts payable	(16,000)	38,687
Accrued expenses and other current liabilities	35,192	(8,501)
Other non-current liabilities	(8,790)	33,221
Cash paid for contingent purchase price consideration	(6,315)	(21,078)
Net cash provided by (used in) continuing operations	136,932	181,017
Net cash provided by discontinued operations	318	34,417
Net cash provided by operating activities	137,250	215,434
Cash Flows from Investing Activities:
Increase in restricted cash	(438,765)	(3,227)
Purchases of property, plant and equipment	(67,947)	(73,035)
Proceeds from sale of property, plant and equipment	1,486	1,144
Cash received from dispositions, net of cash divested	586,625	5,454
Cash paid for business acquisitions, net of cash acquired	(60,135)	(75)
Cash received from sales of marketable securities	99	47
Cash received from equity method investments	14,297	198
Proceeds from sale of equity investments	0	9,526
Decrease in other assets	881	1,024
Net cash provided by (used in) continuing operations	36,541	(58,944)
Net cash used in discontinued operations	(209)	(8,853)
Net cash provided by (used in) investing activities	36,332	(67,797)
Cash Flows from Financing Activities:
Cash paid for financing costs	(16,053)	(5)
Cash paid for contingent purchase price consideration	(14,079)	(23,608)
Cash paid for dividends	(15,970)	(15,970)
Proceeds from issuance of common stock, net of issuance costs	76,457	35,593
Proceeds from issuance of short-term debt	0	806
Proceeds from issuance of long-term debt	2,162,022	41
Payments on short-term debt	(25,584)	0
Payments on long-term debt	(2,129,165)	(47,302)
Net proceeds (payments) under revolving credit facilities	(126,603)	498
Excess tax benefits on exercised stock options	6,102	415
Principal payments on capital lease obligations	(4,339)	(4,639)
Net cash used in continuing operations	(87,212)	(54,171)
Net cash used in discontinued operations	(76)	(1,075)
Net cash used in financing activities	(87,288)	(55,246)
Foreign exchange effect on cash and cash equivalents	(8,674)	(9,445)
Net increase in cash and cash equivalents	77,620	82,946
Cash and cash equivalents, beginning of period - continuing operations	378,461	355,431
Cash and cash equivalents, beginning of period - discontinued operations	23,300	6,477
Cash and cash equivalents, end of period	479,381	444,854
Less: Cash and cash equivalents of discontinued operations, end of period	0	13,503
Cash and cash equivalents of continuing operations, end of period	$ 479,381	$ 431,351

Basis of Presentation of Financ

Basis of Presentation of Financial Information	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2014 included information and footnotes necessary for such presentation and were included in Amendment No. 2 to our Annual Report on Form 10-K/A filed with the Securities and Exchange Commission, or SEC, on May 28, 2015. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2014. As a result of the sale of our health management business in January 2015, which was the largest component of our patient self-testing reporting segment, we no longer report our financial information in four operating segments. Our current reportable operating segments are professional diagnostics, consumer diagnostics and corporate and other. Financial information by segment for the three and nine months ended September 30, 2014 has been retroactively adjusted to reflect this change in reporting segments. Certain reclassifications of prior period amounts have been made in order to retrospectively present discontinued operations. These reclassifications have no effect on net income or equity. During the three and nine months ended September 30, 2015, we recorded $8.0 million of tax-related correcting adjustments related to prior periods which consisted of a $6.6 million net tax benefit related to U.S. taxes on foreign earnings and a $1.4 million tax benefit associated with a release of uncertain tax positions. We considered the correcting adjustments to be immaterial to both the prior periods and the current year financial statements Certain amounts presented may not recalculate directly, due to rounding.

Assets Held for Sale

Assets Held for Sale	9 Months Ended
	Sep. 30, 2015
Assets Held for Sale	(20) Impairment and (Gain) Loss on Dispositions, Net In July 2015, we sold certain assets of our Inverness Medical Innovations Australia Pty Ltd business, which was part of our professional diagnostics reporting unit and business segment, for AUD 0.2 million (approximately $0.1 million as of the date of disposition) in cash proceeds and, as a result of this transaction, we recorded a loss of $1.2 million during the three and nine months ended September 30, 2015. We recorded additional charges of approximately $0.9 million in connection with certain other business closures or divestitures during the three and nine months ended September 30, 2015. In May 2015, we sold our Alere Analytics business, which was part of our professional diagnostics reporting unit and business segment. Under the terms of the sale we received nominal consideration and agreed to contribute working capital of $2.7 million to Alere Analytics, of which $2.4 million was contributed in cash immediately prior to the closing of the sale and the remaining $0.3 million of which was deposited in escrow pending the performance by the buyers under certain contracts. As a result of this transaction we recorded a loss of $4.7 million during the nine months ended September 30, 2015. During the three months ended March 31, 2015, before identifying a buyer for Alere Analytics, our management decided to close the business, and in connection with this decision we recorded an impairment charge of $26.7 million during the nine months ended September 30, 2015, including the write-off of $26.2 million of acquisition-related intangible assets and $0.5 million of fixed assets. In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during the nine months ended September 30, 2015. In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for €7.6 million (approximately $8.2 million at March 31, 2015) and, as a result of this transaction, we recorded a loss on disposition of $7.5 million during the nine months ended September 30, 2015. In December 2014, our management decided to close our Alere Connect, LLC subsidiary, which is part of our professional diagnostics reporting unit and business segment. During the nine months ended September 30, 2015, in connection with this decision, we recorded impairment charges of $1.1 million, consisting primarily of severance costs, inventory write-offs and other closure-related expenses. In April 2014, we sold the Glucostabilizer business of Alere Informatics, Inc., which was part of our professional diagnostics reporting unit and business segment, to Medical Decision Network, LLC for $1.1 million in cash proceeds and a $1.5 million note receivable, which we fully reserved for based on our assessment of collectability. As a result of this transaction, we recorded a loss on disposition of $0.6 million during the nine months ended September 30, 2014. The financial results for the above businesses are immaterial to our consolidated financial results.
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Assets Held for Sale	(24) Assets Held for Sale We account for planned divestitures in accordance with ASU No. 2014-08. A disposal group comprising assets and liabilities that are expected to be recovered primarily through sale rather than continuing use are classified as held for sale on the consolidated balance sheet. Immediately before classification as held for sale, the assets, or components of a disposal group, are assessed for impairment in accordance with our accounting policy. Any impairment losses relating to assets included in the disposal group are recorded in the statement of operations. Sale of BBI On July 2, 2015, we entered into an agreement to sell our BBI business, which is included in our professional diagnostics segment, to Exponent Private Equity LLP, a U.K.-based private equity firm, for a total purchase price of approximately $164.3 million in cash, based on foreign exchange rates on that date, including up to $46.6 million in contingent cash consideration. The final purchase price is subject to a working capital adjustment. BBI Group provides products and services for the diagnostic, healthcare, research, defense and food industries globally. The closing of the BBI sale is subject to the satisfaction of certain closing conditions. The closing of the transaction is anticipated to occur during the fourth quarter of 2015. We expect to use the majority of the proceeds from the sale to pay down existing indebtedness. The following assets and liabilities associated with our BBI business have been segregated and classified as assets held for sale and liabilities related to assets held for sale, as appropriate, on our consolidated balance sheet as of September 30, 2015 (in thousands): September 30, 2015 Assets Accounts receivable, net of allowances of $2,362 at September 30, 2015 $ 10,197 Inventories, net 11,011 Deferred tax assets — current 137 Prepaid expenses and other current assets 3,967 Assets held for sale — current 25,312 Property, plant and equipment, net 10,123 Goodwill 60,145 Finite-lived intangible assets, net 40,344 Other non-current assets 2,423 Assets held for sale — non-current $ 113,035 Liabilities Current portion of capital lease obligations $ 6 Accounts payable 3,584 Accrued expenses and other current liabilities 5,246 Liabilities related to assets held for sale — current 8,836 Capital lease obligations, net of current portion 10 Deferred tax liabilities — non-current 8,497 Other long-term liabilities 1,096 Liabilities related to assets held for sale — non-current $ 9,603 Sale of TechLab Equity Method Investment As of September 30, 2015, we continued to meet the held for sale criteria with respect to our 49% investment in TechLab. We intend to use all or a portion of the proceeds from any sale of this investment to repay a portion of our outstanding indebtedness. Accordingly, we have classified our investment in TechLab, with a value of approximately $13.0 million, in assets held for sale – non-current in our consolidated balance sheet as of September 30, 2015. See Note 19 (b).
Alere Accountable Care Solutions, LLC ("ACS") [Member]
Assets Held for Sale	(2) Discontinued Operations On October 10, 2014, we completed the sale of our ACS subsidiary to ACS Acquisition, LLC (the “Purchaser”), pursuant to the terms of a Membership Interest Purchase Agreement with the Purchaser and Sumit Nagpal. In connection with the sale of ACS, we also agreed to sell our subsidiary Wellogic ME FZ – LLC (“Wellogic,” together with ACS, the “ACS Companies”) to the Purchaser, which we completed in June 2015. The ACS Companies were included in our patient self-testing segment prior to the sale. The purchase price for the ACS Companies consisted of cash proceeds of $2.00 at closing and contingent consideration of up to an aggregate of $7.0 million, consisting of (i) payments based on the gross revenues of the ACS Companies, (ii) payments to be made in connection with financing transactions by the Purchaser or the ACS Companies and (iii) payments to be made in connection with a sale by the Purchaser of the ACS Companies. In connection with the sale, we agreed to reimburse the Purchaser for up to $750,000 of the Purchaser’s and the ACS Companies’ transitional expenses. We accounted for our divestiture of the ACS Companies in accordance with ASC 205, Presentation of Financial Statements. On January 9, 2015, we completed the sale of our health management business to OptumHealth Care Solutions for a purchase price of approximately $600.1 million, subject to a customary post-closing working capital adjustment. We used the net cash proceeds of the sale to repay $575.0 million in aggregate principal amount of outstanding indebtedness under our prior senior secured credit facility. In September 2015, we agreed to pay a post-closing working capital adjustment of $0.25 million, which was accrued on our consolidated balance sheet as of September 30, 2015. We accounted for our divestiture of the health management business in accordance with Accounting Standards Update, or ASU, No. 2014-08. The following assets and liabilities associated with the health management business have been segregated and classified as assets held for sale and liabilities related to assets held for sale, as appropriate, in the consolidated balance sheet as of December 31, 2014 (in thousands): December 31, 2014 Assets Cash and cash equivalents $ 23,300 Restricted cash 361 Accounts receivable, net of allowances of $5,882 at December 31, 2014 50,902 Inventories, net 1,656 Deferred tax assets – current 6,939 Prepaid expenses and other current assets 3,857 Property, plant and equipment, net 57,595 Goodwill 82,665 Finite-lived intangible assets, net 82,428 Deferred tax assets – non-current 3,347 Other non-current assets 2,465 Total assets held for sale $ 315,515 Liabilities Current portion of capital lease obligations $ 799 Accounts payable 5,654 Accrued expenses and other current liabilities 32,822 Capital lease obligations, net of current portion 365 Deferred tax liabilities – non-current 27,453 Other long-term liabilities 11,750 Total liabilities related to assets held for sale $ 78,843 The following summarized financial information related to the businesses of the ACS Companies and the health management business has been segregated from continuing operations and has been reported as discontinued operations in our consolidated statements of operations. The results of the health management business are included in the nine months ended September 30, 2015, given our January 9, 2015 divestiture of this business. The results of the ACS Companies are included in the three and nine months ended September 30, 2014, given our October 31, 2014 divestiture of this business. The results are as follows (in thousands): Three Months Nine Months Ended September 30, 2014 2015 2014 Net revenue $ 89,501 $ 7,373 $ 271,668 Cost of net revenue (54,314 ) (4,413 ) (155,976 ) Sales and marketing (14,270 ) (996 ) (43,152 ) General and administrative (16,924 ) (5,001 ) (75,244 ) Interest expense (149 ) (9 ) (400 ) Other income (expense), net (117 ) 160 (1,189 ) Gain on disposal — 366,191 — Income (loss) from discontinued operations before provision (benefit) for income taxes 3,727 363,305 (4,293 ) Provision (benefit) for income taxes 18,128 146,528 (211 ) Income (loss) from discontinued operations, net of tax $ (14,401 ) $ 216,777 $ (4,082 )

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(3) Cash and Cash Equivalents We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At September 30, 2015, our cash equivalents consisted of money market funds.

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Restricted Cash	(4) Restricted Cash We had restricted cash of $475.0 million and $37.6 million as of September 30, 2015 and December 31, 2014, respectively. Of the $475.0 million as of September 30, 2015, $425.9 million consisted of a deposit of funds with a trustee in connection with the satisfaction and discharge of our obligations associated with the October 1, 2015 redemption of our 8.625% senior subordinated notes due 2018, or the 8.625% notes. As of September 30, 2015, $44.1 million of our restricted cash was classified as non-concurrent on our consolidated balance sheet, as it secures a foreign bank loan arrangement that we entered into during the third quarter of 2015 and, under the terms of the loan agreement, is required to remain on deposit for two years unless the loan is terminated prior to maturity.

Inventories, Net

Inventories, Net	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories, Net	(5) Inventories, Net Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): September 30, 2015 December 31, 2014 Raw materials $ 132,808 $ 122,886 Work-in-process 73,629 82,724 Finished goods 155,789 159,555 $ 362,226 $ 365,165

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	(6) Stock-based Compensation We recorded stock-based compensation expense in our consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of net revenue $ 326 $ 291 $ 866 $ 863 Research and development 287 280 893 (340 ) Sales and marketing 1,260 920 3,605 2,778 General and administrative 5,444 1,678 14,232 4,450 7,317 3,169 19,596 7,751 Benefit for income taxes (472 ) (878 ) (5,374 ) (2,001 ) $ 6,845 $ 2,291 $ 14,222 $ 5,750 In connection with the departure of three of our senior executives, we recorded a reversal of stock-based compensation expense in the amount of $5.6 million during the second quarter of 2014 as a result of the termination of their stock option awards upon their departure. Of the $5.6 million reversal, $2.2 million was recorded through research and development expense and $3.4 million through general and administrative expense.

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Income (Loss) per Common Share	(7) Net Income (Loss) per Common Share The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Basic and diluted net income (loss) per common share: Numerator Income (loss) from continuing operations $ 5,501 $ (84,289 ) $ 18,215 $ (145,080 ) Preferred stock dividends (5,367 ) (5,367 ) (15,926 ) (15,926 ) Income (loss) from continuing operations attributable to common shares 134 (89,656 ) 2,289 (161,006 ) Less: Net income (loss) attributable to non-controlling interest (61 ) (306 ) 386 (136 ) Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries 195 (89,350 ) 1,903 (160,870 ) Income (loss) from discontinued operations — (14,401 ) 216,777 (4,082 ) Net income (loss) available to common stockholders $ 195 $ (103,751 ) $ 218,680 $ (164,952 ) Denominator Weighted-average common shares outstanding — basic 85,895 83,115 85,141 82,719 Weighted-average common shares outstanding — diluted 87,169 83,115 86,279 82,719 Basic net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ 0.00 $ (1.08 ) $ 0.02 $ (1.94 ) Income (loss) from discontinued operations — (0.17 ) 2.55 (0.05 ) Basic net income (loss) per common share $ 0.00 $ (1.25 ) $ 2.57 $ (1.99 ) Diluted net income (loss) per common share: Income (loss) from continuing operations $ 0.00 $ (1.08 ) $ 0.02 $ (1.94 ) Income (loss) from discontinuing operations — (0.17 ) 2.51 (0.05 ) Diluted net income (loss) per common share $ 0.00 $ (1.25 ) $ 2.53 $ (1.99 ) The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share for our continuing operations because the inclusion thereof would be antidilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Denominator Options to purchase shares of common stock 7,062 7,687 7,062 7,687 Warrants — 4 4 4 Conversion shares related to 3% convertible senior subordinated notes 3,411 3,411 3,411 3,411 Conversion shares related to subordinated convertible promissory notes 27 27 27 27 Conversion shares related to Series B convertible preferred stock 10,239 10,239 10,239 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 20,739 21,368 20,743 21,368

Stockholders' Equity and Non-co

Stockholders' Equity and Non-controlling Interests	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity and Non-controlling Interests	(8) Stockholders’ Equity and Non-controlling Interests (a) Preferred Stock For each of the three and nine months ended September 30, 2015 and 2014, Series B preferred stock dividends amounted to $5.3 million and $15.9 million, respectively, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the respective periods. As of September 30, 2015, $5.3 million of Series B preferred stock dividends was accrued. As of October 15, 2015, payments have been made covering all dividend periods through September 30, 2015. The Series B preferred stock dividends for the three and nine months ended September 30, 2015 and 2014 were paid in cash. (b) Changes in Stockholders’ Equity and Non-controlling Interests A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the nine months ended September 30, 2015 and 2014 is provided below (in thousands): Nine Months Ended September 30, 2015 2014 Total Non- Total Total Non- Total Equity, beginning of period $ 1,905,599 $ 4,146 $ 1,909,745 $ 2,073,256 $ 4,882 $ 2,078,138 Issuance of common stock under employee compensation plans 76,457 — 76,457 35,593 — 35,593 Tax withholdings related to net share settlement of restricted stock units (2,240 ) — (2,240 ) — — — Preferred stock dividends (15,970 ) — (15,970 ) (15,970 ) — (15,970 ) Stock-based compensation expense 19,596 — 19,596 7,751 — 7,751 Excess tax benefits on exercised stock options 3,153 — 3,153 (6,302 ) — (6,302 ) Net income (loss) 234,606 386 234,992 (149,026 ) (136 ) (149,162 ) Total other comprehensive loss (123,765 ) — (123,765 ) (69,478 ) — (69,478 ) Equity, end of period $ 2,097,436 $ 4,532 $ 2,101,968 $ 1,875,824 $ 4,746 $ 1,880,570

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Combinations	(9) Business Combinations We account for acquisitions using the acquisition method and include the financial results of the acquired company in our consolidated financial statements from the date of acquisition. Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Net assets acquired are initially recorded at their fair value on a preliminary basis and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. During the three and nine months ended September 30, 2015, we expensed acquisition-related costs of $0.2 million and $0.3 million, respectively, in general and administrative expense. During the three and nine months ended September 30, 2014, we expensed acquisition-related costs of $0.3 million and $0.7 million, respectively, in general and administrative expense. Acquisitions in 2015 US Diagnostics On July 10, 2015, we acquired substantially all of the assets of US Diagnostics, Inc., or USD, located in Huntsville, Alabama, a provider of instant on-site drug testing products designed for quick and accurate drug test results. The aggregate purchase price was approximately $60.1 million and was paid in cash. The operating results of USD are included in our professional diagnostics reporting unit and business segment. Our consolidated statements of operations for each of the three and nine months ended September 30, 2015 included revenue totaling approximately $5.0 million related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $29.4 million, which is deductible for tax purposes. A summary of the preliminary fair values of the net assets acquired from USD is as follows (in thousands): Total Current assets $ 4,652 Property, plant and equipment 182 Goodwill 29,422 Intangible assets 27,200 Total assets acquired $ 61,456 Current liabilities $ 1,321 Total liabilities assumed $ 1,321 Net assets acquired $ 60,135 Cash paid $ 60,135 The following are the intangible assets acquired in connection with the USD acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands): Total Weighted- Trademarks $ 1,600 3.0 - 13.0 years Customer relationships 24,900 13.0 years Non-compete agreements 700 2.0 years Total intangible assets $ 27,200

Restructuring Plans

Restructuring Plans	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring Plans	(10) Restructuring Plans The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Statement of Operations Caption 2015 2014 2015 2014 Cost of net revenue $ 522 $ 5,654 $ 2,921 $ 6,707 Research and development 18 5,457 667 8,488 Sales and marketing 619 1,019 2,572 7,420 General and administrative 1,105 5,167 5,227 14,460 Total operating expenses 2,264 17,297 11,387 37,075 Interest expense, including amortization of original issue discounts and deferred financing costs 6 9 19 32 Total charges $ 2,270 $ 17,306 $ 11,406 $ 37,107 (a) 2014 Restructuring Plans In 2014, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our global sales and marketing, information technology and research and development groups, as well as closing certain business locations in Europe and Asia. The following table summarizes the restructuring activities related to our 2014 restructuring plans for the three and nine months ended September 30, 2015 and 2014 and since inception of these restructuring plans (in thousands): Three Months Ended Nine Months Ended Since Professional Diagnostics 2015 2014 2015 2014 Severance-related costs $ 1,322 $ 5,827 $ 5,385 $ 17,923 $ 33,192 Facility and transition costs 132 1,713 3,045 1,894 6,505 Cash charges 1,454 7,540 8,430 19,817 39,697 Fixed asset and inventory impairments 124 6,322 579 8,402 11,530 Total charges $ 1,578 $ 13,862 $ 9,009 $ 28,219 $ 51,227 Three Months Ended Nine Months Ended Since Corporate and Other 2015 2014 2015 2014 Severance-related costs $ 686 $ 199 $ 1,297 $ 2,399 $ 4,198 Facility and transition costs — 2,979 (13 ) 4,929 11,322 Total cash charges $ 686 $ 3,178 $ 1,284 $ 7,328 $ 15,520 We anticipate incurring approximately $4.2 million in additional costs under our 2014 restructuring plans related to our professional diagnostics business segment, primarily related to the closure of our manufacturing facility in Israel. We may develop additional restructuring plans over the remainder of 2015. As of September 30, 2015, $4.1 million in severance and transition costs arising under our 2014 restructuring plans remain unpaid. (b) Restructuring Plans Prior to 2014 In 2013, management developed cost reduction plans within our professional diagnostics segment impacting businesses in our United States, Europe and Asia Pacific regions. In 2011, management developed plans to consolidate operating activities among certain of our United States, European and Asia Pacific subsidiaries, including transferring the manufacturing of our Panbio products from Australia to our Standard Diagnostics facility in South Korea and eliminating redundant costs among our Axis-Shield subsidiaries. Additionally, in 2008, management developed and initiated plans to transition the Cholestech business to our San Diego, California facility. The following table summarizes the restructuring activities within our professional diagnostics business segment related to our active 2013, 2011 and 2008 restructuring plans for the three and nine months ended September 30, 2015 and 2014 and since inception of these plans (in thousands): Three Months Ended Nine Months Ended Since Professional Diagnostics 2015 2014 2015 2014 Severance-related costs $ — $ 56 $ — $ 990 $ 26,926 Facility and transition costs — 201 1,094 537 11,574 Other exit costs 6 9 19 33 817 Cash charges 6 266 1,113 1,560 39,317 Fixed asset and inventory impairments — — — — 6,776 Intangible asset impairments — — — — 686 Other non-cash charges — — — — 64 Total charges $ 6 $ 266 $ 1,113 $ 1,560 $ 46,843 We do not anticipate incurring significant additional costs under these plans related to our professional diagnostics business segment. As of September 30, 2015, $1.1 million in cash charges remain unpaid under our restructuring plans prior to 2014, primarily related to facility lease obligations, which are anticipated to continue through 2020. (c) Restructuring Reserves The following table summarizes our restructuring reserves related to the restructuring plans described above, of which $4.6 million is included in accrued expenses and other current liabilities and $0.7 million is included in other long-term liabilities on our consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2014 $ 4,590 $ 9,868 $ 290 $ 14,748 Cash charges 6,288 4,387 19 10,694 Payments (8,460 ) (11,166 ) (99 ) (19,725 ) Currency adjustments (156 ) (303 ) — (459 ) Balance, September 30, 2015 $ 2,262 $ 2,786 $ 210 $ 5,258

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	(11) Debt We had the following long-term debt balances outstanding as of the dates indicated (in thousands): September 30, 2015 December 31, 2014 A term loans (1) $ 638,823 $ — B term loans (1) 1,044,842 — Prior credit facility—A term loans (2) — 785,938 Prior credit facility—B term loans (3) — 1,330,810 Prior credit facility—Revolving loans — 127,000 7.25% Senior notes 450,000 450,000 6.5% Senior subordinated notes 425,000 425,000 6.375% Senior subordinated notes 425,000 — 8.625% Senior subordinated notes (4) 400,000 400,000 3% Convertible senior subordinated notes (5) 150,000 150,000 Other lines of credit 1,052 684 Other 57,033 40,828 3,591,750 3,710,260 Less: Short-term debt and current portion of long-term debt (604,092 ) (88,875 ) Long-term debt $ 2,987,658 $ 3,621,385 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) Included “A” term loans and “Delayed Draw” term loans under our prior credit facility. (3) Included term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans under our prior credit facility, which term loans had been converted into and consolidated with the “B” term loans under our prior credit facility. (4) On October 1, 2015, we redeemed the entire $400.0 million principal amount of the 8.625% senior subordinated notes pursuant to the notice of optional redemption that we issued to the holders thereof on June 24, 2015. The redemption price was equal to 102.156% of the principal amount of such notes plus accrued and unpaid interest from April 1, 2015 to (but excluding) October 1, 2015. The balance of such notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheet as of September 30, 2015, as the redemption notice created an obligation to pay the balance on October 1, 2015. The redemption was funded with $425.9 million of cash that had been held in an irrevocable trust with the trustee for such notes, which is classified as restricted cash on our consolidated balance sheet as of September 30, 2015. Upon settlement of the redemption on October 1, 2015, we satisfied and discharged all of our obligations with respect to such notes. (5) The balance of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheet as of September 30, 2015, as these notes mature on May 15, 2016. In connection with our debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Secured credit facility (1) $ 18,161 $ — $ 20,763 $ — Prior credit facility (2) (3) — 24,985 49,437 74,606 7.25% Senior notes 8,524 8,525 25,573 25,574 6.5% Senior subordinated notes 7,274 7,180 21,741 21,534 6.375% Senior subordinated notes 7,002 — 7,544 — 8.625% Senior subordinated notes 9,273 9,271 27,820 27,819 3% Senior subordinated convertible notes 1,246 1,246 3,738 3,738 Other 853 1,125 1,642 3,005 $ 52,333 $ 52,332 $ 158,258 $ 156,276 (1) Includes “A” term loans, “B” term loans and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three and nine months ended September 30, 2015, the amounts include $0.4 million and $1.1 million, respectively, related to the amortization of fees paid for certain debt modifications. For the three and nine months ended September 30, 2014, the amounts include $0.4 million and $1.1 million, respectively, related to the amortization of fees paid for certain debt modifications. (3) Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility during the nine months ended September 30, 2015. (a) Secured Credit Facility On June 18, 2015, we entered into a Credit Agreement, or secured credit facility, with certain lenders, Goldman Sachs Bank USA, as B term loan administrative agent, General Electric Capital Corporation as pro rata administrative agent and collateral agent, and certain other agents and arrangers, and, along with certain of our subsidiaries, a related guaranty and security agreement. The secured credit facility provides for (i) term loans in the aggregate amount of $1.7 billion (consisting of “A” term loans in the aggregate principal amount of $650.0 million and “B” term loans in the aggregate principal amount of $1,050.0 million), all of which were drawn at closing, and (ii) subject to our continued compliance with the terms of the secured credit facility, a $250.0 million revolving line of credit (which revolving line of credit includes a $50.0 million sublimit for the issuance of letters of credit); no amount was drawn under the revolving credit facility at closing. We used approximately $1.68 billion of the proceeds of the term loans drawn at closing to repay in full all indebtedness outstanding under our prior credit facility, whereupon such agreement was terminated (as described below), and to pay various fees and expenses associated with the transactions contemplated by the secured credit facility. Subject to certain limits and restrictions, we may use the remaining proceeds of the term loans, the proceeds of any revolving credit loans and the proceeds of any incremental term loans (described below) or incremental revolving credit commitments (described below) to finance permitted acquisitions, to finance capital expenditures, to provide working capital and for other general corporate purposes. We must repay the “A” term loans in nineteen consecutive quarterly installments, beginning on September 30, 2015 and continuing through March 31, 2020, in the principal amount of $8,125,000 each, followed by a final installment on June 18, 2020, in the principal amount of $495,625,000. We must repay the “B” term loans in twenty-seven consecutive quarterly installments, beginning on September 30, 2015 and continuing through March 31, 2022, in the principal amount of $2,625,000 each, and a final installment on June 18, 2022, in the principal amount of $979,125,000. We may repay any future borrowings under the secured credit facility revolving line of credit at any time (without premium or penalty), but in no event later than June 18, 2020. We are required to make mandatory prepayments of the term loans and mandatory prepayments of any revolving credit loans in various amounts if we have Excess Cash Flow (as defined in the Credit Agreement, and commencing in respect of our fiscal year ending December 31, 2016), if we issue certain types of debt, if we make certain sales of assets outside the ordinary course of business above certain thresholds or if we suffer certain property loss events above certain thresholds. We may make optional prepayments of the term loans from time to time without any premium or penalty, subject to a customary 101% “soft call” protection with respect to certain prepayments or a repricing event with respect to the “B” term loans occurring on or before December 18, 2015. The “A” term loans and any borrowings under the revolving credit facility bear interest at a rate per annum per annum per annum Subject to our pro forma We must comply with various financial and non-financial covenants under the terms of the secured credit facility, which are set forth in the Credit Agreement. The primary financial covenant under the security credit facility consists of a maximum consolidated secured net leverage ratio applicable only to the “A” term loans and the revolving credit loans. The non-financial covenants are subject to certain important exceptions and qualifications. The lenders under the secured credit facility are entitled to accelerate repayment of the loans and terminate the revolving credit commitments thereunder upon the occurrence of any of various events of default as described in the Credit Agreement. Borrowings under the secured credit facility are guaranteed by substantially all of our domestic subsidiaries (other than unrestricted subsidiaries and domestic subsidiaries of certain of our foreign subsidiaries) and are secured by the stock of substantially all of our domestic subsidiaries (other than unrestricted subsidiaries and domestic subsidiaries of certain of our foreign subsidiaries), portions of the stock of certain of our foreign subsidiaries, and substantially all of our and our guarantor subsidiaries’ other property and assets, in each case subject to various exceptions. As of September 30, 2015, aggregate borrowings under the secured credit facility amounted to $1.7 billion, consisting of “A” term loans in the aggregate principal amount of $638.8 million (giving effect to the installment repayment due on such date) and “B” term loans in the aggregate principal amount of $1,044.8 million (giving effect to the installment repayment due on such date). As of September 30, 2015, we were in compliance with the maximum consolidated secured net leverage ratio under the secured credit facility. (b) Prior Credit Facility In connection with entering into the secured credit facility on June 18, 2015, we repaid in full all outstanding indebtedness under and terminated our prior Credit Agreement, or prior credit facility, dated as of June 30, 2011, as amended from time to time, with certain lenders, General Electric Capital Corporation as administrative agent and collateral agent, and certain other agents and arrangers, and certain related guaranty and security agreements. The aggregate outstanding principal amount of the loans repaid under our prior credit facility in connection with the termination thereof was approximately $1.65 billion. We assessed this repayment on a lender-by-lender basis in order to differentiate the portion constituting an extinguishment and the portion constituting a modification. Unamortized deferred financing fees relating to the extinguished portion of the prior credit facility debt were expensed, and the portion relating to modifications of the prior credit facility debt were carried forward to be amortized over the contractual life of the new secured credit facility. (c) 6.375% Senior Subordinated Notes On June 24, 2015, we sold a total of $425.0 million aggregate principal amount of 6.375% senior subordinated notes due 2023, or the 6.375% senior subordinated notes, in a private placement to initial purchasers, who agreed to resell the notes only to qualified institutional buyers and to persons outside the United States; we sold the 6.375% senior subordinated notes at an initial offering price of 100%. Net proceeds from this offering amounted to $417.3 million, which were net of the initial purchasers’ discount and offering expenses totaling approximately $7.7 million. The 6.375% senior subordinated notes were issued under a supplemental indenture dated June 24, 2015, or the 6.375% Indenture. The 6.375% senior subordinated notes accrue interest at the rate of 6.375% per annum We may, at our option, redeem the 6.375% senior subordinated notes, in whole or part, at any time (which may be more than once) on or after July 1, 2018 by paying the principal amount of the notes being redeemed plus a declining premium, plus accrued and unpaid interest to (but excluding) the redemption date. The premium declines from 4.781% during the twelve months on and after July 1, 2018, to 3.188% during the twelve months on and after July 1, 2019, to 1.594% during the twelve months on and after July 1, 2020, to zero on and after July 1, 2021. In addition, at any time (which may be more than once) prior to July 1, 2018, we may, at our option, redeem up to 35% of the aggregate principal amount of the 6.375% senior subordinated notes with money that we raise in certain qualifying equity offerings, so long as (i) we pay 106.375% of the principal amount of the notes being redeemed, plus accrued and unpaid interest to (but excluding) the redemption date; (ii) we redeem the 6.375% senior subordinated notes within 90 days of completing such equity offering; and (iii) at least 65% of the aggregate principal amount of the 6.375% senior subordinated notes remains outstanding afterwards. In addition, at any time (which may be more than once) prior to July 1, 2018, we may, at our option, redeem some or all of the 6.375% senior subordinated notes by paying the principal amount of the 6.375% senior subordinated notes being redeemed plus a make-whole premium, plus accrued and unpaid interest to (but excluding) the redemption date. If a change of control occurs, subject to specified conditions, we must give holders of the 6.375% senior subordinated notes an opportunity to sell their notes to us at a purchase price of 101% of the principal amount of the notes, plus accrued and unpaid interest to (but excluding) the date of the purchase. If we or our restricted subsidiaries engage in asset sales, we or they generally must either invest the net cash proceeds from such sales in our or their businesses within a specified period of time, repay senior indebtedness or make an offer to purchase a principal amount of the 6.375% senior subordinated notes equal to the excess net cash proceeds, subject to certain exceptions. The purchase price of the 6.375% senior subordinated notes would be 100% of their principal amount, plus accrued and unpaid interest. The 6.375% Indenture provides that we and our restricted subsidiaries must comply with various covenants, which are subject to certain important exceptions and qualifications, which are set forth in the 6.375% Indenture. At any time the 6.375% senior subordinated notes are rated investment grade, certain covenants will be suspended with respect to them. The 6.375% Indenture contains events of default entitling the trustee or the holders of the 6.375% senior subordinated notes to declare all amounts owed pursuant to the 6.375% senior subordinated notes immediately payable if any such event of default occurs. The 6.375% senior subordinated notes are our senior subordinated unsecured obligations, are subordinated in right of payment to all of our existing and future senior debt, including our borrowings under our secured credit facility and our 7.25% senior notes, and are equal in right of payment with all of our existing and future senior subordinated debt, including our 8.625% senior subordinated notes (our obligations in respect of which have been fully satisfied and discharged, as described below), our 6.5% senior subordinated notes and our 3% convertible senior subordinated notes. Our obligations under the 6.375% senior subordinated notes and the 6.375% Indenture are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated unsecured basis by certain of our domestic subsidiaries, and the obligations of such domestic subsidiaries under their guarantees are subordinated in right of payment to all of their existing and future senior debt and equal in right of payment to all of their existing and future senior subordinated debt. See Note 23 for guarantor financial information. (d) 8.625% Senior Subordinated Notes On June 24, 2015, we issued a notice of optional redemption to the holders of 8.625% notes that, on October 1, 2015 (the redemption date), we would redeem the entire principal amount of the 8.625% notes then outstanding at a redemption price equal to 102.156% of the principal amount of the 8.625% notes to be redeemed plus accrued and unpaid interest from April 1, 2015 to (but excluding) the redemption date, upon the terms set forth in the notice of optional redemption. The balance of the 8.625% notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheet as of September 30, 2015 as the redemption notice created an obligation to pay the balance on October 1, 2015. We transferred an amount equal to the net proceeds received from the 6.375% notes of $417.3 million plus additional cash of $8.6 million, or a total of $425.9 million, into an irrevocable trust, which was used to fund the redemption of the 8.625% notes on October 1, 2015. The $425.9 million is classified on our consolidated balance sheet as of September 30, 2015 as restricted cash. We redeemed the entire $400.0 million aggregate principal amount of the 8.625% notes on October 1, 2015 and, upon settlement of the redemption on that date, we satisfied and discharged all of our obligations with respect to the 8.625% notes.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	(12) Fair Value Measurements We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1— Level 2— Level 3— The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description September 30, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 157 $ 157 $ — $ — Total assets $ 157 $ 157 $ — $ — Liabilities: Contingent consideration obligations (1) $ 63,591 $ — $ — $ 63,591 Total liabilities $ 63,591 $ — $ — $ 63,591 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 259 $ 259 $ — $ — Total assets $ 259 $ 259 $ — $ — Liabilities: Contingent consideration obligations (1) $ 139,671 $ — $ — $ 139,671 Total liabilities $ 139,671 $ — $ — $ 139,671 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) for additional information on the valuation of our contingent consideration obligations. Changes in the fair value of our Level 3 contingent consideration obligations during the nine months ended September 30, 2015 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2014 $ 139,671 Payments (21,928 ) Present value accretion and adjustments (54,168 ) Foreign currency adjustments 16 Fair value of contingent consideration obligations, September 30, 2015 $ 63,591 At September 30, 2015 and December 31, 2014, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. The carrying amount and estimated fair value of our debt were both $3.6 billion at September 30, 2015. The carrying amount and estimated fair value of our debt were both $3.7 billion at December 31, 2014. The estimated fair value of our debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

Defined Benefit Pension Plan

Defined Benefit Pension Plan	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Defined Benefit Pension Plan	(13) Defined Benefit Pension Plan Our subsidiary in England, Unipath Ltd., has a defined benefit pension plan established for certain of its employees. The net periodic benefit costs are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Service cost $ — $ — $ — $ — Interest cost 234 202 694 604 Expected return on plan assets (240 ) (191 ) (712 ) (571 ) Amortization of prior service costs 344 111 1,019 333 Net periodic benefit cost $ 338 $ 122 $ 1,001 $ 366

Financial Information by Segmen

Financial Information by Segment	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Financial Information by Segment	(14) Financial Information by Segment Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. As a result of the sale of our health management business in January 2015, which was the largest component of our patient self-testing reporting segment, we no longer report our financial information in four operating segments. Our current reportable operating segments are professional diagnostics, consumer diagnostics, and corporate and other. The information below for the three and nine months ended September 30, 2014 has been retroactively adjusted to reflect this change in reporting segments. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and nine months ended September 30, 2015 and 2014 and as of September 30, 2015 and December 31, 2014 is as follows (in thousands): Professional Consumer Corporate Total Three Months Ended September 30, 2015: Net revenue $ 583,297 $ 18,747 $ — $ 602,044 Operating income (loss) $ 54,452 $ 1,038 $ (26,325 ) $ 29,165 Impairment and (gain) loss on dispositions, net $ 2,074 $ — $ — $ 2,074 Depreciation and amortization $ 83,817 $ 717 $ 1,966 $ 86,500 Restructuring charge $ 1,578 $ — $ 686 $ 2,264 Stock-based compensation $ — $ — $ 7,317 $ 7,317 Three Months Ended September 30, 2014: Net revenue $ 628,012 $ 21,198 $ — $ 649,210 Operating income (loss) $ 64,986 $ 3,742 $ (33,386 ) $ 35,342 Depreciation and amortization $ 80,366 $ 841 $ 1,917 $ 83,124 Restructuring charge $ 14,119 $ — $ 3,178 $ 17,297 Stock-based compensation $ — $ — $ 3,169 $ 3,169 Nine Months Ended September 30, 2015: Net revenue $ 1,773,993 $ 65,360 $ — $ 1,839,353 Operating income (loss) $ 219,544 $ 4,321 $ (75,456 ) $ 148,409 Professional Consumer Corporate Total Impairment and (gain) loss on dispositions, net $ 42,408 $ — $ — $ 42,408 Depreciation and amortization $ 226,383 $ 2,153 $ 4,975 $ 233,511 Restructuring charge $ 10,103 $ — $ 1,284 $ 11,387 Stock-based compensation $ — $ — $ 19,596 $ 19,596 Nine Months Ended September 30, 2014: Net revenue $ 1,856,629 $ 65,218 $ — $ 1,921,847 Operating income (loss) $ 129,446 $ 10,617 $ (75,474 ) $ 64,589 Impairment and (gain) loss on dispositions, net $ 638 $ — $ — $ 638 Depreciation and amortization $ 244,698 $ 2,604 $ 3,461 $ 250,763 Restructuring charge $ 29,747 $ — $ 7,328 $ 37,075 Stock-based compensation $ — $ — $ 7,751 $ 7,751 Assets: As of September 30, 2015 $ 5,749,115 $ 200,491 $ 624,559 $ 6,574,165 As of December 31, 2014 $ 6,323,944 $ 216,451 $ 138,561 $ 6,678,956 The following table summarizes our net product sales and services revenue from the professional diagnostics reporting segment by groups of similar products and services, along with license and royalty revenue, for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cardiometabolic $ 208,319 $ 208,248 $ 624,823 $ 631,452 Infectious disease 163,759 184,018 519,145 526,632 Toxicology 162,571 166,381 468,822 491,561 Other 45,349 65,183 147,512 190,986 Total professional diagnostics net product sales and services revenue 579,998 623,830 1,760,302 1,840,631 License and royalty revenue 3,299 4,182 13,691 15,998 Total professional diagnostics net revenue $ 583,297 $ 628,012 $ 1,773,993 $ 1,856,629

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	(15) Related Party Transactions (a) SPD Joint Venture In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiometabolic, diabetes and oral care fields. We account for our 50% interest in the joint venture under the equity method of accounting. We had a net receivable from SPD of $0.9 million as of September 30, 2015 and a net payable to SPD of $4.0 million as of December 31, 2014. Included in the $0.9 million receivable balance as of September 30, 2015 and the $4.0 million payable balance as of December 31, 2014 is approximately $1.5 million of costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $9.1 million and $10.9 million as of September 30, 2015 and December 31, 2014, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture have been classified as other receivables within prepaid and other current assets on our consolidated balance sheets in the amount of $7.4 million and $9.6 million as of September 30, 2015 and December 31, 2014, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $17.3 million and $58.5 million during the three and nine months ended September 30, 2015, respectively, and $19.6 million and $60.8 million during the three and nine months ended September 30, 2014, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.2 million and $0.8 million during the three and nine months ended September 30, 2015, respectively, and $0.3 million and $1.0 million during the three and nine months ended September 30, 2014, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our consolidated statements of operations. Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. As a result of these related transactions, we have recorded $10.0 million and $10.5 million of trade receivables which are included in accounts receivable on our consolidated balance sheets as of September 30, 2015 and December 31, 2014, respectively, and $37.6 million and $34.8 million of trade accounts payable which are included in accounts payable on our consolidated balance sheets as of September 30, 2015 and December 31, 2014, respectively. The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption September 30, 2015 December 31, 2014 Accounts receivable, net of allowances $ 10,049 $ 10,465 Prepaid expenses and other current assets $ 7,404 $ 9,635 Deferred financing costs, net, and other non-current assets $ 9,100 $ 10,875 Accounts payable $ 37,608 $ 34,816 As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. During the three months ended September 30, 2015, SPD appealed the district court’s injunction with respect to sales and advertising of such product, which was based on a finding that SPD violated certain laws with respect to the advertising of such product. The appellate court has issued a stay of the injunction, pending the outcome of the appeal. A ruling on the appeal is expected in the near future. Given the status of this matter, the ultimate resolution of this matter is not known at this time, nor is the potential impact it may have on SPD or us, including whether such resolution of the litigation or any damages imposed by the court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations. In addition, consumers who have used SPD products might make claims or initiate additional litigation against SPD or us on similar grounds as those at issue in the litigation described above in this paragraph. (b) Entrustment Loan Arrangement with SPD Shanghai Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23 million (approximately $3.7 million at September 30, 2015), in order to finance the latter’s short-term working capital needs, with the Royal Bank of Scotland (China) Co., Ltd. Shanghai Branch, or RBS. The agreement governs the setting up of an Entrustment Loan Account with RBS, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to RBS of amounts borrowed from RBS by SPD Shanghai. The Alere Shanghai RBS account is recorded as restricted cash on our balance sheet and amounted to $3.7 million at September 30, 2015.

Other Arrangements

Other Arrangements	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Arrangements	(16) Other Arrangements In September 2014, we entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, to develop diagnostic countermeasures for pandemic influenza. Under the terms of the 3.5 year contract, BARDA will provide up to $12.9 million to us to support the development of a rapid, molecular, low-cost influenza diagnostic device with PCR-like performance at the point-of-care. The project is designed to help support future preparedness and medical response to an influenza pandemic. Funding from BARDA is subject to successful completion of various interim feasibility and development milestones as defined in the agreement. For the three and nine months ended September 30, 2015, we had incurred $0.8 million and $2.2 million, respectively, of qualified expenditures under the contract, for which we had received cash reimbursement from BARDA in the amount of $0.6 million and $1.6 million, respectively, and $0.6 million was recorded as a receivable as of that date. Reimbursements of qualified expenditures under this contract are recorded as a reduction of our related qualified research and development expenditures. In February 2013, we entered into an agreement with the Bill and Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of a validated, low-cost, nucleic-acid assay for clinical Tuberculosis, or TB, detection and drug-resistance test cartridges and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provides for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. Funding under the Gates Loan Agreement will be used in connection with the purchase of equipment for an automated high-throughput manufacturing line and other uses as necessary for the manufacture of the TB and HIV-related products. All loans under the Gates Loan Agreement are evidenced by promissory notes that we have executed and delivered to the Gates Foundation, bear interest at the rate of 3% per annum and, except to the extent earlier repaid by us, mature and are required to be repaid in full on December 31, 2019. As of September 30, 2015, we had borrowed no amounts under the Gates Loan Agreement. As of September 30, 2015, we had received approximately $19.7 million in grant-related funding from the Gates Foundation, which was recorded as restricted cash and deferred grant funding. As of September 30, 2015, we had deferred grant funding of $0.3 million relating to our agreement with the Gates Foundation, which is classified within accrued expenses and other current liabilities on our consolidated balance sheet. As qualified expenditures are incurred under the terms of the grant, we use the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three and nine months ended September 30, 2015, we incurred $0.3 million and $3.9 million, and for the three and nine months ended September 30, 2014, we incurred $2.5 million and $7.0 million, respectively, of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(17) Commitments and Contingencies (a) Acquisition-related Contingent Consideration Obligations We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our consolidated statements of operations. Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria. During the nine months ended September 30, 2015, we revised the fair value estimates for the milestones related to the TwistDx, Inc. contingent consideration obligation to incorporate increased probabilities of success as a result of positive technological developments of related technology and regulatory approvals of certain related platforms. Accordingly, we recorded a charge associated with the resulting change in fair value of $16.2 million, which is included in general and administrative expense in our accompanying consolidated statement of operations. During the nine months ended September 30, 2015, we revised the fair value estimates for certain of the milestones related to the Epocal contingent consideration obligation to reflect decreased probabilities of success and delayed cash inflows and clinical development timelines due to a strategic shift and re-allocation of research and development resources. As a result, we recorded a net reduction to expense during the nine months ended September 30, 2015 of $31.5 million, which is included in general and administrative expense in our accompanying consolidated statement of operations. Additionally, one milestone was achieved during the three months ended September 30, 2015, resulting in a cash payment of $10.0 million during the quarter. Furthermore, during the nine months ended September 30, 2015, we recorded a reduction to expense of $24.5 million associated with a change in the fair value of our Ionian contingent consideration obligation to zero, which was included in the general and administrative expense in our accompanying consolidated statement of operations. The remaining product development milestones under the agreement were not achieved by the July 2015 deadline and, as such, the probability of making the related milestone payments was reduced to zero. The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 103,247 2015 – 2025 (5) $ 51,900 $ 41,100 $ 5,377 Ionian Technologies, Inc. (2) July 12, 2010 $ 24,500 $ — — — 24,500 — DiagnosisOne, Inc. (3) July 31, 2012 $ 22,300 $ — — — 21,000 6,000 Epocal (4) February 1, 2013 $ 75,000 $ 55,500 2015 – 2018 5,700 47,200 10,000 Other Various $ 30,373 $ — (6) 2015 – 2016 5,991 5,871 551 $ 63,591 $ 139,671 $ 21,928 (1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025. (2) The earn-out period under the terms of the acquisition agreement expired July 12, 2015. (3) On March 25, 2015, the remaining earn-out was settled for $6.0 million, of which $4.5 million was paid on March 27, 2015 and $1.5 million was paid on April 3, 2015. (4) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (5) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (6) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric. (b) Legal Proceedings U.S. Securities and Exchange Commission Subpoena On August 28, 2015, we received a subpoena from the U.S. Securities and Exchange Commission, or SEC, which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third-parties (including distributors and foreign government officials) in Africa relating to sales to government entities. We are unable to predict when this matter will be resolved or what further action, if any, SEC may take in connection with it. Matters Relating to our San Diego Facility On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in an FDA Form 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. We submitted evidence of our completion of most of the actions we committed to in response to the FDA Form 483 and warning letter. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this most recent inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection do not meet the threshold of significance requiring regulatory action, but that formal close-out of the October 2012 warning letter could not occur until after a future inspection. In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the OIG and have provided documents in response to the OIG under the subpoena. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. Matters Related to Theft of Laptop In September 2012, a password-protected laptop containing personally identifiable information of approximately 116,000 patients was stolen from an employee of Alere Home Monitoring, or AHM. On January 24, 2013, a class action complaint was filed in the U.S. District Court for the Northern District of California against AHM, asserting claims for damages and other relief under California state law, including under California’s Confidentiality of Medical Information Act, or CMIA, arising out of this theft. On October 7, 2014, the class action was dismissed with leave to amend the complaint. On October 28, 2014, an amended complaint was filed, and on November 17, 2014 AHM responded by filing another motion to dismiss. On February 23, 2015, AHM’s motion to dismiss was granted in part, but denied as to the plaintiffs’ amended CMIA claims. The parties have settled this litigation and, in connection with such settlement, we have paid a nominal amount to the plaintiffs. Claims in the Ordinary Course and Other Matters We are not a party to any other pending legal proceedings that we currently believe could have a material adverse impact on our business. However, on December 10, 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. We are cooperating with this investigation and are providing documents. Our subsidiary, Arriva Medical, LLC, or Arriva, is also in the process of responding to a Civil Investigative Demand, or CID, from the United States Attorney for the Middle District of Tennessee in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The CID requests patient and billing records. We are cooperating with the investigation of the United States Attorney for the Middle District of Tennessee and are providing documents responsive to the CID. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on Alere or its subsidiaries. We have received, from time to time, additional subpoenas and requests for information from the Department of Justice, other federal government agencies and state attorney generals and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. Our diabetes, toxicology and patient self-testing business areas are subject to audit and claims for reimbursement brought in the ordinary course by private third-party payers, including health insurers, Zone Program Integrity Contractors, or ZPICs, and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support or claims relating to the medical necessity of certain testing and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error. Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, and we expect that this will continue to be the case in the future. Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could materially impact our business, results of operations, financial condition, the consolidated statements of operations and cash flows.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	(18) Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we must adopt by the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. Please also see Note 4, Summary of Significant Accounting Policies Recently Issued Standards In August 2015, the FASB issued Accounting Standards Update, or ASU, No. 2015-15, Interest—Imputation of Interest (Subtopic 835-30)—Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting), Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, Revenue from Contracts with Customers In July 2015, the FASB issued ASU No. 2015-12, Plan Accounting: Defined Benefit Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962), and Health and Welfare Benefit Plans (Topic 965)—I. Fully Benefit-Responsive Investment Contracts, II. Plan Investment Disclosures, and III. Measurement Date Practical Expedient, In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers Recently Adopted Standards None.

Equity Investments

Equity Investments	9 Months Ended
	Sep. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Investments	(19) Equity Investments We account for the results from our equity investments under the equity method of accounting in accordance with Accounting Standards Codification, or ASC, 323, Investments — Equity Method and Joint Ventures, (a) SPD We recorded earnings of $5.3 million and $9.5 million during the three and nine months ended September 30, 2015, respectively, and earnings of $5.9 million and $12.8 million during the three and nine months ended September 30, 2014, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods. During the nine months ended September 30, 2015, we received $12.1 million in cash from SPD as a return of capital. (b) TechLab We own 49% of TechLab, Inc., or TechLab, a privately-held developer, manufacturer and distributor of rapid non-invasive intestinal diagnostics tests in the areas of intestinal inflammation, antibiotic-associated diarrhea and parasitology. We recorded losses of $0.3 million and earnings of $1.0 million during the three and nine months ended September 30, 2015, respectively, and earnings of $0.9 million and $1.6 million during the three and nine months ended September 30, 2014, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. During the nine months ended September 30, 2015, we received $2.2 million in cash from TechLab as a return of capital. Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Combined Condensed Results of Operations: 2015 2014 2015 2014 Net revenue $ 56,303 $ 65,397 $ 157,319 $ 155,533 Gross profit $ 43,538 $ 40,268 $ 111,368 $ 120,680 Net income after taxes $ 15,735 $ 12,834 $ 26,831 $ 27,992 Combined Condensed Balance Sheet: September 30, 2015 December 31, 2014 Current assets $ 83,646 $ 90,546 Non-current assets 31,413 33,697 Total assets $ 115,059 $ 124,243 Current liabilities $ 32,352 $ 35,954 Non-current liabilities 5,487 5,884 Total liabilities $ 37,839 $ 41,838 As of September 30, 2015, we continued to meet the held for sale criteria with respect to our 49% investment in TechLab. We intend to use all or a portion of the proceeds from any sale of this investment to repay a portion of our outstanding indebtedness. Accordingly, we have classified our investment in TechLab in assets held for sale – non-current in our consolidated balance sheet as of September 30, 2015.

Direct-response Advertising

Direct-response Advertising	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Direct-response Advertising	(21) Direct-response Advertising In connection with our mail order diabetes business, we incurred direct-response advertising and associated costs in connection with the placement of advertisements. Direct-response advertising and associated costs payable to third parties for the period presented are capitalized and amortized to selling, general and administrative expenses on an accelerated basis in the month following the broadcast month. Management assesses the realizability of the amounts of direct-response advertising costs reported as assets at each balance sheet date by comparing the net carrying value of capitalized advertising to the net present value of estimated future orders expected to result directly from such advertising. Advertising that does not meet the capitalization requirements is expensed in the current period. Any change in existing accounting rules or a business change that impacts expected future orders or that shortens the period over which such net future benefits are estimated to be realized could result in accelerated charges against our earnings. In addition, new or different marketing initiatives that may not qualify for direct-response advertising could result in accelerated charges against our earnings. Whether there is an impairment loss or not is determined by comparing the net carrying value of direct-response advertising costs capitalized as assets at each balance sheet date to the probable remaining future orders expected to result directly from such advertising. If the net carrying value of the assets exceeds the probable remaining future orders expected to result directly from such assets, an impairment loss is recognized in an amount equal to that excess. Future benefits are determined by calculating the net present value of estimated future orders per cost pool. Net present value is calculated based upon the value of an order multiplied by the estimated future orders. Estimate of future orders is determined based on historical customer reorder rates. We perform the impairment test of our direct-response advertising asset in the quarter following the advertising broadcast quarter.

Provision (Benefit) for Income

Provision (Benefit) for Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Provision (Benefit) for Income Taxes	(22) Provision (Benefit) for Income Taxes The provision for income taxes decreased by $84.4 million to an $18.9 million benefit for the three months ended September 30, 2015 from a $65.5 million provision for the three months ended September 30, 2014. The effective tax rate for the three months ended September 30, 2015 and 2014 was 102.7% and (261.2)%, respectively. Our effective tax rate is based on our year-to-date results and projected income (loss) and is primarily impacted by changes in the geographical mix of consolidated pre-tax income (loss), as well as items that are accounted for discretely in the quarter. The change in the effective tax rate for the three months ended September 30, 2015, as compared to the three months ended September 30, 2014, is primarily a result of a discrete tax benefit, including correcting adjustments related to prior periods recorded during the three months ended September 30, 2015 with respect to a net tax benefit related to U.S. taxes on foreign earnings and a release of uncertain tax positions, as well as a discrete tax provision recorded during the three months ended September 30, 2014 related to the establishment of a valuation allowance against deferred tax assets associated with our U.S. foreign tax credit carryforwards. The provision for income taxes decreased by $79.3 million to a $10.0 million benefit for the nine months ended September 30, 2015 from a $69.3 million provision for the nine months ended September 30, 2014. The effective tax rate for the nine months ended September 30, 2015 and 2014 was 473.5% and (77.4)%, respectively. The change in the effective tax rate for the nine months ended September 30, 2015, as compared to the nine months ended September 30, 2014, is primarily a result of a discrete tax benefit, including correcting adjustments related to prior periods recorded during the nine months ended September 30, 2015 with respect to a net tax benefit related to U.S. taxes on foreign earnings and a release of uncertain tax positions, as well as a discrete tax provision recorded during the nine months ended September 30, 2014 related to the establishment of a valuation allowance against deferred tax assets associated with our U.S. foreign tax credit carryforwards.

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	(23) Guarantor Financial Information Our 7.25% senior notes due 2018, our 6.5% senior subordinated notes due 2020 and our 6.375% senior subordinated notes due 2023 are guaranteed, and before their redemption on October 1, 2015, our 8.625% senior subordinated notes due 2018 were guaranteed, by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of September 30, 2015 and December 31, 2014, the related statements of operations and comprehensive income (loss) for each of the three and nine months ended September 30, 2015 and 2014, respectively, and the statements of cash flows for the nine months ended September 30, 2015 and 2014, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting. We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost-sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. For comparative purposes, certain amounts for prior periods have been reclassified to conform to the current period classification. Prior periods have been presented on a basis that is consistent with the current period, giving retrospective effect to the impact of discontinued operations. CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 227,939 $ 309,871 $ (67,406 ) $ 470,404 Services revenue — 115,829 12,512 — 128,341 Net product sales and services revenue — 343,768 322,383 (67,406 ) 598,745 License and royalty revenue — 3,246 4,648 (4,595 ) 3,299 Net revenue — 347,014 327,031 (72,001 ) 602,044 Cost of net product sales 2,090 124,853 175,836 (56,724 ) 246,055 Cost of services revenue 74 81,549 6,951 (8,771 ) 79,803 Cost of net product sales and services revenue 2,164 206,402 182,787 (65,495 ) 325,858 Cost of license and royalty revenue (19 ) 401 5,350 (4,595 ) 1,137 Cost of net revenue 2,145 206,803 188,137 (70,090 ) 326,995 Gross profit (loss) (2,145 ) 140,211 138,894 (1,911 ) 275,049 Operating expenses: Research and development 5,670 15,015 15,326 — 36,011 Sales and marketing 1,335 53,863 51,295 — 106,493 General and administrative 22,960 34,816 43,530 — 101,306 Impairment and (gain) loss on dispositions, net 150 85 1,839 — 2,074 Operating income (loss) (32,260 ) 36,432 26,904 (1,911 ) 29,165 Interest expense, including amortization of original issue discounts and deferred financing costs (51,705 ) (2,613 ) (4,999 ) 6,984 (52,333 ) Other income (expense), net 4,224 3,921 3,584 (6,984 ) 4,745 Income (loss) from continuing operations before provision (benefit) for income taxes (79,741 ) 37,740 25,489 (1,911 ) (18,423 ) Provision (benefit) for income taxes 78,041 (33,431 ) (63,534 ) — (18,924 ) Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax (157,782 ) 71,171 89,023 (1,911 ) 501 Equity in earnings of subsidiaries, net of tax 163,647 — — (163,647 ) — Equity earnings (losses) of unconsolidated entities, net of tax (364 ) — 5,348 16 5,000 Net income 5,501 71,171 94,371 (165,542 ) 5,501 Less: Net loss attributable to non-controlling interests — — (61 ) — (61 ) Net income attributable to Alere Inc. and Subsidiaries 5,501 71,171 94,432 (165,542 ) 5,562 Preferred stock dividends (5,367 ) — — — (5,367 ) Net income (loss) available to common stockholders $ 134 $ 71,171 $ 94,432 $ (165,542 ) $ 195 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2014 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Eliminations Consolidated Net product sales $ — $ 214,585 $ 353,817 $ (60,777 ) $ 507,625 Services revenue — 122,045 15,358 — 137,403 Net product sales and services revenue — 336,630 369,175 (60,777 ) 645,028 License and royalty revenue — 2,993 3,663 (2,474 ) 4,182 Net revenue — 339,623 372,838 (63,251 ) 649,210 Cost of net product sales 912 118,241 204,983 (52,886 ) 271,250 Cost of services revenue 71 74,441 8,448 (7,858 ) 75,102 Cost of net product sales and services revenue 983 192,682 213,431 (60,744 ) 346,352 Cost of license and royalty revenue 28 55 3,627 (2,474 ) 1,236 Cost of net revenue 1,011 192,737 217,058 (63,218 ) 347,588 Gross profit (loss) (1,011 ) 146,886 155,780 (33 ) 301,622 Operating expenses: Research and development 7,256 15,318 16,152 — 38,726 Sales and marketing 1,265 54,422 67,073 — 122,760 General and administrative 33,549 30,323 40,922 — 104,794 Operating income (loss) (43,081 ) 46,823 31,633 (33 ) 35,342 Interest expense, including amortization of original issue discounts and deferred financing costs (51,589 ) (4,420 ) (4,512 ) 8,189 (52,332 ) Other income (expense), net 4,706 4,835 (9,438 ) (8,190 ) (8,087 ) Income (loss) from continuing operations before provision for income taxes (89,964 ) 47,238 17,683 (34 ) (25,077 ) Provision for income taxes 42,727 13,657 9,140 (35 ) 65,489 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (132,691 ) 33,581 8,543 1 (90,566 ) Equity in earnings of subsidiaries, net of tax 49,642 210 — (49,852 ) — Equity earnings of unconsolidated entities, net of tax 560 — 5,779 (62 ) 6,277 Income (loss) from continuing operations (82,489 ) 33,791 14,322 (49,913 ) (84,289 ) Income (loss) from discontinued operations, net of tax (16,201 ) (20,615 ) 22,415 — (14,401 ) Net income (loss) (98,690 ) 13,176 36,737 (49,913 ) (98,690 ) Less: Net loss attributable to non-controlling interests — — (306 ) — (306 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (98,690 ) 13,176 37,043 (49,913 ) (98,384 ) Preferred stock dividends (5,367 ) — — — (5,367 ) Net income (loss) available to common stockholders $ (104,057 ) $ 13,176 $ 37,043 $ (49,913 ) $ (103,751 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Subsidiaries Eliminations Consolidated Net product sales $ — $ 657,751 $ 983,131 $ (194,045 ) $ 1,446,837 Services revenue — 338,869 39,956 — 378,825 Net product sales and services revenue — 996,620 1,023,087 (194,045 ) 1,825,662 License and royalty revenue — 9,676 14,721 (10,706 ) 13,691 Net revenue — 1,006,296 1,037,808 (204,751 ) 1,839,353 Cost of net product sales 2,923 358,983 550,081 (168,810 ) 743,177 Cost of services revenue 204 233,470 22,823 (24,360 ) 232,137 Cost of net product sales and services revenue 3,127 592,453 572,904 (193,170 ) 975,314 Cost of license and royalty revenue (40 ) 1,619 13,558 (10,706 ) 4,431 Cost of net revenue 3,087 594,072 586,462 (203,876 ) 979,745 Gross profit (loss) (3,087 ) 412,224 451,346 (875 ) 859,608 Operating expenses: Research and development 11,213 43,927 36,085 — 91,225 Sales and marketing 4,165 159,191 159,400 — 322,756 General and administrative 67,873 123,874 63,063 — 254,810 Impairment and (gain) loss on dispositions, net 81,051 (8,719 ) (29,924 ) — 42,408 Operating income (loss) (167,389 ) 93,951 222,722 (875 ) 148,409 Interest expense, including amortization of original issue discounts and deferred financing costs (156,889 ) (8,958 ) (13,744 ) 21,333 (158,258 ) Other income (expense), net 11,467 12,796 4,805 (21,333 ) 7,735 Income (loss) from continuing operations before provision (benefit) for income taxes (312,811 ) 97,789 213,783 (875 ) (2,114 ) Provision (benefit) for income taxes 41,068 (20,334 ) (31,051 ) 308 (10,009 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (353,879 ) 118,123 244,834 (1,183 ) 7,895 Equity in earnings of subsidiaries, net of tax 369,200 — — (369,200 ) — Equity earnings of unconsolidated entities, net of tax 982 — 9,340 (2 ) 10,320 Income from continuing operations 16,303 118,123 254,174 (370,385 ) 18,215 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income 234,992 116,211 254,174 (370,385 ) 234,992 Less: Net income attributable to non-controlling interests — — 386 — 386 Net income attributable to Alere Inc. and Subsidiaries 234,992 116,211 253,788 (370,385 ) 234,606 Preferred stock dividends (15,926 ) — — — (15,926 ) Net income available to common stockholders $ 219,066 $ 116,211 $ 253,788 $ (370,385 ) $ 218,680 CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 623,208 $ 1,048,212 $ (172,118 ) $ 1,499,302 Services revenue — 355,132 51,415 — 406,547 Net product sales and services revenue — 978,340 1,099,627 (172,118 ) 1,905,849 License and royalty revenue — 10,312 14,683 (8,997 ) 15,998 Net revenue — 988,652 1,114,310 (181,115 ) 1,921,847 Cost of net product sales 2,291 348,701 591,778 (156,852 ) 785,918 Cost of services revenue 214 216,142 25,123 (20,123 ) 221,356 Cost of net product sales and services revenue 2,505 564,843 616,901 (176,975 ) 1,007,274 Cost of license and royalty revenue 28 194 12,675 (8,997 ) 3,900 Cost of net revenue 2,533 565,037 629,576 (185,972 ) 1,011,174 Gross profit (loss) (2,533 ) 423,615 484,734 4,857 910,673 Operating expenses: Research and development 20,034 45,753 49,068 — 114,855 Sales and marketing 6,329 175,536 209,740 — 391,605 General and administrative 78,257 112,850 147,879 — 338,986 Loss on disposition — 638 — — 638 Operating income (loss) (107,153 ) 88,838 78,047 4,857 64,589 Interest expense, including amortization of original issue discounts and deferred financing costs (154,232 ) (14,933 ) (13,646 ) 26,535 (156,276 ) Other income (expense), net 11,823 15,867 1,068 (26,594 ) 2,164 Income (loss) from continuing operations before provision (benefit) for income taxes (249,562 ) 89,772 65,469 4,798 (89,523 ) Provision (benefit) for income taxes (2,566 ) 42,896 27,319 1,624 69,273 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (246,996 ) 46,876 38,150 3,174 (158,796 ) Equity in earnings of subsidiaries, net of tax 97,307 442 — (97,749 ) — Equity earnings of unconsolidated entities, net of tax 1,387 — 12,516 (187 ) 13,716 Income (loss) from continuing operations (148,302 ) 47,318 50,666 (94,762 ) (145,080 ) Income (loss) from discontinued operations, net of tax (860 ) (26,418 ) 23,196 — (4,082 ) Net income (loss) (149,162 ) 20,900 73,862 (94,762 ) (149,162 ) Less: Net loss attributable to non-controlling interests — — (136 ) — (136 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (149,162 ) 20,900 73,998 (94,762 ) (149,026 ) Preferred stock dividends (15,926 ) — — — (15,926 ) Net income (loss) available to common stockholders $ (165,088 ) $ 20,900 $ 73,998 $ (94,762 ) $ (164,952 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non - Eliminations Consolidated Net income $ 5,501 $ 71,171 $ 94,371 $ (165,542 ) $ 5,501 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (748 ) (570 ) (87,314 ) (180 ) (88,812 ) Minimum pension liability adjustment — — 419 — 419 Other comprehensive loss, before tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Income tax benefit related to items of other comprehensive income — — — — — Other comprehensive loss, net of tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Comprehensive income 4,753 70,601 7,476 (165,722 ) (82,892 ) Less: Comprehensive loss attributable to non-controlling interests — — (61 ) — (61 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 4,753 $ 70,601 $ 7,537 $ (165,722 ) $ (82,831 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2014 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net income (loss) $ (98,690 ) $ 13,176 $ 36,737 $ (49,913 ) $ (98,690 ) Other comprehensive income, before tax: Changes in cumulative translation adjustment (383 ) (104 ) (95,936 ) (2 ) (96,425 ) Unrealized gains on hedging instruments — — 7 — 7 Minimum pension liability adjustment — — 481 — 481 Other comprehensive income, before tax (383 ) (104 ) (95,448 ) (2 ) (95,937 ) Income tax provision (benefit) related to items of other comprehensive loss — — — — — Other comprehensive income, net of tax (383 ) (104 ) (95,448 ) (2 ) (95,937 ) Comprehensive income (loss) (99,073 ) 13,072 (58,711 ) (49,915 ) (194,627 ) Less: Comprehensive loss attributable to non-controlling interests — — (306 ) — (306 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (99,073 ) $ 13,072 $ (58,405 ) $ (49,915 ) $ (194,321 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non - Eliminations Consolidated Net income $ 234,992 $ 116,211 $ 254,174 $ (370,385 ) $ 234,992 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (1,208 ) (453 ) (120,587 ) (180 ) (122,428 ) Minimum pension liability adjustment — — (1,337 ) — (1,337 ) Other comprehensive loss, before tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Income tax benefit related to items of other comprehensive income (loss) — — — — — Other comprehensive loss, net of tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Comprehensive income 233,784 115,758 132,250 (370,565 ) 111,227 Less: Comprehensive income attributable to non-controlling interests — — 386 — 386 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 233,784 $ 115,758 $ 131,864 $ (370,565 ) $ 110,841 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net income (loss) $ (149,162 ) $ 20,900 $ 73,862 $ (94,762 ) $ (149,162 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment (137 ) (178 ) (69,633 ) (2 ) (69,950 ) Unrealized losses on available for sale securities — (17 ) — — (17 ) Unrealized gains on hedging instruments — — 21 — 21 Minimum pension liability adjustment — — 468 — 468 Other comprehensive income (loss), before tax (137 ) (195 ) (69,144 ) (2 ) (69,478 ) Income tax benefit related to items of other comprehensive loss — — — — — Other comprehensive income (loss), net of tax (137 ) (195 ) (69,144 ) (2 ) (69,478 ) Comprehensive income (loss) (149,299 ) 20,705 4,718 (94,764 ) (218,640 ) Less: Comprehensive loss attributable to non-controlling interests — — (136 ) — (136 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (149,299 ) $ 20,705 $ 4,854 $ (94,764 ) $ (218,504 ) CONSOLIDATING BALANCE SHEET September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 142,996 $ 7,649 $ 328,736 $ — $ 479,381 Restricted cash 426,170 — 4,651 — 430,821 Marketable securities — 157 — — 157 Accounts receivable, net of allowances — 205,533 246,833 — 452,366 Inventories, net — 194,697 190,143 (22,614 ) 362,226 Deferred tax assets (39,530 ) 31,285 25,788 (2,119 ) 15,424 Prepaid expenses and other current assets 7,824 31,605 74,901 6,693 121,023 Assets held for sale — current — — 25,312 — 25,312 Intercompany receivables 642,439 762,656 81,594 (1,486,689 ) — Total current assets 1,179,899 1,233,582 977,958 (1,504,729 ) 1,886,710 Property, plant and equipment, net 31,011 229,347 185,403 (446 ) 445,315 Goodwill — 1,824,191 1,018,730 — 2,842,921 Other intangible assets with indefinite lives — 7,662 21,141 (59 ) 28,744 Finite-lived intangible assets, net 3,072 656,064 393,813 — 1,052,949 Restricted cash — — 44,148 — 44,148 Deferred financing costs, net and other non-current assets 44,098 3,716 15,734 (269 ) 63,279 Investments in subsidiaries 3,439,664 179,542 59,431 (3,678,637 ) — Investments in unconsolidated entities 503 14,765 44,640 13,974 73,882 Deferred tax assets — — 7,632 — 7,632 Non-current income tax receivable 2,537 — — — 2,537 Assets held for sale — non-current 13,013 — 113,035 — 126,048 Intercompany notes receivables 2,030,141 676,485 4,967 (2,711,593 ) — Total assets $ 6,743,938 $ 4,825,354 $ 2,886,632 $ (7,881,759 ) $ 6,574,165 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 601,712 $ — $ 2,380 $ — $ 604,092 Current portion of capital lease obligations — 1,404 2,101 — 3,505 Accounts payable 14,000 87,659 92,587 — 194,246 Accrued expenses and other current liabilities (394,578 ) 612,572 95,013 2,329 315,336 Liabilities related to assets held for sale — current — — 8,836 — 8,836 Intercompany payables 1,042,991 263,528 180,170 (1,486,689 ) — Total current liabilities 1,264,125 965,163 381,087 (1,484,360 ) 1,126,015 Long-term liabilities: Long-term debt, net of current portion 2,940,664 — 46,994 — 2,987,658 Capital lease obligations, net of current portion — 2,001 4,269 — 6,270 Deferred tax liabilities (70,862 ) 214,277 63,954 82 207,451 Other long-term liabilities 37,984 62,242 35,243 (269 ) 135,200 Liabilities related to assets held for sale — non-current — — 9,603 — 9,603 Intercompany notes payables 474,591 1,189,716 1,047,286 (2,711,593 ) — Total long-term liabilities 3,382,377 1,468,236 1,207,349 (2,711,780 ) 3,346,182 Total stockholders’ equity 2,097,436 2,391,955 1,293,664 (3,685,619 ) 2,097,436 Non-controlling interests — — 4,532 — 4,532 Total equity 2,097,436 2,391,955 1,298,196 (3,685,619 ) 2,101,968 Total liabilities and equity $ 6,743,938 $ 4,825,354 $ 2,886,632 $ (7,881,759 ) $ 6,574,165 CONSOLIDATING BALANCE SHEET December 31, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 2,149 $ 69,154 $ 307,158 $ — $ 378,461 Restricted cash 5,012 — 32,559 — 37,571 Marketable securities — 259 — — 259 Accounts receivable, net of allowances — 192,775 273,331 — 466,106 Inventories, net — 191,323 195,606 (21,764 ) 365,165 Deferred tax assets 36,347 44,961 31,265 — 112,573 Prepaid expenses and other current assets 9,800 31,410 88,695 2,508 132,413 Assets held for sale – current 1,361 284,369 29,785 — 315,515 Intercompany receivables 404,990 888,688 55,923 (1,349,601 ) — Total current assets 459,659 1,702,939 1,014,322 (1,368,857 ) 1,808,063 Property, plant and equipment, net 30,547 218,613 204,188 222 453,570 Goodwill — 1,795,663 1,131,003 — 2,926,666 Other intangible assets with indefinite lives — 9,287 34,422 (58 ) 43,651 Finite-lived intangible assets, net 6,104 742,760 527,580 — 1,276,444 Deferred financing costs, net and other non-current assets 40,992 5,334 21,541 (35 ) 67,832 Investments in subsidiaries 3,740,004 179,315 58,067 (3,977,386 ) — Investments in unconsolidated entities 13,987 14,765 49,608 13,333 91,693 Deferred tax assets — — 8,569 — 8,569 Non-current income tax receivable 2,468 — — — 2,468 Intercompany notes receivables 2,028,701 649,444 46,676 (2,724,821 ) — Total assets $ 6,322,462 $ 5,318,120 $ 3,095,976 $ (8,057,602 ) $ 6,678,956 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 61,700 $ 2 $ 27,173 $ — $ 88,875 Current portion of capital lease obligations — 1,045 3,196 — 4,241 Accounts payable 21,402 81,741 110,449 — 213,592 Accrued expenses and other current liabilities (536,286 ) 663,221 248,604 (45 ) 375,494 Liabilities related to assets held for sale – current 1,094 77,749 — — 78,843 Intercompany payables 902,576 198,788 248,237 (1,349,601 ) — Total current liabilities 450,486 1,022,546 637,659 (1,349,646 ) 761,045 Long-term liabilities: Long-term debt, net of current portion 3,615,759 — 5,626 — 3,621,385 Capital lease obligations, net of current portion — 4,097 6,463 — 10,560 Deferred tax liabilities (107,844 ) 252,944 69,457 82 214,639 Other long-term liabilities 42,762 46,865 71,988 (33 ) 161,582 Intercompany notes payables 415,700 1,276,245 1,032,876 (2,724,821 ) — Total long-term liabilities 3,966,377 1,580,151 1,186,410 (2,724,772 ) 4,008,166 Total stockholders’ equity 1,905,599 2,715,423 1,267,761 (3,983,184 ) 1,905,599 Non-controlling interests — — 4,146 — 4,146 Total equity 1,905,599 2,715,423 1,271,907 (3,983,184 ) 1,909,745 Total liabilities and equity $ 6,322,462 $ 5,318,120 $ 3,095,976 $ (8,057,602 ) $ 6,678,956 CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 234,992 $ 116,211 $ 254,174 $ (370,385 ) $ 234,992 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income from continuing operations 16,303 118,123 254,174 (370,385 ) 18,215 Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (369,200 ) — — 369,200 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 10,542 19 66 — 10,627 Depreciation and amortization 7,891 128,363 97,250 7 233,511 Non-cash stock-based compensation expense 10,600 4,251 4,745 — 19,596 Impairment of inventory — 133 68 — 201 Impairment of long-lived assets — 64 314 — 378 Loss on sale of fixed assets — 2,768 505 — 3,273 Equity earnings of unconsolidated entities, net of tax (982 ) — (9,340 ) 2 (10,320 ) Deferred income taxes (8,686 ) (30,699 ) (7,794 ) 439 (46,740 ) Loss related to impairment and net (gain) loss on dispositions 81,051 (8,804 ) (29,924 ) — 42,323 Loss on extinguishment of debt 3,480 — — — 3,480 Other non-cash items (376 ) (1,054 ) (3,358 ) 3 (4,785 ) Non-cash change in fair value of contingent purchase price consideration (33,667 ) 16,616 (34,860 ) — (51,911 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (11,370 ) 101 — (11,269 ) Inventories, net — (31,079 ) (27,909 ) 207 (58,781 ) Prepaid expenses and other current assets 3,098 (28,016 ) 4,917 5,048 (14,953 ) Accounts payable (7,435 ) 777 (9,342 ) — (16,000 ) Accrued expenses and other current liabilities 111,628 33,995 (103,572 ) (6,859 ) 35,192 Other non-current liabilities (16,364 ) 740 5,389 1,445 (8,790 ) Cash paid for contingent purchase price consideration (6,302 ) — (13 ) — (6,315 ) Intercompany payable (receivable) 334,642 (246,828 ) (87,992 ) 178 — Net cash provided by (used in) continuing operations 136,223 (52,001 ) 53,425 (715 ) 136,932 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities 136,223 (51,683 ) 53,425 (715 ) 137,250 Cash Flows from Investing Activities: Increase in restricted cash (421,157 ) — (17,608 ) — (438,765 ) Purchases of property, plant and equipment (7,514 ) (25,915 ) (36,093 ) 1,575 (67,947 ) Proceeds from sale of property, plant and equipment — 846 1,554 (914 ) 1,486 Cash received from (used in) disposition, net of cash divested 593,066 (8,722 ) 2,281 — 586,625 Cash paid for business acquisitions, net of cash acquired (60,135 ) — — — (60,135 ) Cash received from sales of (paid for purchase of) marketable securities — 103 (4 ) — 99 Cash received from equity method investments 2,205 — 12,092 — 14,297 (Increase) decrease in other assets 368 497 (219 ) 235 881 Net cash provided by (used in) continuing operations 106,833 (33,191 ) (37,997 ) 896 36,541 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 106,833 (33,400 ) (37,997 ) 896 36,332 Cash Flows from Financing Activities: Cash paid for financing costs (15,836 ) — (217 ) — (16,053 ) Cash paid for contingent purchase price consideration (13,640 ) — (439 ) — (14,079 ) Cash paid for dividends (15,970 ) — — — (15,970 ) Proceeds from issuance of common stock, net of issuance costs 76,457 — — — 76,457 Proceeds from issuance of long-term debt 2,119,125 — 42,897 — 2,162,022 Payments on short-term debt — — (25,584 ) — (25,584 ) Payments on long-term debt (2,128,625 ) — (540 ) — (2,129,165 ) Net proceeds (payments) under revolving credit facilities (127,000 ) — 397 — (126,603 ) Excess tax benefits on exercised stock options 3,264 2,531 307 — 6,102 Principal payments on capital lease obligations — (1,876 ) (2,463 ) — (4,339 ) Net cash provided by (used in) continuing operations (102,225 ) 655 14,358 — (87,212 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash provided by (used in) financing activities (102,225 ) 579 14,358 — (87,288 ) Foreign exchange effect on cash and cash equivalents 16 (301 ) (8,208 ) (181 ) (8,674 ) Net increase (decrease) in cash and cash equivalents 140,847 (84,805 ) 21,578 — 77,620 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 142,996 $ 7,649 $ 328,736 $ — $ 479,381 CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (149,162 ) $ 20,900 $ 73,862 $ (94,762 ) $ (149,162 ) Income (loss) from discontinued operations, net of tax (860 ) (26,418 ) 23,196 — (4,082 ) Income (loss) from continuing operations (148,302 ) 47,318 50,666 (94,762 ) (145,080 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Equity in earnings of subsidiaries, net of tax (97,307 ) (442 ) — 97,749 — Tax benefit related to discontinued operations.. — 9,594 — — 9,594 Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 11,575 32 217 — 11,824 Depreciation and amortization 4,417 132,134 114,218 (6 ) 250,763 Non-cash stock-based compensation expense 1,629 3,463 2,659 — 7,751 Impairment of inventory — — 1,536 — 1,536 Impairment of long-lived assets 1,573 (446 ) 5,739 — 6,866 Loss on sale of fixed assets — 4,078 601 — 4,679 Equity earnings of unconsolidated entities, net of tax (1,387 ) — (12,516 ) 187 (13,716 ) Deferred income taxes 28,030 (12,863 ) (7,320 ) 1,710 9,557 Net loss on dispositions — 638 — — 638 Other non-cash items (988 ) 2,845 1,826 — 3,683 Non-cash change in fair value of contingent purchase price consideration 3,326 9,903 3,813 — 17,042 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (10,136 ) 22,779 — 12,643 Inventories, net — (22,521 ) (3,495 ) (4,430 ) (30,446 ) Prepaid expenses and other current assets 503,712 (444,782 ) (65,138 ) (2,438 ) (8,646 ) Accounts payable 2,637 25,738 10,312 — 38,687 Accrued expenses and other current liabilities (535,345 ) 482,572 46,020 (1,748 ) (8,501 ) Other non-current liabilities 23,922 2,392 2,806 4,101 33,221 Cash paid for contingent purchase price consideration (20,966 ) — (112 ) — (21,078 ) Intercompany payable (receivable) 277,206 (197,561 ) (79,645 ) — — Net cash provided by continuing operations 53,732 31,956 94,966 363 181,017 Net cash provided by discontinued operations 7,881 26,474 62 — 34,417 Net cash provided by operating activities 61,613 58,430 95,028 363 215,434 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 135 (100 ) (3,262 ) — (3,227 ) Purchases of property, plant and equipment (16,611 ) (29,141 ) (29,805 ) 2,522 (73,035 ) Proceeds from sale of property, plant and equipment 268 778 2,853 (2,755 ) 1,144 Cash received from disposition, net of cash divested — 1,081 4,373 — 5,454 Cash paid for business acquisitions, net of cash acquired (75 ) — — — (75 ) Cash received from sales of marketable securities — 43 4 — 47 Cash received from (paid for) investments 477 (278 ) (1 ) — 198 Proceeds from sale of equity investment — — 9,526 — 9,526 (Increase) decrease in other assets (104 ) 140 931 57 1,024 Net cash used in continuing operations (15,910 ) (27,477 ) (15,381 ) (176 ) (58,944 ) Net cash used in discontinued operations — (8,853 ) — — (8,853 ) Net cash used in investing activities (15,910 ) (36,330 ) (15,381 ) (176 ) (67,797 ) Cash Flows from Financing Activities: Cash paid for financing costs (5 ) — — — (5 ) Cash paid for contingent purchase price consideration (23,285 ) — (323 ) — (23,608 ) Cash paid for dividends (15,970 ) — — — (15,970 ) Proceeds from issuance of common stock, net of issuance costs 35,593 — — — 35,593 Proceeds from issuance of short-term debt — — 806 — 806 Proceeds from issuance of long-term debt — — 41 — 41 Payments on long-term debt (45,000 ) (223 ) (2,079 ) — (47,302 ) Net proceeds under revolving credit facilities — — 498 — 498 Excess tax benefits on exercised stock options 65 282 68 — 415 Principal payments on capital lease obligations — (2,246 ) (2,393 ) — (4,639 ) Net cash used in continuing operations (48,602 ) (2,187 ) (3,382 ) — (54,171 ) Net cash used in discontinued operations (579 ) (496 ) — — (1,075 ) Net cash used in financing activities (49,181 ) (2,683 ) (3,382 ) — (55,246 ) Foreign exchange effect on cash and cash equivalents 146 (179 ) (9,225 ) (187 ) (9,445 ) Net increase (decrease) in cash and cash equivalents (3,332 ) 19,238 67,040 — 82,946 Cash and cash equivalents, beginning of period-continuing operations 14,801 78,976 261,654 — 355,431 Cash and cash equivalents, beginning of period-discontinued operations — 6,476 1 — 6,477 Cash and cash equivalents, end of period 11,469 104,690 328,695 — 444,854 Less: Cash and cash equivalents of discontinued operations, end of period.. — 13,502 1 — 13,503 Cash and cash equivalents of continuing operations at end of period $ 11,469 $ 91,188 $ 328,694 $ — $ 431,351

Impairment of Acquired In-proce

Impairment of Acquired In-process Research and Development (IPR&D)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of Acquired In-process Research and Development (IPR&D)	(25) Impairment of Acquired In-process Research and Development (IPR&D) Acquired IPR&D represents the fair value assigned to research and development assets that we acquired as part of business combinations and that have not been completed at the date of acquisition. The acquired IPR&D is capitalized as an intangible asset and tested for impairment at least annually until commercialization, after which time the IPR&D is amortized over its estimated useful life. We utilize a discounted probable future cash flow model on a project-by-project basis to value acquired IPR&D. Significant assumptions used in the model include the period in which material net cash inflows from significant projects are expected to commence, anticipated material changes from historical pricing, margins and expense levels and an appropriate risk adjusted discount rate applied to the project’s cash flows. During the three months ended September 30, 2015, we performed our annual impairment test of our IPR&D assets, and in certain cases found them to be impaired, due to a combination of suspending certain projects to allow for resource allocation to other projects considered more strategic and delays in completing other projects, which resulted in a decrease in estimated future revenues expected to be achieved upon completion. During the three months ended September 30, 2015, we recorded impairment charges totaling $7.4 million to reduce the carrying values of these assets to zero, which was the estimated fair value of each such asset.

Basis of Presentation of Fina30

Basis of Presentation of Financial Information (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2014 included information and footnotes necessary for such presentation and were included in Amendment No. 2 to our Annual Report on Form 10-K/A filed with the Securities and Exchange Commission, or SEC, on May 28, 2015. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2014. As a result of the sale of our health management business in January 2015, which was the largest component of our patient self-testing reporting segment, we no longer report our financial information in four operating segments. Our current reportable operating segments are professional diagnostics, consumer diagnostics and corporate and other. Financial information by segment for the three and nine months ended September 30, 2014 has been retroactively adjusted to reflect this change in reporting segments. Certain reclassifications of prior period amounts have been made in order to retrospectively present discontinued operations. These reclassifications have no effect on net income or equity. During the three and nine months ended September 30, 2015, we recorded $8.0 million of tax-related correcting adjustments related to prior periods which consisted of a $6.6 million net tax benefit related to U.S. taxes on foreign earnings and a $1.4 million tax benefit associated with a release of uncertain tax positions. We considered the correcting adjustments to be immaterial to both the prior periods and the current year financial statements Certain amounts presented may not recalculate directly, due to rounding.
Cash and Cash Equivalents	(3) Cash and Cash Equivalents We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At September 30, 2015, our cash equivalents consisted of money market funds.

Assets Held for Sale (Tables)

Assets Held for Sale (Tables)	9 Months Ended
	Sep. 30, 2015
Summarized Financial Information Related to ACS Companies and Health Management Business	The following summarized financial information related to the businesses of the ACS Companies and the health management business has been segregated from continuing operations and has been reported as discontinued operations in our consolidated statements of operations. The results of the health management business are included in the nine months ended September 30, 2015, given our January 9, 2015 divestiture of this business. The results of the ACS Companies are included in the three and nine months ended September 30, 2014, given our October 31, 2014 divestiture of this business. The results are as follows (in thousands): Three Months Nine Months Ended September 30, 2014 2015 2014 Net revenue $ 89,501 $ 7,373 $ 271,668 Cost of net revenue (54,314 ) (4,413 ) (155,976 ) Sales and marketing (14,270 ) (996 ) (43,152 ) General and administrative (16,924 ) (5,001 ) (75,244 ) Interest expense (149 ) (9 ) (400 ) Other income (expense), net (117 ) 160 (1,189 ) Gain on disposal — 366,191 — Income (loss) from discontinued operations before provision (benefit) for income taxes 3,727 363,305 (4,293 ) Provision (benefit) for income taxes 18,128 146,528 (211 ) Income (loss) from discontinued operations, net of tax $ (14,401 ) $ 216,777 $ (4,082 )
Health Management Business [Member]
Schedule of Assets and Liabilities Associated with Business Segregated and Classified as Assets Held for Sale and Liabilities	We accounted for our divestiture of the health management business in accordance with Accounting Standards Update, or ASU, No. 2014-08. The following assets and liabilities associated with the health management business have been segregated and classified as assets held for sale and liabilities related to assets held for sale, as appropriate, in the consolidated balance sheet as of December 31, 2014 (in thousands): December 31, 2014 Assets Cash and cash equivalents $ 23,300 Restricted cash 361 Accounts receivable, net of allowances of $5,882 at December 31, 2014 50,902 Inventories, net 1,656 Deferred tax assets – current 6,939 Prepaid expenses and other current assets 3,857 Property, plant and equipment, net 57,595 Goodwill 82,665 Finite-lived intangible assets, net 82,428 Deferred tax assets – non-current 3,347 Other non-current assets 2,465 Total assets held for sale $ 315,515 Liabilities Current portion of capital lease obligations $ 799 Accounts payable 5,654 Accrued expenses and other current liabilities 32,822 Capital lease obligations, net of current portion 365 Deferred tax liabilities – non-current 27,453 Other long-term liabilities 11,750 Total liabilities related to assets held for sale $ 78,843
BBI Business [Member]
Schedule of Assets and Liabilities Associated with Business Segregated and Classified as Assets Held for Sale and Liabilities	The following assets and liabilities associated with our BBI business have been segregated and classified as assets held for sale and liabilities related to assets held for sale, as appropriate, on our consolidated balance sheet as of September 30, 2015 (in thousands): September 30, 2015 Assets Accounts receivable, net of allowances of $2,362 at September 30, 2015 $ 10,197 Inventories, net 11,011 Deferred tax assets — current 137 Prepaid expenses and other current assets 3,967 Assets held for sale — current 25,312 Property, plant and equipment, net 10,123 Goodwill 60,145 Finite-lived intangible assets, net 40,344 Other non-current assets 2,423 Assets held for sale — non-current $ 113,035 Liabilities Current portion of capital lease obligations $ 6 Accounts payable 3,584 Accrued expenses and other current liabilities 5,246 Liabilities related to assets held for sale — current 8,836 Capital lease obligations, net of current portion 10 Deferred tax liabilities — non-current 8,497 Other long-term liabilities 1,096 Liabilities related to assets held for sale — non-current $ 9,603

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories are Stated at Lower of Cost (First In, First Out) or Market	Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): September 30, 2015 December 31, 2014 Raw materials $ 132,808 $ 122,886 Work-in-process 73,629 82,724 Finished goods 155,789 159,555 $ 362,226 $ 365,165

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	We recorded stock-based compensation expense in our consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of net revenue $ 326 $ 291 $ 866 $ 863 Research and development 287 280 893 (340 ) Sales and marketing 1,260 920 3,605 2,778 General and administrative 5,444 1,678 14,232 4,450 7,317 3,169 19,596 7,751 Benefit for income taxes (472 ) (878 ) (5,374 ) (2,001 ) $ 6,845 $ 2,291 $ 14,222 $ 5,750

Net Income (Loss) per Common 34

Net Income (Loss) per Common Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Common Share	The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Basic and diluted net income (loss) per common share: Numerator Income (loss) from continuing operations $ 5,501 $ (84,289 ) $ 18,215 $ (145,080 ) Preferred stock dividends (5,367 ) (5,367 ) (15,926 ) (15,926 ) Income (loss) from continuing operations attributable to common shares 134 (89,656 ) 2,289 (161,006 ) Less: Net income (loss) attributable to non-controlling interest (61 ) (306 ) 386 (136 ) Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries 195 (89,350 ) 1,903 (160,870 ) Income (loss) from discontinued operations — (14,401 ) 216,777 (4,082 ) Net income (loss) available to common stockholders $ 195 $ (103,751 ) $ 218,680 $ (164,952 ) Denominator Weighted-average common shares outstanding — basic 85,895 83,115 85,141 82,719 Weighted-average common shares outstanding — diluted 87,169 83,115 86,279 82,719 Basic net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ 0.00 $ (1.08 ) $ 0.02 $ (1.94 ) Income (loss) from discontinued operations — (0.17 ) 2.55 (0.05 ) Basic net income (loss) per common share $ 0.00 $ (1.25 ) $ 2.57 $ (1.99 ) Diluted net income (loss) per common share: Income (loss) from continuing operations $ 0.00 $ (1.08 ) $ 0.02 $ (1.94 ) Income (loss) from discontinuing operations — (0.17 ) 2.51 (0.05 ) Diluted net income (loss) per common share $ 0.00 $ (1.25 ) $ 2.53 $ (1.99 )
Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share	The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share for our continuing operations because the inclusion thereof would be antidilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Denominator Options to purchase shares of common stock 7,062 7,687 7,062 7,687 Warrants — 4 4 4 Conversion shares related to 3% convertible senior subordinated notes 3,411 3,411 3,411 3,411 Conversion shares related to subordinated convertible promissory notes 27 27 27 27 Conversion shares related to Series B convertible preferred stock 10,239 10,239 10,239 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 20,739 21,368 20,743 21,368

Stockholders' Equity and Non-35

Stockholders' Equity and Non-controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity	A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the nine months ended September 30, 2015 and 2014 is provided below (in thousands): Nine Months Ended September 30, 2015 2014 Total Non- Total Total Non- Total Equity, beginning of period $ 1,905,599 $ 4,146 $ 1,909,745 $ 2,073,256 $ 4,882 $ 2,078,138 Issuance of common stock under employee compensation plans 76,457 — 76,457 35,593 — 35,593 Tax withholdings related to net share settlement of restricted stock units (2,240 ) — (2,240 ) — — — Preferred stock dividends (15,970 ) — (15,970 ) (15,970 ) — (15,970 ) Stock-based compensation expense 19,596 — 19,596 7,751 — 7,751 Excess tax benefits on exercised stock options 3,153 — 3,153 (6,302 ) — (6,302 ) Net income (loss) 234,606 386 234,992 (149,026 ) (136 ) (149,162 ) Total other comprehensive loss (123,765 ) — (123,765 ) (69,478 ) — (69,478 ) Equity, end of period $ 2,097,436 $ 4,532 $ 2,101,968 $ 1,875,824 $ 4,746 $ 1,880,570

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Summary of Aggregate Purchase Price Allocation	A summary of the preliminary fair values of the net assets acquired from USD is as follows (in thousands): Total Current assets $ 4,652 Property, plant and equipment 182 Goodwill 29,422 Intangible assets 27,200 Total assets acquired $ 61,456 Current liabilities $ 1,321 Total liabilities assumed $ 1,321 Net assets acquired $ 60,135 Cash paid $ 60,135
Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives	The following are the intangible assets acquired in connection with the USD acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands): Total Weighted- Trademarks $ 1,600 3.0 - 13.0 years Customer relationships 24,900 13.0 years Non-compete agreements 700 2.0 years Total intangible assets $ 27,200

Restructuring Plans (Tables)

Restructuring Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income	The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Statement of Operations Caption 2015 2014 2015 2014 Cost of net revenue $ 522 $ 5,654 $ 2,921 $ 6,707 Research and development 18 5,457 667 8,488 Sales and marketing 619 1,019 2,572 7,420 General and administrative 1,105 5,167 5,227 14,460 Total operating expenses 2,264 17,297 11,387 37,075 Interest expense, including amortization of original issue discounts and deferred financing costs 6 9 19 32 Total charges $ 2,270 $ 17,306 $ 11,406 $ 37,107
Restructuring Activities Related to 2014 Restructuring Plans	The following table summarizes the restructuring activities related to our 2014 restructuring plans for the three and nine months ended September 30, 2015 and 2014 and since inception of these restructuring plans (in thousands): Three Months Ended Nine Months Ended Since Professional Diagnostics 2015 2014 2015 2014 Severance-related costs $ 1,322 $ 5,827 $ 5,385 $ 17,923 $ 33,192 Facility and transition costs 132 1,713 3,045 1,894 6,505 Cash charges 1,454 7,540 8,430 19,817 39,697 Fixed asset and inventory impairments 124 6,322 579 8,402 11,530 Total charges $ 1,578 $ 13,862 $ 9,009 $ 28,219 $ 51,227 Three Months Ended Nine Months Ended Since Corporate and Other 2015 2014 2015 2014 Severance-related costs $ 686 $ 199 $ 1,297 $ 2,399 $ 4,198 Facility and transition costs — 2,979 (13 ) 4,929 11,322 Total cash charges $ 686 $ 3,178 $ 1,284 $ 7,328 $ 15,520
Restructuring Activities within professional diagnostics business segment Related To active Restructuring Plans Prior To 2014	The following table summarizes the restructuring activities within our professional diagnostics business segment related to our active 2013, 2011 and 2008 restructuring plans for the three and nine months ended September 30, 2015 and 2014 and since inception of these plans (in thousands): Three Months Ended Nine Months Ended Since Professional Diagnostics 2015 2014 2015 2014 Severance-related costs $ — $ 56 $ — $ 990 $ 26,926 Facility and transition costs — 201 1,094 537 11,574 Other exit costs 6 9 19 33 817 Cash charges 6 266 1,113 1,560 39,317 Fixed asset and inventory impairments — — — — 6,776 Intangible asset impairments — — — — 686 Other non-cash charges — — — — 64 Total charges $ 6 $ 266 $ 1,113 $ 1,560 $ 46,843
Cash Activity for Restructuring Reserves	The following table summarizes our restructuring reserves related to the restructuring plans described above, of which $4.6 million is included in accrued expenses and other current liabilities and $0.7 million is included in other long-term liabilities on our consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2014 $ 4,590 $ 9,868 $ 290 $ 14,748 Cash charges 6,288 4,387 19 10,694 Payments (8,460 ) (11,166 ) (99 ) (19,725 ) Currency adjustments (156 ) (303 ) — (459 ) Balance, September 30, 2015 $ 2,262 $ 2,786 $ 210 $ 5,258

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-Term Debt Balances Outstanding	We had the following long-term debt balances outstanding as of the dates indicated (in thousands): September 30, 2015 December 31, 2014 A term loans (1) $ 638,823 $ — B term loans (1) 1,044,842 — Prior credit facility—A term loans (2) — 785,938 Prior credit facility—B term loans (3) — 1,330,810 Prior credit facility—Revolving loans — 127,000 7.25% Senior notes 450,000 450,000 6.5% Senior subordinated notes 425,000 425,000 6.375% Senior subordinated notes 425,000 — 8.625% Senior subordinated notes (4) 400,000 400,000 3% Convertible senior subordinated notes (5) 150,000 150,000 Other lines of credit 1,052 684 Other 57,033 40,828 3,591,750 3,710,260 Less: Short-term debt and current portion of long-term debt (604,092 ) (88,875 ) Long-term debt $ 2,987,658 $ 3,621,385 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) Included “A” term loans and “Delayed Draw” term loans under our prior credit facility. (3) Included term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans under our prior credit facility, which term loans had been converted into and consolidated with the “B” term loans under our prior credit facility. (4) On October 1, 2015, we redeemed the entire $400.0 million principal amount of the 8.625% senior subordinated notes pursuant to the notice of optional redemption that we issued to the holders thereof on June 24, 2015. The redemption price was equal to 102.156% of the principal amount of such notes plus accrued and unpaid interest from April 1, 2015 to (but excluding) October 1, 2015. The balance of such notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheet as of September 30, 2015, as the redemption notice created an obligation to pay the balance on October 1, 2015. The redemption was funded with $425.9 million of cash that had been held in an irrevocable trust with the trustee for such notes, which is classified as restricted cash on our consolidated balance sheet as of September 30, 2015. Upon settlement of the redemption on October 1, 2015, we satisfied and discharged all of our obligations with respect to such notes. (5) The balance of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheet as of September 30, 2015, as these notes mature on May 15, 2016.
Long-Term Debt Interest Expense	In connection with our debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Secured credit facility (1) $ 18,161 $ — $ 20,763 $ — Prior credit facility (2) (3) — 24,985 49,437 74,606 7.25% Senior notes 8,524 8,525 25,573 25,574 6.5% Senior subordinated notes 7,274 7,180 21,741 21,534 6.375% Senior subordinated notes 7,002 — 7,544 — 8.625% Senior subordinated notes 9,273 9,271 27,820 27,819 3% Senior subordinated convertible notes 1,246 1,246 3,738 3,738 Other 853 1,125 1,642 3,005 $ 52,333 $ 52,332 $ 158,258 $ 156,276 (1) Includes “A” term loans, “B” term loans and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three and nine months ended September 30, 2015, the amounts include $0.4 million and $1.1 million, respectively, related to the amortization of fees paid for certain debt modifications. For the three and nine months ended September 30, 2014, the amounts include $0.4 million and $1.1 million, respectively, related to the amortization of fees paid for certain debt modifications. (3) Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility during the nine months ended September 30, 2015.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description September 30, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 157 $ 157 $ — $ — Total assets $ 157 $ 157 $ — $ — Liabilities: Contingent consideration obligations (1) $ 63,591 $ — $ — $ 63,591 Total liabilities $ 63,591 $ — $ — $ 63,591 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 259 $ 259 $ — $ — Total assets $ 259 $ 259 $ — $ — Liabilities: Contingent consideration obligations (1) $ 139,671 $ — $ — $ 139,671 Total liabilities $ 139,671 $ — $ — $ 139,671 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note [17(a)] for additional information on the valuation of our contingent consideration obligations.
Changes in Fair Value of Contingent Consideration Obligations	Changes in the fair value of our Level 3 contingent consideration obligations during the nine months ended September 30, 2015 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2014 $ 139,671 Payments (21,928 ) Present value accretion and adjustments (54,168 ) Foreign currency adjustments 16 Fair value of contingent consideration obligations, September 30, 2015 $ 63,591

Defined Benefit Pension Plan (T

Defined Benefit Pension Plan (Tables)	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Net Periodic Benefit Costs	The net periodic benefit costs are as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Service cost $ — $ — $ — $ — Interest cost 234 202 694 604 Expected return on plan assets (240 ) (191 ) (712 ) (571 ) Amortization of prior service costs 344 111 1,019 333 Net periodic benefit cost $ 338 $ 122 $ 1,001 $ 366

Financial Information by Segm41

Financial Information by Segment (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)	Segment information for the three and nine months ended September 30, 2015 and 2014 and as of September 30, 2015 and December 31, 2014 is as follows (in thousands): Professional Consumer Corporate Total Three Months Ended September 30, 2015: Net revenue $ 583,297 $ 18,747 $ — $ 602,044 Operating income (loss) $ 54,452 $ 1,038 $ (26,325 ) $ 29,165 Impairment and (gain) loss on dispositions, net $ 2,074 $ — $ — $ 2,074 Depreciation and amortization $ 83,817 $ 717 $ 1,966 $ 86,500 Restructuring charge $ 1,578 $ — $ 686 $ 2,264 Stock-based compensation $ — $ — $ 7,317 $ 7,317 Three Months Ended September 30, 2014: Net revenue $ 628,012 $ 21,198 $ — $ 649,210 Operating income (loss) $ 64,986 $ 3,742 $ (33,386 ) $ 35,342 Depreciation and amortization $ 80,366 $ 841 $ 1,917 $ 83,124 Restructuring charge $ 14,119 $ — $ 3,178 $ 17,297 Stock-based compensation $ — $ — $ 3,169 $ 3,169 Nine Months Ended September 30, 2015: Net revenue $ 1,773,993 $ 65,360 $ — $ 1,839,353 Operating income (loss) $ 219,544 $ 4,321 $ (75,456 ) $ 148,409 Professional Consumer Corporate Total Impairment and (gain) loss on dispositions, net $ 42,408 $ — $ — $ 42,408 Depreciation and amortization $ 226,383 $ 2,153 $ 4,975 $ 233,511 Restructuring charge $ 10,103 $ — $ 1,284 $ 11,387 Stock-based compensation $ — $ — $ 19,596 $ 19,596 Nine Months Ended September 30, 2014: Net revenue $ 1,856,629 $ 65,218 $ — $ 1,921,847 Operating income (loss) $ 129,446 $ 10,617 $ (75,474 ) $ 64,589 Impairment and (gain) loss on dispositions, net $ 638 $ — $ — $ 638 Depreciation and amortization $ 244,698 $ 2,604 $ 3,461 $ 250,763 Restructuring charge $ 29,747 $ — $ 7,328 $ 37,075 Stock-based compensation $ — $ — $ 7,751 $ 7,751 Assets: As of September 30, 2015 $ 5,749,115 $ 200,491 $ 624,559 $ 6,574,165 As of December 31, 2014 $ 6,323,944 $ 216,451 $ 138,561 $ 6,678,956
Summary of Company's Net Product Sales and Services Revenue from Professional Diagnostics and Consumer Diagnostics Reporting Segments by Groups of Similar Products and Services along with License and Royalty Revenue	The following table summarizes our net product sales and services revenue from the professional diagnostics reporting segment by groups of similar products and services, along with license and royalty revenue, for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cardiometabolic $ 208,319 $ 208,248 $ 624,823 $ 631,452 Infectious disease 163,759 184,018 519,145 526,632 Toxicology 162,571 166,381 468,822 491,561 Other 45,349 65,183 147,512 190,986 Total professional diagnostics net product sales and services revenue 579,998 623,830 1,760,302 1,840,631 License and royalty revenue 3,299 4,182 13,691 15,998 Total professional diagnostics net revenue $ 583,297 $ 628,012 $ 1,773,993 $ 1,856,629

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Balances with SPD within Consolidated Balance Sheets	The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption September 30, 2015 December 31, 2014 Accounts receivable, net of allowances $ 10,049 $ 10,465 Prepaid expenses and other current assets $ 7,404 $ 9,635 Deferred financing costs, net, and other non-current assets $ 9,100 $ 10,875 Accounts payable $ 37,608 $ 34,816

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions	The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 103,247 2015 – 2025 (5) $ 51,900 $ 41,100 $ 5,377 Ionian Technologies, Inc. (2) July 12, 2010 $ 24,500 $ — — — 24,500 — DiagnosisOne, Inc. (3) July 31, 2012 $ 22,300 $ — — — 21,000 6,000 Epocal (4) February 1, 2013 $ 75,000 $ 55,500 2015 – 2018 5,700 47,200 10,000 Other Various $ 30,373 $ — (6) 2015 – 2016 5,991 5,871 551 $ 63,591 $ 139,671 $ 21,928 (1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025. (2) The earn-out period under the terms of the acquisition agreement expired July 12, 2015. (3) On March 25, 2015, the remaining earn-out was settled for $6.0 million, of which $4.5 million was paid on March 27, 2015 and $1.5 million was paid on April 3, 2015. (4) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (5) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (6) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric.

Guarantor Financial Informati44

Guarantor Financial Information (Tables)	9 Months Ended
	Sep. 30, 2015
Financial Information Combined Condensed Results of Operations	CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 227,939 $ 309,871 $ (67,406 ) $ 470,404 Services revenue — 115,829 12,512 — 128,341 Net product sales and services revenue — 343,768 322,383 (67,406 ) 598,745 License and royalty revenue — 3,246 4,648 (4,595 ) 3,299 Net revenue — 347,014 327,031 (72,001 ) 602,044 Cost of net product sales 2,090 124,853 175,836 (56,724 ) 246,055 Cost of services revenue 74 81,549 6,951 (8,771 ) 79,803 Cost of net product sales and services revenue 2,164 206,402 182,787 (65,495 ) 325,858 Cost of license and royalty revenue (19 ) 401 5,350 (4,595 ) 1,137 Cost of net revenue 2,145 206,803 188,137 (70,090 ) 326,995 Gross profit (loss) (2,145 ) 140,211 138,894 (1,911 ) 275,049 Operating expenses: Research and development 5,670 15,015 15,326 — 36,011 Sales and marketing 1,335 53,863 51,295 — 106,493 General and administrative 22,960 34,816 43,530 — 101,306 Impairment and (gain) loss on dispositions, net 150 85 1,839 — 2,074 Operating income (loss) (32,260 ) 36,432 26,904 (1,911 ) 29,165 Interest expense, including amortization of original issue discounts and deferred financing costs (51,705 ) (2,613 ) (4,999 ) 6,984 (52,333 ) Other income (expense), net 4,224 3,921 3,584 (6,984 ) 4,745 Income (loss) from continuing operations before provision (benefit) for income taxes (79,741 ) 37,740 25,489 (1,911 ) (18,423 ) Provision (benefit) for income taxes 78,041 (33,431 ) (63,534 ) — (18,924 ) Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax (157,782 ) 71,171 89,023 (1,911 ) 501 Equity in earnings of subsidiaries, net of tax 163,647 — — (163,647 ) — Equity earnings (losses) of unconsolidated entities, net of tax (364 ) — 5,348 16 5,000 Net income 5,501 71,171 94,371 (165,542 ) 5,501 Less: Net loss attributable to non-controlling interests — — (61 ) — (61 ) Net income attributable to Alere Inc. and Subsidiaries 5,501 71,171 94,432 (165,542 ) 5,562 Preferred stock dividends (5,367 ) — — — (5,367 ) Net income (loss) available to common stockholders $ 134 $ 71,171 $ 94,432 $ (165,542 ) $ 195 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2014 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Eliminations Consolidated Net product sales $ — $ 214,585 $ 353,817 $ (60,777 ) $ 507,625 Services revenue — 122,045 15,358 — 137,403 Net product sales and services revenue — 336,630 369,175 (60,777 ) 645,028 License and royalty revenue — 2,993 3,663 (2,474 ) 4,182 Net revenue — 339,623 372,838 (63,251 ) 649,210 Cost of net product sales 912 118,241 204,983 (52,886 ) 271,250 Cost of services revenue 71 74,441 8,448 (7,858 ) 75,102 Cost of net product sales and services revenue 983 192,682 213,431 (60,744 ) 346,352 Cost of license and royalty revenue 28 55 3,627 (2,474 ) 1,236 Cost of net revenue 1,011 192,737 217,058 (63,218 ) 347,588 Gross profit (loss) (1,011 ) 146,886 155,780 (33 ) 301,622 Operating expenses: Research and development 7,256 15,318 16,152 — 38,726 Sales and marketing 1,265 54,422 67,073 — 122,760 General and administrative 33,549 30,323 40,922 — 104,794 Operating income (loss) (43,081 ) 46,823 31,633 (33 ) 35,342 Interest expense, including amortization of original issue discounts and deferred financing costs (51,589 ) (4,420 ) (4,512 ) 8,189 (52,332 ) Other income (expense), net 4,706 4,835 (9,438 ) (8,190 ) (8,087 ) Income (loss) from continuing operations before provision for income taxes (89,964 ) 47,238 17,683 (34 ) (25,077 ) Provision for income taxes 42,727 13,657 9,140 (35 ) 65,489 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (132,691 ) 33,581 8,543 1 (90,566 ) Equity in earnings of subsidiaries, net of tax 49,642 210 — (49,852 ) — Equity earnings of unconsolidated entities, net of tax 560 — 5,779 (62 ) 6,277 Income (loss) from continuing operations (82,489 ) 33,791 14,322 (49,913 ) (84,289 ) Income (loss) from discontinued operations, net of tax (16,201 ) (20,615 ) 22,415 — (14,401 ) Net income (loss) (98,690 ) 13,176 36,737 (49,913 ) (98,690 ) Less: Net loss attributable to non-controlling interests — — (306 ) — (306 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (98,690 ) 13,176 37,043 (49,913 ) (98,384 ) Preferred stock dividends (5,367 ) — — — (5,367 ) Net income (loss) available to common stockholders $ (104,057 ) $ 13,176 $ 37,043 $ (49,913 ) $ (103,751 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Subsidiaries Eliminations Consolidated Net product sales $ — $ 657,751 $ 983,131 $ (194,045 ) $ 1,446,837 Services revenue — 338,869 39,956 — 378,825 Net product sales and services revenue — 996,620 1,023,087 (194,045 ) 1,825,662 License and royalty revenue — 9,676 14,721 (10,706 ) 13,691 Net revenue — 1,006,296 1,037,808 (204,751 ) 1,839,353 Cost of net product sales 2,923 358,983 550,081 (168,810 ) 743,177 Cost of services revenue 204 233,470 22,823 (24,360 ) 232,137 Cost of net product sales and services revenue 3,127 592,453 572,904 (193,170 ) 975,314 Cost of license and royalty revenue (40 ) 1,619 13,558 (10,706 ) 4,431 Cost of net revenue 3,087 594,072 586,462 (203,876 ) 979,745 Gross profit (loss) (3,087 ) 412,224 451,346 (875 ) 859,608 Operating expenses: Research and development 11,213 43,927 36,085 — 91,225 Sales and marketing 4,165 159,191 159,400 — 322,756 General and administrative 67,873 123,874 63,063 — 254,810 Impairment and (gain) loss on dispositions, net 81,051 (8,719 ) (29,924 ) — 42,408 Operating income (loss) (167,389 ) 93,951 222,722 (875 ) 148,409 Interest expense, including amortization of original issue discounts and deferred financing costs (156,889 ) (8,958 ) (13,744 ) 21,333 (158,258 ) Other income (expense), net 11,467 12,796 4,805 (21,333 ) 7,735 Income (loss) from continuing operations before provision (benefit) for income taxes (312,811 ) 97,789 213,783 (875 ) (2,114 ) Provision (benefit) for income taxes 41,068 (20,334 ) (31,051 ) 308 (10,009 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (353,879 ) 118,123 244,834 (1,183 ) 7,895 Equity in earnings of subsidiaries, net of tax 369,200 — — (369,200 ) — Equity earnings of unconsolidated entities, net of tax 982 — 9,340 (2 ) 10,320 Income from continuing operations 16,303 118,123 254,174 (370,385 ) 18,215 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income 234,992 116,211 254,174 (370,385 ) 234,992 Less: Net income attributable to non-controlling interests — — 386 — 386 Net income attributable to Alere Inc. and Subsidiaries 234,992 116,211 253,788 (370,385 ) 234,606 Preferred stock dividends (15,926 ) — — — (15,926 ) Net income available to common stockholders $ 219,066 $ 116,211 $ 253,788 $ (370,385 ) $ 218,680 CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 623,208 $ 1,048,212 $ (172,118 ) $ 1,499,302 Services revenue — 355,132 51,415 — 406,547 Net product sales and services revenue — 978,340 1,099,627 (172,118 ) 1,905,849 License and royalty revenue — 10,312 14,683 (8,997 ) 15,998 Net revenue — 988,652 1,114,310 (181,115 ) 1,921,847 Cost of net product sales 2,291 348,701 591,778 (156,852 ) 785,918 Cost of services revenue 214 216,142 25,123 (20,123 ) 221,356 Cost of net product sales and services revenue 2,505 564,843 616,901 (176,975 ) 1,007,274 Cost of license and royalty revenue 28 194 12,675 (8,997 ) 3,900 Cost of net revenue 2,533 565,037 629,576 (185,972 ) 1,011,174 Gross profit (loss) (2,533 ) 423,615 484,734 4,857 910,673 Operating expenses: Research and development 20,034 45,753 49,068 — 114,855 Sales and marketing 6,329 175,536 209,740 — 391,605 General and administrative 78,257 112,850 147,879 — 338,986 Loss on disposition — 638 — — 638 Operating income (loss) (107,153 ) 88,838 78,047 4,857 64,589 Interest expense, including amortization of original issue discounts and deferred financing costs (154,232 ) (14,933 ) (13,646 ) 26,535 (156,276 ) Other income (expense), net 11,823 15,867 1,068 (26,594 ) 2,164 Income (loss) from continuing operations before provision (benefit) for income taxes (249,562 ) 89,772 65,469 4,798 (89,523 ) Provision (benefit) for income taxes (2,566 ) 42,896 27,319 1,624 69,273 Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (246,996 ) 46,876 38,150 3,174 (158,796 ) Equity in earnings of subsidiaries, net of tax 97,307 442 — (97,749 ) — Equity earnings of unconsolidated entities, net of tax 1,387 — 12,516 (187 ) 13,716 Income (loss) from continuing operations (148,302 ) 47,318 50,666 (94,762 ) (145,080 ) Income (loss) from discontinued operations, net of tax (860 ) (26,418 ) 23,196 — (4,082 ) Net income (loss) (149,162 ) 20,900 73,862 (94,762 ) (149,162 ) Less: Net loss attributable to non-controlling interests — — (136 ) — (136 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (149,162 ) 20,900 73,998 (94,762 ) (149,026 ) Preferred stock dividends (15,926 ) — — — (15,926 ) Net income (loss) available to common stockholders $ (165,088 ) $ 20,900 $ 73,998 $ (94,762 ) $ (164,952 )
Financial Information Combined Condensed Balance Sheet	CONSOLIDATING BALANCE SHEET September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 142,996 $ 7,649 $ 328,736 $ — $ 479,381 Restricted cash 426,170 — 4,651 — 430,821 Marketable securities — 157 — — 157 Accounts receivable, net of allowances — 205,533 246,833 — 452,366 Inventories, net — 194,697 190,143 (22,614 ) 362,226 Deferred tax assets (39,530 ) 31,285 25,788 (2,119 ) 15,424 Prepaid expenses and other current assets 7,824 31,605 74,901 6,693 121,023 Assets held for sale — current — — 25,312 — 25,312 Intercompany receivables 642,439 762,656 81,594 (1,486,689 ) — Total current assets 1,179,899 1,233,582 977,958 (1,504,729 ) 1,886,710 Property, plant and equipment, net 31,011 229,347 185,403 (446 ) 445,315 Goodwill — 1,824,191 1,018,730 — 2,842,921 Other intangible assets with indefinite lives — 7,662 21,141 (59 ) 28,744 Finite-lived intangible assets, net 3,072 656,064 393,813 — 1,052,949 Restricted cash — — 44,148 — 44,148 Deferred financing costs, net and other non-current assets 44,098 3,716 15,734 (269 ) 63,279 Investments in subsidiaries 3,439,664 179,542 59,431 (3,678,637 ) — Investments in unconsolidated entities 503 14,765 44,640 13,974 73,882 Deferred tax assets — — 7,632 — 7,632 Non-current income tax receivable 2,537 — — — 2,537 Assets held for sale — non-current 13,013 — 113,035 — 126,048 Intercompany notes receivables 2,030,141 676,485 4,967 (2,711,593 ) — Total assets $ 6,743,938 $ 4,825,354 $ 2,886,632 $ (7,881,759 ) $ 6,574,165 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 601,712 $ — $ 2,380 $ — $ 604,092 Current portion of capital lease obligations — 1,404 2,101 — 3,505 Accounts payable 14,000 87,659 92,587 — 194,246 Accrued expenses and other current liabilities (394,578 ) 612,572 95,013 2,329 315,336 Liabilities related to assets held for sale — current — — 8,836 — 8,836 Intercompany payables 1,042,991 263,528 180,170 (1,486,689 ) — Total current liabilities 1,264,125 965,163 381,087 (1,484,360 ) 1,126,015 Long-term liabilities: Long-term debt, net of current portion 2,940,664 — 46,994 — 2,987,658 Capital lease obligations, net of current portion — 2,001 4,269 — 6,270 Deferred tax liabilities (70,862 ) 214,277 63,954 82 207,451 Other long-term liabilities 37,984 62,242 35,243 (269 ) 135,200 Liabilities related to assets held for sale — non-current — — 9,603 — 9,603 Intercompany notes payables 474,591 1,189,716 1,047,286 (2,711,593 ) — Total long-term liabilities 3,382,377 1,468,236 1,207,349 (2,711,780 ) 3,346,182 Total stockholders’ equity 2,097,436 2,391,955 1,293,664 (3,685,619 ) 2,097,436 Non-controlling interests — — 4,532 — 4,532 Total equity 2,097,436 2,391,955 1,298,196 (3,685,619 ) 2,101,968 Total liabilities and equity $ 6,743,938 $ 4,825,354 $ 2,886,632 $ (7,881,759 ) $ 6,574,165 CONSOLIDATING BALANCE SHEET December 31, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 2,149 $ 69,154 $ 307,158 $ — $ 378,461 Restricted cash 5,012 — 32,559 — 37,571 Marketable securities — 259 — — 259 Accounts receivable, net of allowances — 192,775 273,331 — 466,106 Inventories, net — 191,323 195,606 (21,764 ) 365,165 Deferred tax assets 36,347 44,961 31,265 — 112,573 Prepaid expenses and other current assets 9,800 31,410 88,695 2,508 132,413 Assets held for sale – current 1,361 284,369 29,785 — 315,515 Intercompany receivables 404,990 888,688 55,923 (1,349,601 ) — Total current assets 459,659 1,702,939 1,014,322 (1,368,857 ) 1,808,063 Property, plant and equipment, net 30,547 218,613 204,188 222 453,570 Goodwill — 1,795,663 1,131,003 — 2,926,666 Other intangible assets with indefinite lives — 9,287 34,422 (58 ) 43,651 Finite-lived intangible assets, net 6,104 742,760 527,580 — 1,276,444 Deferred financing costs, net and other non-current assets 40,992 5,334 21,541 (35 ) 67,832 Investments in subsidiaries 3,740,004 179,315 58,067 (3,977,386 ) — Investments in unconsolidated entities 13,987 14,765 49,608 13,333 91,693 Deferred tax assets — — 8,569 — 8,569 Non-current income tax receivable 2,468 — — — 2,468 Intercompany notes receivables 2,028,701 649,444 46,676 (2,724,821 ) — Total assets $ 6,322,462 $ 5,318,120 $ 3,095,976 $ (8,057,602 ) $ 6,678,956 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 61,700 $ 2 $ 27,173 $ — $ 88,875 Current portion of capital lease obligations — 1,045 3,196 — 4,241 Accounts payable 21,402 81,741 110,449 — 213,592 Accrued expenses and other current liabilities (536,286 ) 663,221 248,604 (45 ) 375,494 Liabilities related to assets held for sale – current 1,094 77,749 — — 78,843 Intercompany payables 902,576 198,788 248,237 (1,349,601 ) — Total current liabilities 450,486 1,022,546 637,659 (1,349,646 ) 761,045 Long-term liabilities: Long-term debt, net of current portion 3,615,759 — 5,626 — 3,621,385 Capital lease obligations, net of current portion — 4,097 6,463 — 10,560 Deferred tax liabilities (107,844 ) 252,944 69,457 82 214,639 Other long-term liabilities 42,762 46,865 71,988 (33 ) 161,582 Intercompany notes payables 415,700 1,276,245 1,032,876 (2,724,821 ) — Total long-term liabilities 3,966,377 1,580,151 1,186,410 (2,724,772 ) 4,008,166 Total stockholders’ equity 1,905,599 2,715,423 1,267,761 (3,983,184 ) 1,905,599 Non-controlling interests — — 4,146 — 4,146 Total equity 1,905,599 2,715,423 1,271,907 (3,983,184 ) 1,909,745 Total liabilities and equity $ 6,322,462 $ 5,318,120 $ 3,095,976 $ (8,057,602 ) $ 6,678,956
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss)	CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non - Eliminations Consolidated Net income $ 5,501 $ 71,171 $ 94,371 $ (165,542 ) $ 5,501 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (748 ) (570 ) (87,314 ) (180 ) (88,812 ) Minimum pension liability adjustment — — 419 — 419 Other comprehensive loss, before tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Income tax benefit related to items of other comprehensive income — — — — — Other comprehensive loss, net of tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Comprehensive income 4,753 70,601 7,476 (165,722 ) (82,892 ) Less: Comprehensive loss attributable to non-controlling interests — — (61 ) — (61 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 4,753 $ 70,601 $ 7,537 $ (165,722 ) $ (82,831 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2014 (in thousands) Issuer Guarantor Subsidiaries Non-Guarantor Subsidiaries Eliminations Consolidated Net income (loss) $ (98,690 ) $ 13,176 $ 36,737 $ (49,913 ) $ (98,690 ) Other comprehensive income, before tax: Changes in cumulative translation adjustment (383 ) (104 ) (95,936 ) (2 ) (96,425 ) Unrealized gains on hedging instruments — — 7 — 7 Minimum pension liability adjustment — — 481 — 481 Other comprehensive income, before tax (383 ) (104 ) (95,448 ) (2 ) (95,937 ) Income tax provision (benefit) related to items of other comprehensive loss — — — — — Other comprehensive income, net of tax (383 ) (104 ) (95,448 ) (2 ) (95,937 ) Comprehensive income (loss) (99,073 ) 13,072 (58,711 ) (49,915 ) (194,627 ) Less: Comprehensive loss attributable to non-controlling interests — — (306 ) — (306 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (99,073 ) $ 13,072 $ (58,405 ) $ (49,915 ) $ (194,321 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non - Eliminations Consolidated Net income $ 234,992 $ 116,211 $ 254,174 $ (370,385 ) $ 234,992 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (1,208 ) (453 ) (120,587 ) (180 ) (122,428 ) Minimum pension liability adjustment — — (1,337 ) — (1,337 ) Other comprehensive loss, before tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Income tax benefit related to items of other comprehensive income (loss) — — — — — Other comprehensive loss, net of tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Comprehensive income 233,784 115,758 132,250 (370,565 ) 111,227 Less: Comprehensive income attributable to non-controlling interests — — 386 — 386 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 233,784 $ 115,758 $ 131,864 $ (370,565 ) $ 110,841 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net income (loss) $ (149,162 ) $ 20,900 $ 73,862 $ (94,762 ) $ (149,162 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment (137 ) (178 ) (69,633 ) (2 ) (69,950 ) Unrealized losses on available for sale securities — (17 ) — — (17 ) Unrealized gains on hedging instruments — — 21 — 21 Minimum pension liability adjustment — — 468 — 468 Other comprehensive income (loss), before tax (137 ) (195 ) (69,144 ) (2 ) (69,478 ) Income tax benefit related to items of other comprehensive loss — — — — — Other comprehensive income (loss), net of tax (137 ) (195 ) (69,144 ) (2 ) (69,478 ) Comprehensive income (loss) (149,299 ) 20,705 4,718 (94,764 ) (218,640 ) Less: Comprehensive loss attributable to non-controlling interests — — (136 ) — (136 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (149,299 ) $ 20,705 $ 4,854 $ (94,764 ) $ (218,504 )
Guarantor Financial Information Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 234,992 $ 116,211 $ 254,174 $ (370,385 ) $ 234,992 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income from continuing operations 16,303 118,123 254,174 (370,385 ) 18,215 Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (369,200 ) — — 369,200 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 10,542 19 66 — 10,627 Depreciation and amortization 7,891 128,363 97,250 7 233,511 Non-cash stock-based compensation expense 10,600 4,251 4,745 — 19,596 Impairment of inventory — 133 68 — 201 Impairment of long-lived assets — 64 314 — 378 Loss on sale of fixed assets — 2,768 505 — 3,273 Equity earnings of unconsolidated entities, net of tax (982 ) — (9,340 ) 2 (10,320 ) Deferred income taxes (8,686 ) (30,699 ) (7,794 ) 439 (46,740 ) Loss related to impairment and net (gain) loss on dispositions 81,051 (8,804 ) (29,924 ) — 42,323 Loss on extinguishment of debt 3,480 — — — 3,480 Other non-cash items (376 ) (1,054 ) (3,358 ) 3 (4,785 ) Non-cash change in fair value of contingent purchase price consideration (33,667 ) 16,616 (34,860 ) — (51,911 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (11,370 ) 101 — (11,269 ) Inventories, net — (31,079 ) (27,909 ) 207 (58,781 ) Prepaid expenses and other current assets 3,098 (28,016 ) 4,917 5,048 (14,953 ) Accounts payable (7,435 ) 777 (9,342 ) — (16,000 ) Accrued expenses and other current liabilities 111,628 33,995 (103,572 ) (6,859 ) 35,192 Other non-current liabilities (16,364 ) 740 5,389 1,445 (8,790 ) Cash paid for contingent purchase price consideration (6,302 ) — (13 ) — (6,315 ) Intercompany payable (receivable) 334,642 (246,828 ) (87,992 ) 178 — Net cash provided by (used in) continuing operations 136,223 (52,001 ) 53,425 (715 ) 136,932 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities 136,223 (51,683 ) 53,425 (715 ) 137,250 Cash Flows from Investing Activities: Increase in restricted cash (421,157 ) — (17,608 ) — (438,765 ) Purchases of property, plant and equipment (7,514 ) (25,915 ) (36,093 ) 1,575 (67,947 ) Proceeds from sale of property, plant and equipment — 846 1,554 (914 ) 1,486 Cash received from (used in) disposition, net of cash divested 593,066 (8,722 ) 2,281 — 586,625 Cash paid for business acquisitions, net of cash acquired (60,135 ) — — — (60,135 ) Cash received from sales of (paid for purchase of) marketable securities — 103 (4 ) — 99 Cash received from equity method investments 2,205 — 12,092 — 14,297 (Increase) decrease in other assets 368 497 (219 ) 235 881 Net cash provided by (used in) continuing operations 106,833 (33,191 ) (37,997 ) 896 36,541 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 106,833 (33,400 ) (37,997 ) 896 36,332 Cash Flows from Financing Activities: Cash paid for financing costs (15,836 ) — (217 ) — (16,053 ) Cash paid for contingent purchase price consideration (13,640 ) — (439 ) — (14,079 ) Cash paid for dividends (15,970 ) — — — (15,970 ) Proceeds from issuance of common stock, net of issuance costs 76,457 — — — 76,457 Proceeds from issuance of long-term debt 2,119,125 — 42,897 — 2,162,022 Payments on short-term debt — — (25,584 ) — (25,584 ) Payments on long-term debt (2,128,625 ) — (540 ) — (2,129,165 ) Net proceeds (payments) under revolving credit facilities (127,000 ) — 397 — (126,603 ) Excess tax benefits on exercised stock options 3,264 2,531 307 — 6,102 Principal payments on capital lease obligations — (1,876 ) (2,463 ) — (4,339 ) Net cash provided by (used in) continuing operations (102,225 ) 655 14,358 — (87,212 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash provided by (used in) financing activities (102,225 ) 579 14,358 — (87,288 ) Foreign exchange effect on cash and cash equivalents 16 (301 ) (8,208 ) (181 ) (8,674 ) Net increase (decrease) in cash and cash equivalents 140,847 (84,805 ) 21,578 — 77,620 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents of continuing operations, end of period $ 142,996 $ 7,649 $ 328,736 $ — $ 479,381 CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2014 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (149,162 ) $ 20,900 $ 73,862 $ (94,762 ) $ (149,162 ) Income (loss) from discontinued operations, net of tax (860 ) (26,418 ) 23,196 — (4,082 ) Income (loss) from continuing operations (148,302 ) 47,318 50,666 (94,762 ) (145,080 ) Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities: Equity in earnings of subsidiaries, net of tax (97,307 ) (442 ) — 97,749 — Tax benefit related to discontinued operations.. — 9,594 — — 9,594 Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 11,575 32 217 — 11,824 Depreciation and amortization 4,417 132,134 114,218 (6 ) 250,763 Non-cash stock-based compensation expense 1,629 3,463 2,659 — 7,751 Impairment of inventory — — 1,536 — 1,536 Impairment of long-lived assets 1,573 (446 ) 5,739 — 6,866 Loss on sale of fixed assets — 4,078 601 — 4,679 Equity earnings of unconsolidated entities, net of tax (1,387 ) — (12,516 ) 187 (13,716 ) Deferred income taxes 28,030 (12,863 ) (7,320 ) 1,710 9,557 Net loss on dispositions — 638 — — 638 Other non-cash items (988 ) 2,845 1,826 — 3,683 Non-cash change in fair value of contingent purchase price consideration 3,326 9,903 3,813 — 17,042 Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (10,136 ) 22,779 — 12,643 Inventories, net — (22,521 ) (3,495 ) (4,430 ) (30,446 ) Prepaid expenses and other current assets 503,712 (444,782 ) (65,138 ) (2,438 ) (8,646 ) Accounts payable 2,637 25,738 10,312 — 38,687 Accrued expenses and other current liabilities (535,345 ) 482,572 46,020 (1,748 ) (8,501 ) Other non-current liabilities 23,922 2,392 2,806 4,101 33,221 Cash paid for contingent purchase price consideration (20,966 ) — (112 ) — (21,078 ) Intercompany payable (receivable) 277,206 (197,561 ) (79,645 ) — — Net cash provided by continuing operations 53,732 31,956 94,966 363 181,017 Net cash provided by discontinued operations 7,881 26,474 62 — 34,417 Net cash provided by operating activities 61,613 58,430 95,028 363 215,434 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 135 (100 ) (3,262 ) — (3,227 ) Purchases of property, plant and equipment (16,611 ) (29,141 ) (29,805 ) 2,522 (73,035 ) Proceeds from sale of property, plant and equipment 268 778 2,853 (2,755 ) 1,144 Cash received from disposition, net of cash divested — 1,081 4,373 — 5,454 Cash paid for business acquisitions, net of cash acquired (75 ) — — — (75 ) Cash received from sales of marketable securities — 43 4 — 47 Cash received from (paid for) investments 477 (278 ) (1 ) — 198 Proceeds from sale of equity investment — — 9,526 — 9,526 (Increase) decrease in other assets (104 ) 140 931 57 1,024 Net cash used in continuing operations (15,910 ) (27,477 ) (15,381 ) (176 ) (58,944 ) Net cash used in discontinued operations — (8,853 ) — — (8,853 ) Net cash used in investing activities (15,910 ) (36,330 ) (15,381 ) (176 ) (67,797 ) Cash Flows from Financing Activities: Cash paid for financing costs (5 ) — — — (5 ) Cash paid for contingent purchase price consideration (23,285 ) — (323 ) — (23,608 ) Cash paid for dividends (15,970 ) — — — (15,970 ) Proceeds from issuance of common stock, net of issuance costs 35,593 — — — 35,593 Proceeds from issuance of short-term debt — — 806 — 806 Proceeds from issuance of long-term debt — — 41 — 41 Payments on long-term debt (45,000 ) (223 ) (2,079 ) — (47,302 ) Net proceeds under revolving credit facilities — — 498 — 498 Excess tax benefits on exercised stock options 65 282 68 — 415 Principal payments on capital lease obligations — (2,246 ) (2,393 ) — (4,639 ) Net cash used in continuing operations (48,602 ) (2,187 ) (3,382 ) — (54,171 ) Net cash used in discontinued operations (579 ) (496 ) — — (1,075 ) Net cash used in financing activities (49,181 ) (2,683 ) (3,382 ) — (55,246 ) Foreign exchange effect on cash and cash equivalents 146 (179 ) (9,225 ) (187 ) (9,445 ) Net increase (decrease) in cash and cash equivalents (3,332 ) 19,238 67,040 — 82,946 Cash and cash equivalents, beginning of period-continuing operations 14,801 78,976 261,654 — 355,431 Cash and cash equivalents, beginning of period-discontinued operations — 6,476 1 — 6,477 Cash and cash equivalents, end of period 11,469 104,690 328,695 — 444,854 Less: Cash and cash equivalents of discontinued operations, end of period.. — 13,502 1 — 13,503 Cash and cash equivalents of continuing operations at end of period $ 11,469 $ 91,188 $ 328,694 $ — $ 431,351
Swiss Precision Diagnostics And Techlab [Member]
Financial Information Combined Condensed Results of Operations	Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Combined Condensed Results of Operations: 2015 2014 2015 2014 Net revenue $ 56,303 $ 65,397 $ 157,319 $ 155,533 Gross profit $ 43,538 $ 40,268 $ 111,368 $ 120,680 Net income after taxes $ 15,735 $ 12,834 $ 26,831 $ 27,992
Financial Information Combined Condensed Balance Sheet	Combined Condensed Balance Sheet: September 30, 2015 December 31, 2014 Current assets $ 83,646 $ 90,546 Non-current assets 31,413 33,697 Total assets $ 115,059 $ 124,243 Current liabilities $ 32,352 $ 35,954 Non-current liabilities 5,487 5,884 Total liabilities $ 37,839 $ 41,838

Basis of Presentation of Fina45

Basis of Presentation of Financial Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Basis Of Presentation [Line Items]
Prior period tax related adjustments	$ 18,924	$ (65,489)	$ 10,009	$ (69,273)
Prior Period [Member]
Basis Of Presentation [Line Items]
Prior period tax related adjustments	8,000		8,000
Domestic income tax benefit on foreign earnings	6,600		6,600
Uncertain tax benefit	$ 1,400		$ 1,400

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($)	Jan. 09, 2015	Oct. 10, 2014	Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation ,working capital adjustment			$ 250,000
Alere Accountable Care Solutions, LLC ("ACS") [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds on sale of discontinued operations		$ 2
Contingent consideration receivable on sale of discontinued operations		7,000,000
Alere Accountable Care Solutions, LLC ("ACS") [Member] | Maximum [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reimbursable expenses payable to purchaser		$ 750,000
Health Management Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds on sale of discontinued operations	$ 600,100,000
Health Management Business [Member] | Secured Credit Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured credit facility	$ 575,000,000

Discontinued Operations - Sched

Discontinued Operations - Schedule of Assets and Liabilities Associated with Health Management Business Segregated and Classified as Assets Held for Sale and Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Assets
Cash and cash equivalents	$ 0	$ 23,300	$ 13,503	$ 6,477
Restricted cash	430,821	37,571
Goodwill	2,842,921	2,926,666
Liabilities
Deferred tax liabilities - non-current	$ 207,451	214,639
Health Management Business [Member]
Assets
Cash and cash equivalents		23,300
Restricted cash		361
Accounts receivable, net of allowances of $5,882 at December 31, 2014		50,902
Inventories, net		1,656
Deferred tax assets - current		6,939
Prepaid expenses and other current assets		3,857
Property, plant and equipment, net		57,595
Goodwill		82,665
Finite-lived intangible assets, net		82,428
Deferred tax assets - non-current		3,347
Other non-current assets		2,465
Total assets held for sale		315,515
Liabilities
Current portion of capital lease obligations		799
Accounts payable		5,654
Accrued expenses and other current liabilities		32,822
Capital lease obligations, net of current portion		365
Deferred tax liabilities - non-current		27,453
Other long-term liabilities		11,750
Total liabilities related to assets held for sale		$ 78,843

Discontinued Operations - Sch48

Discontinued Operations - Schedule of Assets and Liabilities Associated with Health Management Business Segregated and Classified as Assets Held for Sale and Liabilities (Parenthetical) (Detail) $ in Thousands	Dec. 31, 2014USD ($)
Health Management Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, allowances	$ 5,882

Discontinued Operations - Summa

Discontinued Operations - Summarized Financial Information Related to ACS Companies and Health Management Business (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations, net of tax	$ 0	$ (14,401)	$ 216,777	$ (4,082)
Alere Accountable Care Solutions, LLC ("ACS") and Health Management Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue		89,501	7,373	271,668
Cost of net revenue		(54,314)	(4,413)	(155,976)
Sales and marketing		(14,270)	(996)	(43,152)
General and administrative		(16,924)	(5,001)	(75,244)
Interest expense		(149)	(9)	(400)
Other income (expense), net		(117)	160	(1,189)
Gain on disposal		0	366,191	0
Income (loss) from discontinued operations before provision (benefit) for income taxes		3,727	363,305	(4,293)
Provision (benefit) for income taxes		18,128	146,528	(211)
Income (loss) from discontinued operations, net of tax		$ (14,401)	$ 216,777	$ (4,082)

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash investments maturity period	Three months or less

Restricted Cash - Additional In

Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	Sep. 30, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash		$ 475,000	$ 37,600
Long-term debt, Interest rate		8.625%
Debt instrument, maturity date	Oct. 1, 2015	Oct. 1, 2015
Securities for loan agreement of restricted cash		$ 44,148
Securities for loan agreement deposit period		2 years
8.625% Senior Subordinated Notes [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 425,900	$ 425,900

Inventories, Net - Inventories

Inventories, Net - Inventories are Stated at Lower of Cost (First In, First Out) or Market (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 132,808	$ 122,886
Work-in-process	73,629	82,724
Finished goods	155,789	159,555
Inventories, net	$ 362,226	$ 365,165

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,317	$ 3,169	$ 19,596	$ 7,751
Benefit for income taxes	(472)	(878)	(5,374)	(2,001)
Stock-based compensation, net of tax	6,845	2,291	14,222	5,750
Cost of Net Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	326	291	866	863
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	287	280	893	(340)
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	1,260	920	3,605	2,778
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 5,444	$ 1,678	$ 14,232	$ 4,450

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended
	Jun. 30, 2014USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock-based compensation expense	$ 5.6
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock-based compensation expense	2.2
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reversal of stock-based compensation expense	$ 3.4

Net Income (Loss) Per Common 55

Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Income (loss) from continuing operations	$ 5,501	$ (84,289)	$ 18,215	$ (145,080)
Preferred stock dividends	(5,367)	(5,367)	(15,926)	(15,926)
Income (loss) from continuing operations attributable to common shares	134	(89,656)	2,289	(161,006)
Less: Net income (loss) attributable to non-controlling interest	(61)	(306)	386	(136)
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	195	(89,350)	1,903	(160,870)
Income (loss) from discontinued operations	0	(14,401)	216,777	(4,082)
Net income (loss) available to common stockholders	$ 195	$ (103,751)	$ 218,680	$ (164,952)
Denominator:
Weighted-average common shares outstanding - basic	85,895	83,115	85,141	82,719
Weighted-average common shares outstanding - diluted	87,169	83,115	86,279	82,719
Basic net income (loss) per common share:
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	$ 0	$ (1.08)	$ 0.02	$ (1.94)
Income (loss) from discontinued operations	0	(0.17)	2.55	(0.05)
Basic net income (loss) per common share	0	(1.25)	2.57	(1.99)
Diluted net income (loss) per common share:
Income (loss) from continuing operations	0	(1.08)	0.02	(1.94)
Income (loss) from discontinuing operations	0	(0.17)	2.51	(0.05)
Diluted net income (loss) per common share	$ 0	$ (1.25)	$ 2.53	$ (1.99)

Net Income (Loss) Per Common 56

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	20,739	21,368	20,743	21,368
Options to Purchase Shares of Common Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	7,062	7,687	7,062	7,687
Warrants [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	4	4	4
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	3,411	3,411	3,411	3,411
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	27	27	27	27
Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,239	10,239	10,239	10,239

Net Income (Loss) Per Common 57

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Parenthetical) (Detail)	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	8.625%
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	3.00%	3.00%

Stockholders' Equity and Non-58

Stockholders' Equity and Non-controlling Interests - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Preferred stock dividends	$ 5,367	$ 5,367	$ 15,926	$ 15,926
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock dividends	5,300	5,300	15,900	15,900
Preferred stock dividends accrued	5,300		5,300
Preferred stock dividends cash paid	$ 5,300	$ 5,300	$ 15,900	$ 15,900

Stockholders' Equity and Non-59

Stockholders' Equity and Non-controlling Interests - Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			$ 1,909,745	$ 2,078,138
Issuance of common stock under employee compensation plans			76,457	35,593
Tax withholdings related to net share settlement of restricted stock units			(2,240)	0
Preferred stock dividends			(15,970)	(15,970)
Stock-based compensation expense			19,596	7,751
Excess tax benefits on exercised stock options			3,153	(6,302)
Net income (loss)	$ 5,501	$ (98,690)	234,992	(149,162)
Total other comprehensive loss	(88,393)	(95,937)	(123,765)	(69,478)
Equity, end of period	2,101,968	1,880,570	2,101,968	1,880,570
Total Stockholders' Equity [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			1,905,599	2,073,256
Issuance of common stock under employee compensation plans			76,457	35,593
Tax withholdings related to net share settlement of restricted stock units			(2,240)	0
Preferred stock dividends			(15,970)	(15,970)
Stock-based compensation expense			19,596	7,751
Excess tax benefits on exercised stock options			3,153	(6,302)
Net income (loss)			234,606	(149,026)
Total other comprehensive loss			(123,765)	(69,478)
Equity, end of period	2,097,436	1,875,824	2,097,436	1,875,824
Non-controlling Interests [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			4,146	4,882
Issuance of common stock under employee compensation plans			0	0
Tax withholdings related to net share settlement of restricted stock units			0	0
Preferred stock dividends			0	0
Stock-based compensation expense			0	0
Excess tax benefits on exercised stock options			0	0
Net income (loss)			386	(136)
Total other comprehensive loss			0	0
Equity, end of period	$ 4,532	$ 4,746	$ 4,532	$ 4,746

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jul. 10, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
General and administrative expense related to acquisition	$ 200	$ 300	$ 300	$ 700
Goodwill	2,842,921		2,842,921			$ 2,926,666
U.S. Diagnostics [Member]
Business Acquisition [Line Items]
Preliminary aggregate purchase price					$ 60,100
Total revenue related to acquisition	5,000		5,000
Goodwill	$ 29,400		$ 29,400

Business Combinations - Summary

Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Business Combinations [Abstract]
Current assets	$ 4,652
Property, plant and equipment	182
Goodwill	29,422
Intangible assets	27,200
Total assets acquired	61,456
Current liabilities	1,321
Total liabilities assumed	1,321
Net assets acquired	60,135
Cash paid	$ 60,135

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Finite And Infinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 27,200
Trademarks [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 1,600
Trademarks [Member] | Minimum [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Weighted-average Useful Life	3 years
Trademarks [Member] | Maximum [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Weighted-average Useful Life	13 years
Customer Relationships [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 24,900
Weighted-average Useful Life	13 years
Non-Competition Agreements [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 700
Weighted-average Useful Life	2 years

Restructuring Plans - Aggregate

Restructuring Plans - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2,264	$ 17,297	$ 11,387	$ 37,075
Restructuring charges	2,270	17,306	11,406	37,107
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6	9	19	32
Cost of Net Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	522	5,654	2,921	6,707
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	18	5,457	667	8,488
Sales and Marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	619	1,019	2,572	7,420
General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,105	5,167	5,227	14,460
Total Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2,264	$ 17,297	$ 11,387	$ 37,075

Restructuring Plans - Restructu

Restructuring Plans - Restructuring Activities Related to Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		93 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2,264	$ 17,297	$ 11,387	$ 37,075
Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,578	14,119	10,103	29,747
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	686	3,178	1,284	7,328
2014 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,578	13,862	9,009	28,219	$ 51,227
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,322	5,827	5,385	17,923	33,192
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs (Recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	132	1,713	3,045	1,894	6,505
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges (Recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,454	7,540	8,430	19,817	39,697
2014 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	124	6,322	579	8,402	11,530
2014 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	686	3,178	1,284	7,328	15,520
2014 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	686	199	1,297	2,399	4,198
2014 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs (Recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	2,979	(13)	4,929	11,322
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Other non-cash charges	0	0	0	0	64
Restructuring charges	6	266	1,113	1,560	46,843
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	56	0	990	26,926
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member] | Facility and Transition Costs (Recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	201	1,094	537	11,574
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member] | Cash Charges (Recoveries) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6	266	1,113	1,560	39,317
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	0	0	0	6,776
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6	9	19	33	817
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member] | Professional Diagnostics [Member] | Intangible Asset Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 0	$ 0	$ 0	$ 0	$ 686

Restructuring Plans - Additiona

Restructuring Plans - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves included in accrued expenses and other current liabilities	$ 4.6
Restructuring reserves included in other long-term liabilities	0.7
2014 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	4.1
Restructuring Plan Two Thousand Thirteen Two Thousand Eleven and Two Thousand Eight [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	1.1
Professional Diagnostics [Member] | 2014 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	$ 4.2

Restructuring Plans - Cash Acti

Restructuring Plans - Cash Activity for Restructuring Reserves (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Cash charges	$ (2,264)	$ (17,297)	$ (11,387)	$ (37,075)
Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			14,748
Cash charges			10,694
Payments			(19,725)
Currency adjustments			(459)
Restructuring Reserve, Ending Balance	5,258		5,258
Severance-Related Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			4,590
Cash charges			6,288
Payments			(8,460)
Currency adjustments			(156)
Restructuring Reserve, Ending Balance	2,262		2,262
Facility and Transition Costs (Recoveries) [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			9,868
Cash charges			4,387
Payments			(11,166)
Currency adjustments			(303)
Restructuring Reserve, Ending Balance	2,786		2,786
Other Exit Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			290
Cash charges			19
Payments			(99)
Currency adjustments			0
Restructuring Reserve, Ending Balance	$ 210		$ 210

Debt - Long-Term Debt Balances

Debt - Long-Term Debt Balances Outstanding (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 24, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt, Total	$ 3,591,750		$ 3,710,260
Less: Short-term debt and current portion of long-term debt	(604,092)		(88,875)
Long-term debt	2,987,658		3,621,385
A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	638,823		0
B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	1,044,842		0
Prior Credit Facility - A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0		785,938
Prior Credit Facility - B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0		1,330,810
Prior Credit Facility Revolving Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0		127,000
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	450,000		450,000
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	425,000		425,000
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	425,000	$ 425,000
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	400,000		400,000
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	150,000		150,000
Other Lines of Credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	1,052		684
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 57,033		$ 40,828

Debt - Long-Term Debt Balance68

Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail) - USD ($) $ in Thousands	Oct. 01, 2015	Sep. 30, 2015	Jun. 24, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Long-term debt, Interest rate		8.625%		8.625%
Long-term debt, Total		$ 3,591,750		$ 3,591,750	$ 3,710,260
Maturity date			Oct. 1, 2015	Oct. 1, 2015
Restricted cash		$ 475,000		$ 475,000	$ 37,600
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		7.25%		7.25%	7.25%	7.25%
Long-term debt, Total		$ 450,000		$ 450,000	$ 450,000
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		6.50%		6.50%	6.50%	6.50%
Long-term debt, Total		$ 425,000		$ 425,000	$ 425,000
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		6.375%	6.375%	6.375%	6.375%	6.375%
Long-term debt, Total		$ 425,000	$ 425,000	$ 425,000
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		8.625%		8.625%	8.625%	8.625%
Long-term debt, Total		$ 400,000		$ 400,000	$ 400,000
Maturity date				Oct. 1, 2015
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate		3.00%		3.00%	3.00%	3.00%
Long-term debt, Total		$ 150,000		$ 150,000	$ 150,000
Maturity date		May 15, 2016
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage			102.156%
Restricted cash		$ 425,900	$ 425,900	$ 425,900
Subsequent Events [Member]
Debt Instrument [Line Items]
Maturity date	Oct. 1, 2015
Subsequent Events [Member] | 8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	8.625%
Long-term debt, Total	$ 400,000
Debt instrument, redemption price, percentage	102.156%

Debt - Long-Term Debt Interest

Debt - Long-Term Debt Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 52,333	$ 52,332	$ 158,258	$ 156,276
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	18,161	0	20,763	0
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	24,985	49,437	74,606
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	8,524	8,525	25,573	25,574
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,274	7,180	21,741	21,534
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,002	0	7,544	0
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	9,273	9,271	27,820	27,819
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	1,246	1,246	3,738	3,738
Other [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 853	$ 1,125	$ 1,642	$ 3,005

Debt - Long-Term Debt Interes70

Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 24, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt, Interest rate	8.625%		8.625%
Amortization fee	$ 400	$ 400	$ 1,100	$ 1,100
Loss on extinguishment of debt			3,480	$ 0
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 3,500
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%	7.25%		7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%	6.50%		6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%	6.375%	6.375%	6.375%
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	8.625%	8.625%	8.625%	8.625%		8.625%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%	3.00%		3.00%

Debt - Secured Credit Facility

Debt - Secured Credit Facility - Additional Information (Detail) - USD ($)	Jun. 18, 2015	Sep. 30, 2015	Sep. 30, 2014
Debt Instrument [Line Items]
Sublimit for the issuance of letters of credit	$ 250,000,000
Proceeds of term loans under secured credit facility		$ 2,162,022,000	$ 41,000
Letter of Credit [Member]
Debt Instrument [Line Items]
Sublimit for the issuance of letters of credit	50,000,000
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Aggregate term loans amount under secured credit facility	1,700,000,000	1,700,000,000
Proceeds of term loans under secured credit facility	1,680,000,000
A Term Loans [Member]
Debt Instrument [Line Items]
Aggregate term loans amount under secured credit facility	650,000,000	$ 638,800,000
Number of installments for repayments of term loans		Nineteen consecutive quarterly installments
Term loan installment		$ 8,125,000
Term loan final installment		$ 495,625,000
Consolidated secured leverage ratio Base Rate		2.00%
Consolidated secured leverage ratio Eurodollar Rate		3.00%
Lines of credit interest rate percentage		3.20%
B Term Loans [Member]
Debt Instrument [Line Items]
Aggregate term loans amount under secured credit facility	$ 1,050,000,000	$ 1,044,800,000
Number of installments for repayments of term loans		Twenty-seven consecutive quarterly installments
Term loan installment		$ 2,625,000
Term loan final installment		$ 979,125,000
Soft call protection percentage		101.00%
Floor rate applicable to term loans based on Eurodollar rate		1.00%
Percentage of fee on the unused portion of revolving credit facility		0.50%
Lines of credit interest rate percentage		4.25%
B Term Loans [Member] | Minimum [Member]
Debt Instrument [Line Items]
Consolidated secured leverage ratio Base Rate		2.00%
Consolidated secured leverage ratio Eurodollar Rate		3.00%
B Term Loans [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated secured leverage ratio Base Rate		2.25%
Consolidated secured leverage ratio Eurodollar Rate		3.25%

Debt - Prior Credit Facility -

Debt - Prior Credit Facility - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Aggregate outstanding principal amount	$ 1,650

Debt - 6.375% Senior Subordinat

Debt - 6.375% Senior Subordinated Notes - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 24, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Long-term debt, Total		$ 3,591,750	$ 3,710,260
Long-term debt, Interest rate		8.625%
Percentage of aggregate principal amount redeemed		35.00%
Percentage of aggregate principal amount redeemed paid		106.375%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 425,000	$ 425,000
Long-term debt, Interest rate	6.375%	6.375%	6.375%	6.375%
Initial offering price		100.00%
Net proceeds from senior notes offering	$ 417,300	$ 417,300
Net purchasers discount		$ 7,700
Percentage of redemption premium for period one		4.781%
Percentage of redemption premium for period two		3.188%
Percentage of redemption premium for period three		1.594%
Percentage of redemption premium for period four		0.00%
Period of redemption of notes		90 days
Percentage of aggregate principal amount outstanding		65.00%
Percentage of aggregate principal amount to be sold		101.00%
Percentage of purchase price of aggregate principal amount		100.00%

Debt - 8.625% Senior Subordinat

Debt - 8.625% Senior Subordinated Notes - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 01, 2015	Jun. 24, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Long-term debt, Total			$ 3,591,750	$ 3,710,260
Long-term debt, Interest rate			8.625%
Maturity date		Oct. 1, 2015	Oct. 1, 2015
Restricted cash			$ 475,000	$ 37,600
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage		102.156%
Additional cash allocated to redemption fund		$ 8,600
Restricted cash		425,900	425,900
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total		$ 425,000	$ 425,000
Long-term debt, Interest rate		6.375%	6.375%	6.375%	6.375%
Net proceeds from senior notes offering		$ 417,300	$ 417,300
Subsequent Events [Member]
Debt Instrument [Line Items]
Maturity date	Oct. 1, 2015
Subsequent Events [Member] | 8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 400,000
Long-term debt, Interest rate	8.625%
Debt instrument, redemption price, percentage	102.156%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	$ 157	$ 259
Total assets	157	259
Liabilities:
Contingent consideration obligations	63,591	139,671
Total liabilities	63,591	139,671
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	157	259
Total assets	157	259
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	63,591	139,671
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	63,591	139,671
Total liabilities	$ 63,591	$ 139,671

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) - Unobservable Inputs (Level 3) [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration obligations, December 31, 2014	$ 139,671
Payments	(21,928)
Present value accretion and adjustments	(54,168)
Foreign currency adjustments	16
Fair value of contingent consideration obligations, September 30, 2015	$ 63,591

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Billions	Sep. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Estimated fair value of debt	$ 3.6	$ 3.7
Debt, Total	$ 3.6	$ 3.7

Defined Benefit Pension Plan -

Defined Benefit Pension Plan - Net Periodic Benefit Costs (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	234	202	694	604
Expected return on plan assets	(240)	(191)	(712)	(571)
Amortization of prior service costs	344	111	1,019	333
Net periodic benefit cost	$ 338	$ 122	$ 1,001	$ 366

Financial Information by Segm79

Financial Information by Segment - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015Segments
Segment Reporting [Abstract]
Number of operating segments	4

Financial Information by Segm80

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net revenue	$ 602,044	$ 649,210	$ 1,839,353	$ 1,921,847
Operating income (loss)	29,165	35,342	148,409	64,589
Impairment and (gain) loss on dispositions, net	2,074	0	42,408	638
Depreciation and amortization	86,500	83,124	233,511	250,763
Restructuring charge	2,264	17,297	11,387	37,075
Stock-based compensation	7,317	3,169	19,596	7,751
Assets	6,574,165		6,574,165		$ 6,678,956
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	583,297	628,012	1,773,993	1,856,629
Operating income (loss)	54,452	64,986	219,544	129,446
Impairment and (gain) loss on dispositions, net	2,074		42,408	638
Depreciation and amortization	83,817	80,366	226,383	244,698
Restructuring charge	1,578	14,119	10,103	29,747
Stock-based compensation	0	0	0	0
Assets	5,749,115		5,749,115		6,323,944
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	18,747	21,198	65,360	65,218
Operating income (loss)	1,038	3,742	4,321	10,617
Impairment and (gain) loss on dispositions, net	0		0	0
Depreciation and amortization	717	841	2,153	2,604
Restructuring charge	0	0	0	0
Stock-based compensation	0	0	0	0
Assets	200,491		200,491		216,451
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Operating income (loss)	(26,325)	(33,386)	(75,456)	(75,474)
Impairment and (gain) loss on dispositions, net	0		0	0
Depreciation and amortization	1,966	1,917	4,975	3,461
Restructuring charge	686	3,178	1,284	7,328
Stock-based compensation	7,317	$ 3,169	19,596	$ 7,751
Assets	$ 624,559		$ 624,559		$ 138,561

Financial Information by Segm81

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics and Consumer Diagnostics Reporting Segments by Groups of Similar Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Sales revenue net	$ 598,745	$ 645,028	$ 1,825,662	$ 1,905,849
Total professional diagnostics net product sales and services revenue	128,341	137,403	378,825	406,547
License and royalty revenue	3,299	4,182	13,691	15,998
Net revenue	602,044	649,210	1,839,353	1,921,847
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	583,297	628,012	1,773,993	1,856,629
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Total professional diagnostics net product sales and services revenue	579,998	623,830	1,760,302	1,840,631
License and royalty revenue	3,299	4,182	13,691	15,998
Net revenue	583,297	628,012	1,773,993	1,856,629
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Cardiometabolic [Member]
Segment Reporting Information [Line Items]
Sales revenue net	208,319	208,248	624,823	631,452
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Sales revenue net	163,759	184,018	519,145	526,632
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Sales revenue net	162,571	166,381	468,822	491,561
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Sales revenue net	$ 45,349	$ 65,183	$ 147,512	$ 190,986

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2015CNY (¥)	May. 31, 2007
Related Party Transaction [Line Items]
Restructuring charges	$ 2,264,000	$ 17,297,000	$ 11,387,000	$ 37,075,000
Restricted cash	475,000,000		475,000,000		$ 37,600,000
SPD Shanghai [Member]
Related Party Transaction [Line Items]
Restricted cash	3,700,000		3,700,000
SPD Shanghai [Member] | Maximum [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party	3,700,000		3,700,000			¥ 23,000,000
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Joint venture ownership percentage with Procter & Gamble							50.00%
Net receivable from SPD	900,000		900,000
Net payable to SPD					4,000,000
Restructuring charges			1,500,000		1,500,000
Long-term receivable cost related to restructuring plan	9,100,000		9,100,000		10,900,000
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables	7,400,000		7,400,000		9,600,000
Trade receivables from SPD	10,000,000		10,000,000		10,500,000
Trade payable to SPD	37,600,000		37,600,000		$ 34,800,000
SPD Joint Venture [Member] | Sales Revenue Goods [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	17,300,000	19,600,000	58,500,000	60,800,000
SPD Joint Venture [Member] | Sales Revenue Services [Member]
Related Party Transaction [Line Items]
Revenue from joint venture	$ 200,000	$ 300,000	$ 800,000	$ 1,000,000

Related Party Transactions - Re

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 452,366	$ 466,106
Prepaid expenses and other current assets	121,023	132,413
Deferred financing costs, net, and other non-current assets	63,279	67,832
Accounts payable	194,246	213,592
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	10,049	10,465
Prepaid expenses and other current assets	7,404	9,635
Deferred financing costs, net, and other non-current assets	9,100	10,875
Accounts payable	$ 37,608	$ 34,816

Other Arrangements - Additional

Other Arrangements - Additional Information (Detail) - USD ($) $ in Millions	Jun. 24, 2015	Sep. 30, 2014	Feb. 28, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Period of contract		3 years 6 months
The amount provided for development of diagnostic device by BARDA as defined in the agreement		$ 12.9
Net expenditure incurred under the contract				$ 0.8		$ 2.2
The amount of cash reimbursement received from BARDA				0.6		1.6
Amount of accounts receivable				0.6		$ 0.6
Maturity date	Oct. 1, 2015					Oct. 1, 2015
Gates Foundation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded			$ 21.6
Cash received from grant-related funding						$ 19.7
Qualified expenditures				$ 0.3	$ 2.5	$ 3.9	$ 7
Gates Loan Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Aggregate principal amount of subordinated term loan			$ 20.6
Loan bearing interest rate				3.00%		3.00%
Maturity date						Dec. 31, 2019
Deferred grant fund				$ 0.3		$ 0.3

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended	9 Months Ended
	Sep. 30, 2012Patient	Sep. 30, 2015USD ($)Milestone
Loss Contingencies [Line Items]
Number of patients for whom claim for damages filed for inadvertent disclosure of personally identifiable information | Patient	116,000
TwistDx, Inc. [Member]
Loss Contingencies [Line Items]
Change in fair value of contingent consideration		$ 16.2
Epocal [Member]
Loss Contingencies [Line Items]
Change in fair value of contingent consideration		$ (31.5)
Number of milestone achieved in relation with contingent consideration | Milestone		1
Cash payment		$ 10
Ionian Technologies, Inc. [Member]
Loss Contingencies [Line Items]
Change in fair value of contingent consideration		$ (24.5)

Commitments and Contingencies86

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Apr. 03, 2015	Mar. 27, 2015	Dec. 31, 2014
Business Acquisition, Contingent Consideration [Line Items]
Estimated Fair Value	$ 63,591,000			$ 139,671,000
Payments made during 2015	$ 21,928,000
Ionian Technologies, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Jul. 12, 2010
Acquisition Date Fair Value	$ 24,500,000
Maximum Remaining Earn-out Potential	$ 0
Estimated Fair Value				24,500,000
DiagnosisOne, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Jul. 31, 2012
Acquisition Date Fair Value	$ 22,300,000
Maximum Remaining Earn-out Potential	0
Estimated Fair Value				21,000,000
Payments made during 2015	$ 6,000,000	$ 1,500,000	$ 4,500,000
TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Mar. 11, 2010
Acquisition Date Fair Value	$ 35,600,000
Maximum Remaining Earn-out Potential	103,247,000
Estimated Fair Value	51,900,000			41,100,000
Payments made during 2015	$ 5,377,000
TwistDx, Inc. [Member] | Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,015
TwistDx, Inc. [Member] | Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,025
Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Feb. 1, 2013
Acquisition Date Fair Value	$ 75,000,000
Maximum Remaining Earn-out Potential	55,500,000
Estimated Fair Value	5,700,000			47,200,000
Payments made during 2015	$ 10,000,000
Epocal [Member] | Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,015
Epocal [Member] | Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,018
Other [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Various
Acquisition Date Fair Value	$ 30,373,000
Maximum Remaining Earn-out Potential	0
Estimated Fair Value	5,991,000			$ 5,871,000
Payments made during 2015	$ 551,000
Other [Member] | Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,015
Other [Member] | Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016

Commitments and Contingencies87

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Apr. 03, 2015	Mar. 27, 2015	Mar. 25, 2015
Business Acquisition, Contingent Consideration [Line Items]
Payments made under acquisition related contingent obligations	$ 21,928
Earn-out period	15 years
Ionian Technologies, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Earn-out period under terms of acquisition agreement expiration date	Jul. 12, 2015
DiagnosisOne, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration remaining earn-out settlement				$ 6,000
Payments made under acquisition related contingent obligations	$ 6,000	$ 1,500	$ 4,500

Equity Investments - Additional

Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 31, 2007
Schedule of Equity Method Investments [Line Items]
Equity earnings (loss) of unconsolidated entities, net of tax	$ 5,000	$ 6,277	$ 10,320	$ 13,716
SPD Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage					50.00%
SPD [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings (loss) of unconsolidated entities, net of tax	$ 5,300	5,900	9,500	12,800
Return of capital			$ 12,100
SPD [Member] | SPD Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage	50.00%		50.00%
TechLab [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings (loss) of unconsolidated entities, net of tax	$ (300)	$ 900	$ 1,000	$ 1,600
Return of capital			$ 2,200
TechLab [Member] | SPD Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage	49.00%		49.00%

Equity Investments - Financial

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]
Net revenue	$ 56,303	$ 65,397	$ 157,319	$ 155,533
Gross profit	43,538	40,268	111,368	120,680
Net income after taxes	$ 15,735	$ 12,834	$ 26,831	$ 27,992

Equity Investments - Financia90

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]
Current assets	$ 83,646	$ 90,546
Non-current assets	31,413	33,697
Total assets	115,059	124,243
Current liabilities	32,352	35,954
Non-current liabilities	5,487	5,884
Total liabilities	$ 37,839	$ 41,838

Impairment and (Gain) Loss on D

Impairment and (Gain) Loss on Dispositions, Net - Additional Information (Detail) € in Millions, AUD in Millions, $ in Millions	1 Months Ended					3 Months Ended	9 Months Ended
	Jul. 31, 2015USD ($)	Jul. 31, 2015AUD	Mar. 31, 2015USD ($)	Mar. 31, 2015EUR (€)	Apr. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	May. 31, 2015USD ($)
Gesellschaft Fur Patientenhilfe Dgp Mbh [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of business			$ 8.2	€ 7.6
Loss on sale of disposal of group							$ 7.5
Glucostabilizer Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of business					$ 1.1
Loss on sale of disposal of group								$ 0.6
Glucostabilizer Business [Member] | Medical Decision Network Llc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Note receivable					$ 1.5
Alere Analytics [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) from sale of assets							(4.7)
Impairment charges							26.7
Write-off of intangible assets							26.2
Write-off of fixed assets							0.5
Contribution to working capital									$ 2.7
Alere Analytics [Member] | Cash [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to working capital									2.4
Alere Analytics [Member] | Escrow [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to working capital									$ 0.3
AdnaGen Gmbh [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets			$ 4.6
Gain (loss) from sale of assets							(0.3)
Alere Connect Llc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges							1.1
Inverness Medical Innovations Australia Pty Ltd business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 0.1	AUD 0.2
Gain (loss) from sale of assets						$ (1.2)	(1.2)
Business closures or divestitures costs						$ 0.9	$ 0.9

Provision (Benefit) for Incom92

Provision (Benefit) for Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Increase (decrease) in income tax provision	$ (84,400)		$ (79,300)
Provision (benefit) for income taxes	$ (18,924)	$ 65,489	$ (10,009)	$ 69,273
Effective tax rate	102.70%	(261.20%)	473.50%	(77.40%)

Guarantor Financial Informati93

Guarantor Financial Information - Additional Information (Detail)	Jun. 24, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Interest rate of debt instrument		8.625%
Maturity date	Oct. 1, 2015	Oct. 1, 2015
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument		7.25%	7.25%	7.25%
Maturity year of debt instrument		2,018
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument		8.625%	8.625%	8.625%
Maturity year of debt instrument		2,018
Maturity date		Oct. 1, 2015
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument		6.50%	6.50%	6.50%
Maturity year of debt instrument		2,020
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.375%	6.375%	6.375%	6.375%
Maturity year of debt instrument		2,023

Guarantor Financial Informati94

Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 470,404	$ 507,625	$ 1,446,837	$ 1,499,302
Services revenue	128,341	137,403	378,825	406,547
Net product sales and services revenue	598,745	645,028	1,825,662	1,905,849
License and royalty revenue	3,299	4,182	13,691	15,998
Net revenue	602,044	649,210	1,839,353	1,921,847
Cost of net product sales	246,055	271,250	743,177	785,918
Cost of services revenue	79,803	75,102	232,137	221,356
Cost of net product sales and services revenue	325,858	346,352	975,314	1,007,274
Cost of license and royalty revenue	1,137	1,236	4,431	3,900
Cost of net revenue	326,995	347,588	979,745	1,011,174
Gross profit (loss)	275,049	301,622	859,608	910,673
Operating expenses:
Research and development	36,011	38,726	91,225	114,855
Sales and marketing	106,493	122,760	322,756	391,605
General and administrative	101,306	104,794	254,810	338,986
Impairment and (gain) loss on dispositions, net	2,074	0	42,408	638
Operating income (loss)	29,165	35,342	148,409	64,589
Interest expense, including amortization of original issue discounts and deferred financing costs	(52,333)	(52,332)	(158,258)	(156,276)
Other income (expense), net	4,745	(8,087)	7,735	2,164
Income (loss) from continuing operations before provision (benefit) for income taxes	(18,423)	(25,077)	(2,114)	(89,523)
Provision (benefit) for income taxes	(18,924)	65,489	(10,009)	69,273
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax	501	(90,566)	7,895	(158,796)
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings (losses) of unconsolidated entities, net of tax	5,000	6,277	10,320	13,716
Income (loss) from continuing operations	5,501	(84,289)	18,215	(145,080)
Income (loss) from discontinued operations, net of tax	0	(14,401)	216,777	(4,082)
Net income (loss)	5,501	(98,690)	234,992	(149,162)
Less: Net income (loss) attributable to non-controlling interests	(61)	(306)	386	(136)
Net income (loss) attributable to Alere Inc. and Subsidiaries	5,562	(98,384)	234,606	(149,026)
Preferred stock dividends	(5,367)	(5,367)	(15,926)	(15,926)
Net income (loss) available to common stockholders	195	(103,751)	218,680	(164,952)
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	0	0	0	0
Services revenue	0	0	0	0
Net product sales and services revenue	0	0	0	0
License and royalty revenue	0	0	0	0
Net revenue	0	0	0	0
Cost of net product sales	2,090	912	2,923	2,291
Cost of services revenue	74	71	204	214
Cost of net product sales and services revenue	2,164	983	3,127	2,505
Cost of license and royalty revenue	(19)	28	(40)	28
Cost of net revenue	2,145	1,011	3,087	2,533
Gross profit (loss)	(2,145)	(1,011)	(3,087)	(2,533)
Operating expenses:
Research and development	5,670	7,256	11,213	20,034
Sales and marketing	1,335	1,265	4,165	6,329
General and administrative	22,960	33,549	67,873	78,257
Impairment and (gain) loss on dispositions, net	150		81,051	0
Operating income (loss)	(32,260)	(43,081)	(167,389)	(107,153)
Interest expense, including amortization of original issue discounts and deferred financing costs	(51,705)	(51,589)	(156,889)	(154,232)
Other income (expense), net	4,224	4,706	11,467	11,823
Income (loss) from continuing operations before provision (benefit) for income taxes	(79,741)	(89,964)	(312,811)	(249,562)
Provision (benefit) for income taxes	78,041	42,727	41,068	(2,566)
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax	(157,782)	(132,691)	(353,879)	(246,996)
Equity in earnings of subsidiaries, net of tax	163,647	49,642	369,200	97,307
Equity earnings (losses) of unconsolidated entities, net of tax	(364)	560	982	1,387
Income (loss) from continuing operations		(82,489)	16,303	(148,302)
Income (loss) from discontinued operations, net of tax		(16,201)	218,689	(860)
Net income (loss)	5,501	(98,690)	234,992	(149,162)
Less: Net income (loss) attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	5,501	(98,690)	234,992	(149,162)
Preferred stock dividends	(5,367)	(5,367)	(15,926)	(15,926)
Net income (loss) available to common stockholders	124	(104,057)	219,066	(165,088)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	227,939	214,585	657,751	623,208
Services revenue	115,829	122,045	338,869	355,132
Net product sales and services revenue	343,768	336,630	996,620	978,340
License and royalty revenue	3,246	2,993	9,676	10,312
Net revenue	347,014	339,623	1,006,296	988,652
Cost of net product sales	124,853	118,241	358,983	348,701
Cost of services revenue	81,549	74,441	233,470	216,142
Cost of net product sales and services revenue	206,402	192,682	592,453	564,843
Cost of license and royalty revenue	401	55	1,619	194
Cost of net revenue	206,803	192,737	594,072	565,037
Gross profit (loss)	140,211	146,886	412,224	423,615
Operating expenses:
Research and development	15,015	15,318	43,927	45,753
Sales and marketing	53,863	54,422	159,191	175,536
General and administrative	34,816	30,323	123,874	112,850
Impairment and (gain) loss on dispositions, net	85		(8,719)	638
Operating income (loss)	36,432	46,823	93,951	88,838
Interest expense, including amortization of original issue discounts and deferred financing costs	(2,613)	(4,420)	(8,958)	(14,933)
Other income (expense), net	3,921	4,835	12,796	15,867
Income (loss) from continuing operations before provision (benefit) for income taxes	37,740	47,238	97,789	89,772
Provision (benefit) for income taxes	(33,431)	13,657	(20,334)	42,896
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax	71,171	33,581	118,123	46,876
Equity in earnings of subsidiaries, net of tax	0	210	0	442
Equity earnings (losses) of unconsolidated entities, net of tax	0	0	0	0
Income (loss) from continuing operations		33,791	118,123	47,318
Income (loss) from discontinued operations, net of tax		(20,615)	(1,912)	(26,418)
Net income (loss)	71,171	13,176	116,211	20,900
Less: Net income (loss) attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	71,171	13,176	116,211	20,900
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	71,171	13,176	116,211	20,900
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	309,871	353,817	983,131	1,048,212
Services revenue	12,512	15,358	39,956	51,415
Net product sales and services revenue	322,383	369,175	1,023,087	1,099,627
License and royalty revenue	4,648	3,663	14,721	14,683
Net revenue	327,031	372,838	1,037,808	1,114,310
Cost of net product sales	175,836	204,983	550,081	591,778
Cost of services revenue	6,951	8,448	22,823	25,123
Cost of net product sales and services revenue	182,787	213,431	572,904	616,901
Cost of license and royalty revenue	5,350	3,627	13,558	12,675
Cost of net revenue	188,137	217,058	586,462	629,576
Gross profit (loss)	138,894	155,780	451,346	484,734
Operating expenses:
Research and development	15,326	16,152	36,085	49,068
Sales and marketing	51,295	67,073	159,400	209,740
General and administrative	43,530	40,922	63,063	147,879
Impairment and (gain) loss on dispositions, net	1,839		(29,924)	0
Operating income (loss)	26,904	31,633	222,722	78,047
Interest expense, including amortization of original issue discounts and deferred financing costs	(4,999)	(4,512)	(13,744)	(13,646)
Other income (expense), net	3,584	(9,438)	4,805	1,068
Income (loss) from continuing operations before provision (benefit) for income taxes	25,489	17,683	213,783	65,469
Provision (benefit) for income taxes	(63,534)	9,140	(31,051)	27,319
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax	89,023	8,543	244,834	38,150
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings (losses) of unconsolidated entities, net of tax	5,348	5,779	9,340	12,516
Income (loss) from continuing operations		14,322	254,174	50,666
Income (loss) from discontinued operations, net of tax		22,415	0	23,196
Net income (loss)	94,371	36,737	254,174	73,862
Less: Net income (loss) attributable to non-controlling interests	(61)	(306)	386	(136)
Net income (loss) attributable to Alere Inc. and Subsidiaries	94,432	37,043	253,788	73,998
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	94,432	37,043	253,788	73,998
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	(67,406)	(60,777)	(194,045)	(172,118)
Services revenue	0	0	0	0
Net product sales and services revenue	(67,406)	(60,777)	(194,045)	(172,118)
License and royalty revenue	(4,595)	(2,474)	(10,706)	(8,997)
Net revenue	(72,001)	(63,251)	(204,751)	(181,115)
Cost of net product sales	(56,724)	(52,886)	(168,810)	(156,852)
Cost of services revenue	(8,771)	(7,858)	(24,360)	(20,123)
Cost of net product sales and services revenue	(65,495)	(60,744)	(193,170)	(176,975)
Cost of license and royalty revenue	(4,595)	(2,474)	(10,706)	(8,997)
Cost of net revenue	(70,090)	(63,218)	(203,876)	(185,972)
Gross profit (loss)	(1,911)	(33)	(875)	4,857
Operating expenses:
Research and development	0	0	0	0
Sales and marketing	0	0	0	0
General and administrative	0	0	0	0
Impairment and (gain) loss on dispositions, net	0		0	0
Operating income (loss)	(1,911)	(33)	(875)	4,857
Interest expense, including amortization of original issue discounts and deferred financing costs	6,984	8,189	21,333	26,535
Other income (expense), net	(6,984)	(8,190)	(21,333)	(26,594)
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,911)	(34)	(875)	4,798
Provision (benefit) for income taxes	0	(35)	308	1,624
Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax	(1,911)	1	(1,183)	3,174
Equity in earnings of subsidiaries, net of tax	(163,647)	(49,852)	(369,200)	(97,749)
Equity earnings (losses) of unconsolidated entities, net of tax	16	(62)	(2)	(187)
Income (loss) from continuing operations		(49,913)	(370,385)	(94,762)
Income (loss) from discontinued operations, net of tax		0	0	0
Net income (loss)	(165,542)	(49,913)	(370,385)	(94,762)
Less: Net income (loss) attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(165,542)	(49,913)	(370,385)	(94,762)
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	$ (165,542)	$ (49,913)	$ (370,385)	$ (94,762)

Guarantor Financial Informati95

Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ 5,501	$ (98,690)	$ 234,992	$ (149,162)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(88,812)	(96,425)	(122,428)	(69,950)
Unrealized losses on available for sale securities	0	0	0	(17)
Unrealized gains on hedging instruments	0	7	0	21
Minimum pension liability adjustment	419	481	(1,337)	468
Other comprehensive income (loss), before tax	(88,393)	(95,937)	(123,765)	(69,478)
Income tax provision (benefit) related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(88,393)	(95,937)	(123,765)	(69,478)
Comprehensive income (loss)	(82,892)	(194,627)	111,227	(218,640)
Less: Comprehensive income (loss) attributable to non-controlling interests	(61)	(306)	386	(136)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(82,831)	(194,321)	110,841	(218,504)
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	5,501	(98,690)	234,992	(149,162)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(748)	(383)	(1,208)	(137)
Unrealized losses on available for sale securities				0
Unrealized gains on hedging instruments		0		0
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	(748)	(383)	(1,208)	(137)
Income tax provision (benefit) related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(748)	(383)	(1,208)	(137)
Comprehensive income (loss)	4,753	(99,073)	233,784	(149,299)
Less: Comprehensive income (loss) attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	4,753	(99,073)	233,784	(149,299)
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	71,171	13,176	116,211	20,900
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(570)	(104)	(453)	(178)
Unrealized losses on available for sale securities				(17)
Unrealized gains on hedging instruments		0		0
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	(570)	(104)	(453)	(195)
Income tax provision (benefit) related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(570)	(104)	(453)	(195)
Comprehensive income (loss)	70,601	13,072	115,758	20,705
Less: Comprehensive income (loss) attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	70,601	13,072	115,758	20,705
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	94,371	36,737	254,174	73,862
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(87,314)	(95,936)	(120,587)	(69,633)
Unrealized losses on available for sale securities				0
Unrealized gains on hedging instruments		7		21
Minimum pension liability adjustment	419	481	(1,337)	468
Other comprehensive income (loss), before tax	(86,895)	(95,448)	(121,924)	(69,144)
Income tax provision (benefit) related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(86,895)	(95,448)	(121,924)	(69,144)
Comprehensive income (loss)	7,476	(58,711)	132,250	4,718
Less: Comprehensive income (loss) attributable to non-controlling interests	(61)	(306)	386	(136)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	7,537	(58,405)	131,864	4,854
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(165,542)	(49,913)	(370,385)	(94,762)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(180)	(2)	(180)	(2)
Unrealized losses on available for sale securities				0
Unrealized gains on hedging instruments		0		0
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	(180)	(2)	(180)	(2)
Income tax provision (benefit) related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(180)	(2)	(180)	(2)
Comprehensive income (loss)	(165,722)	(49,915)	(370,565)	(94,764)
Less: Comprehensive income (loss) attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ (165,722)	$ (49,915)	$ (370,565)	$ (94,764)

Guarantor Financial Informati96

Guarantor Financial Information - Guarantor Financial Information Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 479,381	$ 378,461	$ 431,351	$ 355,431
Restricted cash	430,821	37,571
Marketable securities	157	259
Accounts receivable, net of allowances	452,366	466,106
Inventories, net	362,226	365,165
Deferred tax assets	15,424	112,573
Prepaid expenses and other current assets	121,023	132,413
Assets held for sale - current	25,312	315,515
Intercompany receivables		0
Total current assets	1,886,710	1,808,063
Property, plant and equipment, net	445,315	453,570
Goodwill	2,842,921	2,926,666
Other intangible assets with indefinite lives	28,744	43,651
Finite-lived intangible assets, net	1,052,949	1,276,444
Restricted cash	44,148
Deferred financing costs, net and other non-current assets	63,279	67,832
Investments in subsidiaries		0
Investments in unconsolidated entities	73,882	91,693
Deferred tax assets	7,632	8,569
Non-current income tax receivable	2,537	2,468
Assets held for sale - non-current	126,048	0
Intercompany notes receivables		0
Total assets	6,574,165	6,678,956
Current liabilities:
Short-term debt and current portion of long-term debt	604,092	88,875
Current portion of capital lease obligations	3,505	4,241
Accounts payable	194,246	213,592
Accrued expenses and other current liabilities	315,336	375,494
Liabilities related to assets held for sale - current	8,836	78,843
Intercompany payables		0
Total current liabilities	1,126,015	761,045
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	2,987,658	3,621,385
Capital lease obligations, net of current portion	6,270	10,560
Deferred tax liabilities	207,451	214,639
Other long-term liabilities	135,200	161,582
Liabilities related to assets held for sale - non-current	9,603	0
Intercompany notes payables		0
Total long-term liabilities	3,346,182	4,008,166
Total stockholders' equity	2,097,436	1,905,599
Non-controlling interests	4,532	4,146
Total equity	2,101,968	1,909,745	1,880,570	2,078,138
Total liabilities and equity	6,574,165	6,678,956
Issuer [Member]
CURRENT ASSETS:
Cash and cash equivalents	142,996	2,149	11,469	14,801
Restricted cash	426,170	5,012
Marketable securities		0
Accounts receivable, net of allowances		0
Inventories, net		0
Deferred tax assets	(39,530)	36,347
Prepaid expenses and other current assets	7,824	9,800
Assets held for sale - current		1,361
Intercompany receivables	642,439	404,990
Total current assets	1,179,899	459,659
Property, plant and equipment, net	31,011	30,547
Goodwill		0
Other intangible assets with indefinite lives		0
Finite-lived intangible assets, net	3,072	6,104
Deferred financing costs, net and other non-current assets	44,098	40,992
Investments in subsidiaries	3,439,664	3,740,004
Investments in unconsolidated entities	503	13,987
Deferred tax assets		0
Non-current income tax receivable	2,537	2,468
Assets held for sale - non-current	13,013
Intercompany notes receivables	2,030,141	2,028,701
Total assets	6,743,938	6,322,462
Current liabilities:
Short-term debt and current portion of long-term debt	601,712	61,700
Current portion of capital lease obligations		0
Accounts payable	14,000	21,402
Accrued expenses and other current liabilities	(394,578)	(536,286)
Liabilities related to assets held for sale - current		1,094
Intercompany payables	1,042,991	902,576
Total current liabilities	1,264,125	450,486
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	2,940,664	3,615,759
Capital lease obligations, net of current portion		0
Deferred tax liabilities	(70,862)	(107,844)
Other long-term liabilities	37,984	42,762
Intercompany notes payables	474,591	415,700
Total long-term liabilities	3,382,377	3,966,377
Total stockholders' equity	2,097,436	1,905,599
Non-controlling interests		0
Total equity	2,097,436	1,905,599
Total liabilities and equity	6,743,938	6,322,462
Guarantor Subsidiaries [Member]
CURRENT ASSETS:
Cash and cash equivalents	7,649	69,154	91,188	78,976
Restricted cash		0
Marketable securities	157	259
Accounts receivable, net of allowances	205,533	192,775
Inventories, net	194,697	191,323
Deferred tax assets	31,285	44,961
Prepaid expenses and other current assets	31,605	31,410
Assets held for sale - current		284,369
Intercompany receivables	762,656	888,688
Total current assets	1,233,582	1,702,939
Property, plant and equipment, net	229,347	218,613
Goodwill	1,824,191	1,795,663
Other intangible assets with indefinite lives	7,662	9,287
Finite-lived intangible assets, net	656,064	742,760
Deferred financing costs, net and other non-current assets	3,716	5,334
Investments in subsidiaries	179,542	179,315
Investments in unconsolidated entities	14,765	14,765
Deferred tax assets		0
Non-current income tax receivable		0
Intercompany notes receivables	676,485	649,444
Total assets	4,825,354	5,318,120
Current liabilities:
Short-term debt and current portion of long-term debt		2
Current portion of capital lease obligations	1,404	1,045
Accounts payable	87,659	81,741
Accrued expenses and other current liabilities	612,572	663,221
Liabilities related to assets held for sale - current		77,749
Intercompany payables	263,528	198,788
Total current liabilities	965,163	1,022,546
LONG-TERM LIABILITIES:
Long-term debt, net of current portion		0
Capital lease obligations, net of current portion	2,001	4,097
Deferred tax liabilities	214,277	252,944
Other long-term liabilities	62,242	46,865
Intercompany notes payables	1,189,716	1,276,245
Total long-term liabilities	1,468,236	1,580,151
Total stockholders' equity	2,391,955	2,715,423
Non-controlling interests		0
Total equity	2,391,955	2,715,423
Total liabilities and equity	4,825,354	5,318,120
Non-Guarantor Subsidiaries [Member]
CURRENT ASSETS:
Cash and cash equivalents	328,736	307,158	328,694	261,654
Restricted cash	4,651	32,559
Marketable securities		0
Accounts receivable, net of allowances	246,833	273,331
Inventories, net	190,143	195,606
Deferred tax assets	25,788	31,265
Prepaid expenses and other current assets	74,901	88,695
Assets held for sale - current	25,312	29,785
Intercompany receivables	81,594	55,923
Total current assets	977,958	1,014,322
Property, plant and equipment, net	185,403	204,188
Goodwill	1,018,730	1,131,003
Other intangible assets with indefinite lives	21,141	34,422
Finite-lived intangible assets, net	393,813	527,580
Restricted cash	44,148
Deferred financing costs, net and other non-current assets	15,734	21,541
Investments in subsidiaries	59,431	58,067
Investments in unconsolidated entities	44,640	49,608
Deferred tax assets	7,632	8,569
Non-current income tax receivable		0
Assets held for sale - non-current	113,035
Intercompany notes receivables	4,967	46,676
Total assets	2,886,632	3,095,976
Current liabilities:
Short-term debt and current portion of long-term debt	2,380	27,173
Current portion of capital lease obligations	2,101	3,196
Accounts payable	92,587	110,449
Accrued expenses and other current liabilities	95,013	248,604
Liabilities related to assets held for sale - current	8,836	0
Intercompany payables	180,170	248,237
Total current liabilities	381,087	637,659
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	46,994	5,626
Capital lease obligations, net of current portion	4,269	6,463
Deferred tax liabilities	63,954	69,457
Other long-term liabilities	35,243	71,988
Liabilities related to assets held for sale - non-current	9,603
Intercompany notes payables	1,047,286	1,032,876
Total long-term liabilities	1,207,349	1,186,410
Total stockholders' equity	1,293,664	1,267,761
Non-controlling interests	4,532	4,146
Total equity	1,298,196	1,271,907
Total liabilities and equity	2,886,632	3,095,976
Eliminations [Member]
CURRENT ASSETS:
Cash and cash equivalents	0	0	$ 0	$ 0
Restricted cash		0
Marketable securities		0
Accounts receivable, net of allowances		0
Inventories, net	(22,614)	(21,764)
Deferred tax assets	(2,119)	0
Prepaid expenses and other current assets	6,693	2,508
Assets held for sale - current		0
Intercompany receivables	(1,486,689)	(1,349,601)
Total current assets	(1,504,729)	(1,368,857)
Property, plant and equipment, net	(446)	222
Goodwill		0
Other intangible assets with indefinite lives	(59)	(58)
Finite-lived intangible assets, net		0
Deferred financing costs, net and other non-current assets	(269)	(35)
Investments in subsidiaries	(3,678,637)	(3,977,386)
Investments in unconsolidated entities	13,974	13,333
Deferred tax assets		0
Non-current income tax receivable		0
Intercompany notes receivables	(2,711,593)	(2,724,821)
Total assets	(7,881,759)	(8,057,602)
Current liabilities:
Short-term debt and current portion of long-term debt		0
Current portion of capital lease obligations		0
Accounts payable		0
Accrued expenses and other current liabilities	2,329	(45)
Liabilities related to assets held for sale - current		0
Intercompany payables	(1,486,689)	(1,349,601)
Total current liabilities	(1,484,360)	(1,349,646)
LONG-TERM LIABILITIES:
Long-term debt, net of current portion		0
Capital lease obligations, net of current portion		0
Deferred tax liabilities	82	82
Other long-term liabilities	(269)	(33)
Intercompany notes payables	(2,711,593)	(2,724,821)
Total long-term liabilities	(2,711,780)	(2,724,772)
Total stockholders' equity	(3,685,619)	(3,983,184)
Non-controlling interests		0
Total equity	(3,685,619)	(3,983,184)
Total liabilities and equity	$ (7,881,759)	$ (8,057,602)

Guarantor Financial Informati97

Guarantor Financial Information - Guarantor Financial Information Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Cash Flows from Operating Activities:
Net income (loss)	$ 5,501	$ (98,690)	$ 234,992	$ (149,162)
Income (loss) from discontinued operations, net of tax	0	(14,401)	216,777	(4,082)
Income (loss) from continuing operations	5,501	(84,289)	18,215	(145,080)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Tax benefit related to discontinued operations			0	9,594
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			10,627	11,824
Depreciation and amortization	86,500	83,124	233,511	250,763
Non-cash stock-based compensation expense	7,317	3,169	19,596	7,751
Impairment of inventory			201	1,536
Impairment of long-lived assets			378	6,866
Loss on sale of fixed assets			3,273	4,679
Equity earnings of unconsolidated entities, net of tax	(5,000)	(6,277)	(10,320)	(13,716)
Deferred income taxes			(46,740)	9,557
Impairment and (gain) loss on dispositions, net	2,074	0	42,408	638
Loss on extinguishment of debt			3,480	0
Other non-cash items			(4,785)	3,683
Non-cash change in fair value of contingent purchase price consideration			(51,911)	17,042
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			(11,269)	12,643
Inventories, net			(58,781)	(30,446)
Prepaid expenses and other current assets			(14,953)	(8,646)
Accounts payable			(16,000)	38,687
Accrued expenses and other current liabilities			35,192	(8,501)
Other non-current liabilities			(8,790)	33,221
Cash paid for contingent purchase price consideration			(6,315)	(21,078)
Intercompany payable (receivable)			0	0
Net cash provided by (used in) continuing operations			136,932	181,017
Net cash provided by discontinued operations			318	34,417
Net cash provided by (used in) operating activities			137,250	215,434
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			(438,765)	(3,227)
Purchases of property, plant and equipment			(67,947)	(73,035)
Proceeds from sale of property, plant and equipment			1,486	1,144
Cash received from (used in) disposition, net of cash divested			586,625	5,454
Cash paid for business acquisitions, net of cash acquired			(60,135)	(75)
Cash received from sales of (paid for purchase of) marketable securities			99	47
Cash received from (paid for) investments				198
Cash received from equity method investments			14,297	198
Proceeds from sale of equity investment			0	9,526
(Increase) decrease in other assets			881	1,024
Net cash provided by (used in) continuing operations			36,541	(58,944)
Net cash used in discontinued operations			(209)	(8,853)
Net cash provided by (used in) investing activities			36,332	(67,797)
Cash Flows from Financing Activities:
Cash paid for financing costs			(16,053)	(5)
Cash paid for contingent purchase price consideration			(14,079)	(23,608)
Cash paid for dividends			(15,970)	(15,970)
Proceeds from issuance of common stock, net of issuance costs			76,457	35,593
Proceeds from issuance of short-term debt			0	806
Proceeds from issuance of long-term debt			2,162,022	41
Payments on short-term debt			(25,584)	0
Payments on long-term debt			(2,129,165)	(47,302)
Net proceeds (payments) under revolving credit facilities			(126,603)	498
Excess tax benefits on exercised stock options			6,102	415
Principal payments on capital lease obligations			(4,339)	(4,639)
Net cash provided by (used in) continuing operations			(87,212)	(54,171)
Net cash used in discontinued operations			(76)	(1,075)
Net cash provided by (used in) financing activities			(87,288)	(55,246)
Foreign exchange effect on cash and cash equivalents			(8,674)	(9,445)
Net increase (decrease) in cash and cash equivalents			77,620	82,946
Cash and cash equivalents, beginning of period - continuing operations			378,461	355,431
Cash and cash equivalents, beginning of period - discontinued operations			23,300	6,477
Cash and cash equivalents, end of period	479,381	444,854	479,381	444,854
Less: Cash and cash equivalents of discontinued operations, end of period	0	13,503	0	13,503
Cash and cash equivalents of continuing operations, end of period	479,381	431,351	479,381	431,351
Issuer [Member]
Cash Flows from Operating Activities:
Net income (loss)	5,501	(98,690)	234,992	(149,162)
Income (loss) from discontinued operations, net of tax		(16,201)	218,689	(860)
Income (loss) from continuing operations		(82,489)	16,303	(148,302)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	(163,647)	(49,642)	(369,200)	(97,307)
Tax benefit related to discontinued operations				0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			10,542	11,575
Depreciation and amortization			7,891	4,417
Non-cash stock-based compensation expense			10,600	1,629
Impairment of inventory			0	0
Impairment of long-lived assets			0	1,573
Loss on sale of fixed assets			0	0
Equity earnings of unconsolidated entities, net of tax	364	(560)	(982)	(1,387)
Deferred income taxes			(8,686)	28,030
Impairment and (gain) loss on dispositions, net	150		81,051	0
Loss on extinguishment of debt			3,480
Other non-cash items			(376)	(988)
Non-cash change in fair value of contingent purchase price consideration			(33,667)	3,326
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			0	0
Inventories, net			0	0
Prepaid expenses and other current assets			3,098	503,712
Accounts payable			(7,435)	2,637
Accrued expenses and other current liabilities			111,628	(535,345)
Other non-current liabilities			(16,364)	23,922
Cash paid for contingent purchase price consideration			(6,302)	(20,966)
Intercompany payable (receivable)			334,642	277,206
Net cash provided by (used in) continuing operations			136,223	53,732
Net cash provided by discontinued operations			0	7,881
Net cash provided by (used in) operating activities			136,223	61,613
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			(421,157)	135
Purchases of property, plant and equipment			(7,514)	(16,611)
Proceeds from sale of property, plant and equipment			0	268
Cash received from (used in) disposition, net of cash divested			593,066	0
Cash paid for business acquisitions, net of cash acquired			(60,135)	(75)
Cash received from sales of (paid for purchase of) marketable securities			0	0
Cash received from (paid for) investments				477
Cash received from equity method investments			2,205
Proceeds from sale of equity investment				0
(Increase) decrease in other assets			368	(104)
Net cash provided by (used in) continuing operations			106,833	(15,910)
Net cash used in discontinued operations			0	0
Net cash provided by (used in) investing activities			106,833	(15,910)
Cash Flows from Financing Activities:
Cash paid for financing costs			(15,836)	(5)
Cash paid for contingent purchase price consideration			(13,640)	(23,285)
Cash paid for dividends			(15,970)	(15,970)
Proceeds from issuance of common stock, net of issuance costs			76,457	35,593
Proceeds from issuance of short-term debt				0
Proceeds from issuance of long-term debt			2,119,125	0
Payments on short-term debt			0
Payments on long-term debt			(2,128,625)	(45,000)
Net proceeds (payments) under revolving credit facilities			(127,000)	0
Excess tax benefits on exercised stock options			3,264	65
Principal payments on capital lease obligations			0	0
Net cash provided by (used in) continuing operations			(102,225)	(48,602)
Net cash used in discontinued operations			0	(579)
Net cash provided by (used in) financing activities			(102,225)	(49,181)
Foreign exchange effect on cash and cash equivalents			16	146
Net increase (decrease) in cash and cash equivalents			140,847	(3,332)
Cash and cash equivalents, beginning of period - continuing operations			2,149	14,801
Cash and cash equivalents, beginning of period - discontinued operations			0	0
Cash and cash equivalents, end of period		11,469		11,469
Less: Cash and cash equivalents of discontinued operations, end of period		0		0
Cash and cash equivalents of continuing operations, end of period	142,996	11,469	142,996	11,469
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	71,171	13,176	116,211	20,900
Income (loss) from discontinued operations, net of tax		(20,615)	(1,912)	(26,418)
Income (loss) from continuing operations		33,791	118,123	47,318
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	0	(210)	0	(442)
Tax benefit related to discontinued operations				9,594
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			19	32
Depreciation and amortization			128,363	132,134
Non-cash stock-based compensation expense			4,251	3,463
Impairment of inventory			133	0
Impairment of long-lived assets			64	(446)
Loss on sale of fixed assets			2,768	4,078
Equity earnings of unconsolidated entities, net of tax	0	0	0	0
Deferred income taxes			(30,699)	(12,863)
Impairment and (gain) loss on dispositions, net	85		(8,719)	638
Loss on extinguishment of debt			0
Other non-cash items			(1,054)	2,845
Non-cash change in fair value of contingent purchase price consideration			16,616	9,903
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			(11,370)	(10,136)
Inventories, net			(31,079)	(22,521)
Prepaid expenses and other current assets			(28,016)	(444,782)
Accounts payable			777	25,738
Accrued expenses and other current liabilities			33,995	482,572
Other non-current liabilities			740	2,392
Cash paid for contingent purchase price consideration			0	0
Intercompany payable (receivable)			(246,828)	(197,561)
Net cash provided by (used in) continuing operations			(52,001)	31,956
Net cash provided by discontinued operations			318	26,474
Net cash provided by (used in) operating activities			(51,683)	58,430
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			0	(100)
Purchases of property, plant and equipment			(25,915)	(29,141)
Proceeds from sale of property, plant and equipment			846	778
Cash received from (used in) disposition, net of cash divested			(8,722)	1,081
Cash paid for business acquisitions, net of cash acquired			0	0
Cash received from sales of (paid for purchase of) marketable securities			103	43
Cash received from (paid for) investments				(278)
Cash received from equity method investments			0
Proceeds from sale of equity investment				0
(Increase) decrease in other assets			497	140
Net cash provided by (used in) continuing operations			(33,191)	(27,477)
Net cash used in discontinued operations			(209)	(8,853)
Net cash provided by (used in) investing activities			(33,400)	(36,330)
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			0	0
Cash paid for dividends			0	0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of short-term debt				0
Proceeds from issuance of long-term debt			0	0
Payments on short-term debt			0
Payments on long-term debt			0	(223)
Net proceeds (payments) under revolving credit facilities			0	0
Excess tax benefits on exercised stock options			2,531	282
Principal payments on capital lease obligations			(1,876)	(2,246)
Net cash provided by (used in) continuing operations			655	(2,187)
Net cash used in discontinued operations			(76)	(496)
Net cash provided by (used in) financing activities			579	(2,683)
Foreign exchange effect on cash and cash equivalents			(301)	(179)
Net increase (decrease) in cash and cash equivalents			(84,805)	19,238
Cash and cash equivalents, beginning of period - continuing operations			69,154	78,976
Cash and cash equivalents, beginning of period - discontinued operations			23,300	6,476
Cash and cash equivalents, end of period		104,690		104,690
Less: Cash and cash equivalents of discontinued operations, end of period		13,502		13,502
Cash and cash equivalents of continuing operations, end of period	7,649	91,188	7,649	91,188
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income (loss)	94,371	36,737	254,174	73,862
Income (loss) from discontinued operations, net of tax		22,415	0	23,196
Income (loss) from continuing operations		14,322	254,174	50,666
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Tax benefit related to discontinued operations				0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			66	217
Depreciation and amortization			97,250	114,218
Non-cash stock-based compensation expense			4,745	2,659
Impairment of inventory			68	1,536
Impairment of long-lived assets			314	5,739
Loss on sale of fixed assets			505	601
Equity earnings of unconsolidated entities, net of tax	(5,348)	(5,779)	(9,340)	(12,516)
Deferred income taxes			(7,794)	(7,320)
Impairment and (gain) loss on dispositions, net	1,839		(29,924)	0
Loss on extinguishment of debt			0
Other non-cash items			(3,358)	1,826
Non-cash change in fair value of contingent purchase price consideration			(34,860)	3,813
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			101	22,779
Inventories, net			(27,909)	(3,495)
Prepaid expenses and other current assets			4,917	(65,138)
Accounts payable			(9,342)	10,312
Accrued expenses and other current liabilities			(103,572)	46,020
Other non-current liabilities			5,389	2,806
Cash paid for contingent purchase price consideration			(13)	(112)
Intercompany payable (receivable)			(87,992)	(79,645)
Net cash provided by (used in) continuing operations			53,425	94,966
Net cash provided by discontinued operations			0	62
Net cash provided by (used in) operating activities			53,425	95,028
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			(17,608)	(3,262)
Purchases of property, plant and equipment			(36,093)	(29,805)
Proceeds from sale of property, plant and equipment			1,554	2,853
Cash received from (used in) disposition, net of cash divested			2,281	4,373
Cash paid for business acquisitions, net of cash acquired			0	0
Cash received from sales of (paid for purchase of) marketable securities			(4)	4
Cash received from (paid for) investments				(1)
Cash received from equity method investments			12,092
Proceeds from sale of equity investment				9,526
(Increase) decrease in other assets			(219)	931
Net cash provided by (used in) continuing operations			(37,997)	(15,381)
Net cash used in discontinued operations			0	0
Net cash provided by (used in) investing activities			(37,997)	(15,381)
Cash Flows from Financing Activities:
Cash paid for financing costs			(217)	0
Cash paid for contingent purchase price consideration			(439)	(323)
Cash paid for dividends			0	0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of short-term debt				806
Proceeds from issuance of long-term debt			42,897	41
Payments on short-term debt			(25,584)
Payments on long-term debt			(540)	(2,079)
Net proceeds (payments) under revolving credit facilities			397	498
Excess tax benefits on exercised stock options			307	68
Principal payments on capital lease obligations			(2,463)	(2,393)
Net cash provided by (used in) continuing operations			14,358	(3,382)
Net cash used in discontinued operations			0	0
Net cash provided by (used in) financing activities			14,358	(3,382)
Foreign exchange effect on cash and cash equivalents			(8,208)	(9,225)
Net increase (decrease) in cash and cash equivalents			21,578	67,040
Cash and cash equivalents, beginning of period - continuing operations			307,158	261,654
Cash and cash equivalents, beginning of period - discontinued operations			0	1
Cash and cash equivalents, end of period		328,695		328,695
Less: Cash and cash equivalents of discontinued operations, end of period		1		1
Cash and cash equivalents of continuing operations, end of period	328,736	328,694	328,736	328,694
Eliminations [Member]
Cash Flows from Operating Activities:
Net income (loss)	(165,542)	(49,913)	(370,385)	(94,762)
Income (loss) from discontinued operations, net of tax		0	0	0
Income (loss) from continuing operations		(49,913)	(370,385)	(94,762)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	163,647	49,852	369,200	97,749
Tax benefit related to discontinued operations				0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			0	0
Depreciation and amortization			7	(6)
Non-cash stock-based compensation expense			0	0
Impairment of inventory			0	0
Impairment of long-lived assets			0	0
Loss on sale of fixed assets			0	0
Equity earnings of unconsolidated entities, net of tax	(16)	62	2	187
Deferred income taxes			439	1,710
Impairment and (gain) loss on dispositions, net	0		0	0
Loss on extinguishment of debt			0
Other non-cash items			3	0
Non-cash change in fair value of contingent purchase price consideration			0	0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			0	0
Inventories, net			207	(4,430)
Prepaid expenses and other current assets			5,048	(2,438)
Accounts payable			0	0
Accrued expenses and other current liabilities			(6,859)	(1,748)
Other non-current liabilities			1,445	4,101
Cash paid for contingent purchase price consideration			0	0
Intercompany payable (receivable)			178	0
Net cash provided by (used in) continuing operations			(715)	363
Net cash provided by discontinued operations			0	0
Net cash provided by (used in) operating activities			(715)	363
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			0	0
Purchases of property, plant and equipment			1,575	2,522
Proceeds from sale of property, plant and equipment			(914)	(2,755)
Cash received from (used in) disposition, net of cash divested			0	0
Cash paid for business acquisitions, net of cash acquired			0	0
Cash received from sales of (paid for purchase of) marketable securities			0	0
Cash received from (paid for) investments				0
Cash received from equity method investments			0
Proceeds from sale of equity investment				0
(Increase) decrease in other assets			235	57
Net cash provided by (used in) continuing operations			896	(176)
Net cash used in discontinued operations			0	0
Net cash provided by (used in) investing activities			896	(176)
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			0	0
Cash paid for dividends			0	0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of short-term debt				0
Proceeds from issuance of long-term debt			0	0
Payments on short-term debt			0
Payments on long-term debt			0	0
Net proceeds (payments) under revolving credit facilities			0	0
Excess tax benefits on exercised stock options			0	0
Principal payments on capital lease obligations			0	0
Net cash provided by (used in) continuing operations			0	0
Net cash used in discontinued operations			0	0
Net cash provided by (used in) financing activities			0	0
Foreign exchange effect on cash and cash equivalents			(181)	(187)
Net increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents, beginning of period - continuing operations			0	0
Cash and cash equivalents, beginning of period - discontinued operations			0	0
Cash and cash equivalents, end of period		0		0
Less: Cash and cash equivalents of discontinued operations, end of period		0		0
Cash and cash equivalents of continuing operations, end of period	$ 0	$ 0	$ 0	$ 0

Assets Held For Sale - Addition

Assets Held For Sale - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Jul. 02, 2015	Dec. 31, 2014	May. 31, 2007
Assets Held For Sale [Line Items]
Assets held for sale - non-current	$ 126,048		$ 0
SPD Joint Venture [Member]
Assets Held For Sale [Line Items]
Ownership percentage				50.00%
TechLab [Member]
Assets Held For Sale [Line Items]
Assets held for sale - non-current	$ 13,000
TechLab [Member] | SPD Joint Venture [Member]
Assets Held For Sale [Line Items]
Ownership percentage	49.00%
BBI Business [Member]
Assets Held For Sale [Line Items]
Sale of business, purchase price		$ 164,300
Sale of business, contingent consideration		$ 46,600

Assets Held For Sale - Schedule

Assets Held For Sale - Schedule of Assets and Liabilities Associated with BBI Business Segregated and Classified as Assets Held for Sale and Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Assets
Assets held for sale - current	$ 25,312	$ 315,515
Goodwill	2,842,921	2,926,666
Assets held for sale - non-current	126,048	0
Liabilities
Liabilities related to assets held for sale - current	8,836	78,843
Deferred tax liabilities - non-current	207,451	214,639
Liabilities related to assets held for sale - non-current	9,603	$ 0
BBI Business [Member] | Discontinued Operations, Held-for-sale [Member]
Assets
Accounts receivable, net of allowances of $2,362 at September 30, 2015	10,197
Inventories, net	11,011
Deferred tax assets - current	137
Prepaid expenses and other current assets	3,967
Assets held for sale - current	25,312
Property, plant and equipment, net	10,123
Goodwill	60,145
Finite-lived intangible assets, net	40,344
Other non-current assets	2,423
Assets held for sale - non-current	113,035
Liabilities
Current portion of capital lease obligations	6
Accounts payable	3,584
Accrued expenses and other current liabilities	5,246
Liabilities related to assets held for sale - current	8,836
Capital lease obligations, net of current portion	10
Deferred tax liabilities - non-current	8,497
Other long-term liabilities	1,096
Liabilities related to assets held for sale - non-current	$ 9,603

Assets Held For Sale - Sched100

Assets Held For Sale - Schedule of Assets and Liabilities Associated with BBI Business Segregated and Classified as Assets Held for Sale and Liabilities (Parenthetical) (Detail) $ in Thousands	Sep. 30, 2015USD ($)
BBI Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, allowances	$ 2,362

Impairment of Acquired In-pr101

Impairment of Acquired In-process Research and Development (IPR&D) - Additional Information (Detail) - Acquired In-process Research and Development (IPR&D) [Member]	3 Months Ended
	Sep. 30, 2015USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment charges	$ 7,400,000
Estimated fair value	$ 0